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Abstract 
The aim of this thesis was to investigate the cellular uptake, in cellulo DNA 
binding and cytotoxicity of Ru(II) complexes that reversibly bind to DNA  in 
vitro with an accompanying increase in MLCT (metal-to-ligand charge-
transfer) luminescence (the DNA light switch effect). Such complexes offer 
many advantages as luminescent probes of DNA structure but poor cellular 
uptake restricts their use in live cells. Using a combination of confocal laser 
scanning microscopy (CLSM) and transmission electron microscopy (TEM), 
Ru(II)tpphz (tpphz = tetrapyrido[3,2-a:2’,3’-c:3’’,2’’-h:2’’’,3’’’-j]phenazine)  
metallo-intercalators are shown to be internalised by MCF-7 human breast 
cancer cells where they successfully target nuclear DNA. Cell viability 
studies revealed a cytotoxic potency comparable to cisplatin, which is 
retained for cisplatin-resistant tumour cells. The dinuclear Ru(II)tpphz 
complex, [{Ru(phen)2}2(tpphz)]4+ [3.1] (phen = 1,10-phenanthroline), was 
shown to function as a multifunctional biological imaging agent staining the 
DNA of eukaryotic and prokaryotic cells for both CLSM and TEM while 
confocal microscopy reveals multiple emission peaks that function as 
markers for cellular DNA structure. Cell viability studies revealed that [3.1] 
displays a high toxicity towards cancer cell lines over an extended 
incubation time, of particular interest as [3.1] binds quadruplex DNA with a 
high affinity. The synthesis of several derivatives of [3.1], with bpy (2,2’-
bipyridine), 5mp (5-methyl-phen) and dmp (2,9-dimethyl-phen) replacing 
phen as the ancillary ligand, has shown how the ancillary ligand can affect 
such properties as luminescence, DNA binding affinity, cellular uptake and 
cytotoxicity, which resulted in the derivation of the ancillary ligand “toxicity 
series” of dmp > phen > 5mp > bpy. Using inhibition studies, a common 
finding is the uptake mechanism of these Ru(II) complexes is a non-
endocytic mode of active transport and nuclear uptake has been shown to 
be a concentration-dependent process. This work has established the rate of 
cellular uptake to be the most important factor that governs the cytotoxicity 
of such complexes and not in vitro DNA binding affinity. 
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hrs  hours 
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M  cell phase, mitosis 
MCF-7  cell line, origin: human breast carcinoma  
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MLCT  metal-to-ligand charge-transfer 
mins  minutes 
MS  mass spectroscopy 
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide 
NDB  nucleic acid database 
NMR  nuclear magnetic resonance 
N^N  nitrogen-coordinating bidentate ancillary ligand 
PBS  phosphate buffered saline 
PDT  photodynamic therapy 
phen   1,10-phenanthroline  
Phi    9,10-phenanthrenequinone diimine 
PI  propidium iodide 
py  pyridine 
RNA  ribonucleic acid 
RNAi  RNA interference 
RPMI  cell media, RPMI-1640 (Roswell Park Memorial Institute) 
S  cell phase, synthesis 
S. aureus Staphylococcus aureus 
Saos-2  cell line, origin: human osteosarcoma 
T  thymine 
taptp    4,5,9,18-tetraazaphenanthreno[9,10-b] triphenylene 
TEM  transmission electron microscopy 
tpm  tris-(1-pyrazolyl)methane 
tpphz  tetrapyrido[3,2-a:2’,3’-c:3’’,2’’-h:2’’’,3’’’-j]phenazine 
TRAP   telomere repair amplification protocol 
Tris  tris(hydroxymethyl)aminomethane 
UV-vis  ultraviolet-visible 
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Chapter 1 
Introduction 
 
1.1 DNA 
In all eukaryotic and prokaryotic organisms the storage of genetic 
information is encoded almost entirely in the biopolymer deoxyribonucleic 
acid (DNA). The “genetic code” within DNA is contained in the cells of the 
organism and provides the blueprint for the formation of ribonucleic acid 
(RNA) and proteins, which are the functional components of cells. The flow 
of biological information, whereby a section of DNA is transcribed into RNA 
which in turn is responsible for the synthesis of specific proteins 
(translation), is set out in “the central dogma of molecular biology”, as 
formalised by Crick (Figure 1.1).1  
 
Figure 1.1 The central dogma of molecular biology. 
 
The central dogma also describes the process of DNA replication which 
allows organisms to make copies of their genomes. Along with the ability of 
cells to replicate themselves, this enables each new generation of the cell 
(and therefore the organism) to undergo the exact same transfer of 
information encoded by the cell’s DNA and this serves as the basis of 
biological inheritance and genetics.  
DNA RNA
DNA 
polymerase
RNA polymerase ribosome
replication transcription translation
protein
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1.1.1 DNA structure 
DNA is a linear polymer composed of repeating nucleotide units, each 
comprised of a nitrogen heterocyclic base, a pentose sugar and a phosphate 
group (Figure 1.2). The four nitrogenous bases in DNA can be adenine (A), 
guanine (G), cytosine (C) or thymine (T) and it is through sequences of these 
bases that the genetic information of the organism is contained and then 
expressed via translation and transcription. Each nucleotide in the DNA 
molecule is linked by a phosphodiester bond between the 3’ and 5’ carbon 
atoms on adjacent sugar rings and sequences of DNA are written in the 5’  
3’ direction.  
 
 
Figure 1.2 a, DNA nucleosides and nucleotides. b, Nucleotides of DNA lined 
by phosphodiester bonds and chemical structure of the nitrogenous bases. 
 
The most energetically favourable form of DNA, and the form the molecule 
usually takes up in living organisms, is the right-handed double helix B-DNA, 
which was first described by Watson and Crick using Franklin’s crystal 
structure.2 The structure of B-DNA consists of two strands of DNA running 
in opposite directions held together by hydrogen bonding between pairs of 
a b
adenine (A)
guanine (G)
cytosine (C)
thymine (T)
nucleoside
nucleotide
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bases on opposing strands; adenine pairs with thymine and guanine pairs 
with cytosine (Figure 1.3a,b). The double helix of B-DNA possesses two 
grooves: the major groove (width = 12 Å) and minor groove (width = 6 Å) as 
shown in Figure 1.3c. 
 
 
Figure 1.3 a, DNA base pairs. b, Two opposite strands of DNA are 
complimentary to each other. c, B-DNA double helix showing grooves (Nucleic 
acid Database (NDB) ID: BD0003). 
 
1.1.2 Cellular DNA 
In eukaryotic cells, the genomic DNA of the organism is organised into linear 
sets of chromosomes located within the cell nucleus (Figure 1.4a,b). The 
complete human genome contains over 3 x 109 base pairs which code for 
approximately 2 x 104 genes3 and is stored on 23 chromosome pairs, one set 
originating from the mother and one from the father. To allow the large 
amount of DNA to fit into the relatively small cell nucleus, chromosomal 
DNA is folded with histone and scaffold proteins to form chromatin (Figure 
1.4c). Chromatin is organised into two different forms: heterochromatin, 
major 
groove
minor 
groove
A
C
C
G
G
T
A
C
C
G
G
T
T
G
G
C
C
A
T
G
G
C
C
A
5’ 3’
3’ 5’
a b c
AT base pair
GC base pair
Chapter 1: Introduction 
4 
 
which contains tightly packed DNA, and euchromatin, which contains DNA 
in an extended form.4 The compact chromatin structure is also dynamic, 
allowing protein access for vital processes such as gene transcription, DNA 
replication and DNA repair.5  
 
 
 
 
 
 
Figure 1.4 a, Eukaryotic cell showing location of nucleus. b, Cell nucleus 
structure. c, Chromatin structure showing DNA organisation. 
 
 
 
a
inner membrane
outer membrane
nucleolus
chromatin
nuclear pore
b
1 µM5 µM
nucleus
2 nm 700 nm 1400 nm300 nm
double 
helix
histone protein scaffold protein
extended 
chromsome
metaphase (condensed) 
chromsome
11 nm
nucleosomes
“beads on a string”
30 nm
30 nm fibre
c 
Chapter 1: Introduction 
5 
 
1.1.2.1 Mitochondrial DNA 
In addition to the nucleus, mitochondria of cells also contain DNA (Figure 
1.5). Mitochondria are membrane-enclosed organelles 0.5 – 10 µm in 
diameter that generate chemical energy for the cell in the form of adenosine 
triphosphate (ATP), which is converted to adenosine diphosphate (ADP) in 
biochemical reactions. Mitochondrial DNA is a separate genome to that of 
the organism and takes the form of a circular DNA molecule containing 
approximately 17,000 base pairs.4 
 
 
Figure 1.5 Mitochondrion location (a) and structure (b). 
 
1.1.3 Cell division and the cell cycle 
The ability for cells to divide and multiply is fundamentally important to the 
growth and maintenance of the organism. During eukaryotic cell division, 
chromosomes are first duplicated through DNA replication before pairs of 
chromosomes condense and then separate using a mitotic spindle into two 
identical sets located in opposite regions of the cell (mitosis). The parent cell 
then divides to form two daughter cells (cytokinesis), each of which 
contains one of these sets and thus an exact copy of the parental DNA 
(Figure 1.6a). The series of events that cells undergo leading up to cell 
division is described by the cell cycle. This consists of four distinct phases: 
G1, S (DNA synthesis), G2 and M (mitotic phase). G1, S and G2 phases are 
collectively known as interphase (Figure 1.6b). In addition to these there is 
inner membrane
outer membrane
matrix
DNA
ATP synthase particles
1 µM
a
mitochondrion
5 µM
b
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the resting phase G0, where cells remain viable but do not proliferate. The 
cell cycle is strictly regulated by numerous proteins and monitored by 
checkpoints which operate within S-phase, between S and M phase, as well 
as at the G1/S and G2/M phase boundaries. In addition, a spindle checkpoint 
ensures that segregation of sister chromatids cannot occur unless all 
chromosome pairs are attached to the mitotic spindle, thus preventing 
aneuploidy (an abnormal number of chromosomes).4 
 
 
Figure 1.6 a, Mitotic cell division showing DNA content. Bar indicates cell cycle 
phase. b, The cell cycle with checkpoint locations indicated in dotted lines. 
 
The condensed chromosome and mitotic spindle structures can be used to 
identify the different stages of mitosis whereas interphase chromosomes 
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exist in an extended form, compartmentalised into discrete territories in the 
nucleus (Figure 1.7).6  
 
 
Figure 1.7 a, Mitotic chromosomes (stained red) and mitotic spindle (green). b, 
Individual chromosomes (yellow) from a metaphase spread (left) occupy distinct 
territories in the interphase nucleus (right).6 
 
1.1.4 DNA replication  
As previously discussed, the ability of the cells of an organism to replicate 
the DNA within them is essential for the growth and proliferation of that 
organism. For eukaryotes, this process initially involves the double helix of 
DNA being unwound by topoisomerase and helicases to form a replication 
fork before the synthesis of two new DNA strands by DNA polymerases 
(Figure 1.8a). A consequence of the specific Watson-Crick base pairing of 
DNA is that each strand is able to act as a template for the synthesis of the 
complementary strand, meaning that two identical copies of the DNA 
molecule are formed, essential for mitotic cell division. DNA polymerases 
are only able to synthesise DNA in the 5’ to 3’ direction and initially requires 
an 8-12 base segment of RNA to act as a primer. After this is completed, the 
RNA primer is removed and the remaining gaps are filled in by DNA 
polymerase. As a consequence, while synthesis of the leading strand is 
continuous, synthesis of the 3’ to 5’ strand (the lagging strand) occurs in 
short Okazaki fragments each requiring an RNA primer. The repair 
synthesis, which converts the RNA primer into DNA, has no binding site for 
the terminal 5’ end and, as a result, the DNA cannot be fully synthesised, 
ba
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resulting in a single stranded DNA overhang at the 3’ end of the newly 
synthesised DNA molecule (Figure 1.8b). 
 
 
Figure 1.8 a, DNA replication fork. Topoisomerase and helicase unwind the 
DNA double helix and two new strands are synthesised. b, Synthesis of the 
leading strand and lagging strand. As synthesis occurs only in the 5’ to 3’ 
direction this leaves a single stranded overhang at the 3’ end. 
 
1.1.5 Telomeres 
When a replication fork reaches the end of a linear chromosome there is no 
place to produce the RNA primer and so the DNA cannot be synthesised to 
the 3’ end resulting in a gap.4 For eukaryotic organisms that contain linear 
chromosomes (as opposed to the majority of prokaryotes, which possess 
circular chromosomes), this would result in the shortening of chromosomes 
and a loss in genetic information with each cell division. To overcome this 
“end replication problem”, eukaryotes contain repetitive non-coding DNA 
sequences located at the end the end of their chromosomes called telomeres 
(Figure 1.9). The repeat sequence and length varies depending on the 
organism, although telomeric DNA that is rich in guanine is a common 
property.7 The telomeric DNA overhang of cells is reduced each time the cell 
divides and it is thought this shortening serves as a control for the life cycle 
5’
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a b
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of cells by placing a limit upon the number of divisions each cell is able to 
undergo.8, 9  
 
Figure 1.9 a, Chromosome schematic showing telomeres. b, Fluorescence 
micrograph of HeLa metaphase chromosomes (red) showing labelled telomeres 
(green).10  
 
1.1.6 Cancer 
In the UK, one in three people will develop cancer during their lives11 and 
cancer research represents one of the most active areas of modern science. 
So what defines and causes this disease? Cancer cells are cells that display 
uncontrolled growth along with the ability to invade neighbouring tissues. 
When this proliferation becomes uncontrollable, the cancer cells cluster 
together in a tumour, which can then spread to multiple areas of the body if 
not removed (metastases). Cancer is a result of multiple genetic changes 
which, in the majority of cases, has originated from DNA mutations within a 
single abnormal cell.4 The targeting of these mutations for potential drug 
development is a common theme in anti-cancer research. For example, in 
half of all cancers the tumour suppressor p53 gene, which normally 
regulates the cell cycle once DNA damage or mutation has been detected, is 
either absent or damaged.12 Attempts to restore the function of this gene to 
induce cell cycle arrest or apoptosis specifically in cancer cells (commonly at 
the G1/S boundary) is a current anti-cancer therapeutic goal.13 Another 
property of the majority of cancers is they possess short telomeres but the 
enzyme that controls the synthesis of telomeric DNA, telomerase, is very 
active.14 This enables the cancer cells to escape telomere-dependent 
3’
5’ 3’
5’
telomere
ba
coding DNA
telomeric DNA
overhang
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mechanisms of cell death and proliferate, making the maintenance of 
telomeres crucial to the growth of cancers. For this reason, the inhibition of 
telomerase is viewed as an attractive target for cancer therapeutics.15  
 
1.1.7 Quadruplex DNA 
Quadruplex DNA is a non-duplex DNA structure and is formed from a unit of 
four guanine bases associated in a planar Hoogsteen base-pair arrangement 
called a G-tetrad. Quadruplexes comprise of stacked G-tetrads held together 
by π-π stacking interactions and are stabilised by monovalent cations such 
as Na+ and K+ (Figure 1.10a,b). Figure 1.10c,d shows the crystal structure of 
a four-stranded “propeller type” G3 quadruplex (Gn = n tetrats) solved by 
Neidle and co-workers.16 A wide variety of quadruplex topologies have been 
observed, with variation in strand direction, loop size and base sequence.17 
G-rich DNA sequences readily form quadruplexes in the presence of such 
ions in vitro but the existence and exact role of quadruplexes in vivo remains 
under debate.  
 
1.1.7.1 Biological significance 
As human telomeric DNA is composed of G-rich TTAGGG repeats (telomere 
length ~2 x 103 and a single stranded 3’ overhang of ~200 bases),18 these 
regions are therefore prime candidates for the formation of quadruplexes in 
vivo. As telomerase is a reverse transcriptase that requires single stranded 
DNA as a template for the synthesis of new telomeric DNA, the formation of 
quadruplexes at the single stranded overhang of chromosomes would be 
predicted to interfere with telomere maintenance. Thus, targeting the 
telomerase/telomere relationship is a current anti-cancer strategy and, as 
part of this approach, it is thought that the induction/stabilisation of 
quadruplex DNA using small molecules may potentially halt tumour growth 
while displaying minimal cytotoxicity towards normal cells.19, 20 G-rich 
sequences exist elsewhere in the genome and it has been proposed that 
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quadruplexes may be directly involved in such applications as gene 
regulation and transcription.21 
 
Figure 1.10 a, G-tetrad. b, Quadruplex formed by stacking of G-tetrads. M+ = 
Na+ or K+. c, d, Crystal structure of quadruplex DNA (NDB ID: UD0017).  
 
1.2 Small molecule binding to DNA 
The processes described by the central dogma are initiated, regulated and 
terminated by molecules and/or proteins that bind to nucleic acids in site-
specific ways. Consequently, synthetic molecules that are able to interact 
with nucleic acids are able to interfere with these steps (positively or 
negatively) and so find a variety of uses as biophysical and therapeutic 
agents. The structure of DNA allows several different mechanisms by which 
small molecules can bind to DNA, which will be described in this section. 
= M+
a b
c d
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1.2.1 Irreversible binding 
Molecules can form covalent bonds to the phosphodiester backbone, sugar 
residues or bases of the DNA molecule. The induction of DNA damage by a  
drug molecule forms the basis of “classical chemotherapy”, where, as a 
result of genetic instability, cancer cells are unable to affect the correct cell 
cycle checkpoint response to the induced damage and consequently 
undergo cell cycle arrest (typically at the G1/S and G2/M checkpoints), 
which ultimately leads to cell death. Rapidly dividing cells, such as cancer 
cells, are preferentially targeted by this approach.22  
 
1.2.2 Reversible binding 
As well as irreversibly forming covalent bonds, small molecules are also able 
to bind reversibly to DNA. This can occur by three main mechanisms: 
electrostatic interactions, groove binding and intercalation. 
 
1.2.2.1 Electrostatic interactions 
The negative charge of DNA means that cationic molecules are able to 
associate with the biopolymer. These can range from simple cations such as 
Na+ and Mg2+ to cationic polyamines such as spermidine and spermine 
(Figure 1.11), which have been suggested to be able to modulate DNA-
protein interactions via DNA binding and disrupt cellular function, 
particularly cell proliferation, as a result.23 
 
 
Figure 1.11 Cationic polyamines spermidine and spermine. 
 
spermidine spermine
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1.2.2.2 Groove binding 
The major and minor groove in B-DNA provide suitable binding sites 
through reversible van der Waals, hydrophobic and hydrogen bonding 
interactions. An example of a minor-groove binding molecule is Hoechst 
33258, which is a commonly used fluorescent DNA stain. Figure 1.12 shows 
the crystal structure of Hoechst 33258 located in the minor groove and the 
nuclear DNA of HeLa cervical cancer cells fluorescently labelled by the 
molecule. 
 
 
Figure 1.12 a, Chemical structure of the groove-binder Hoechst 33258. b, X-
ray crystal structure of Hoechst 33258 located in the minor groove of B-DNA 
(NDB ID: GDL022). c, Fluorescence microscopy image showing the DNA of 
HeLa cells stained by Hoechst 33258.24 
 
1.2.2.3 Intercalation 
First described by Lerman in 1961,25 this mode of reversible DNA-binding 
interaction involves planar aromatic compounds being inserted between 
adjacent base pairs in the DNA double helix. Intercalation involves 
significant π system overlap between DNA bases and the intercalated 
a b
c
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molecule, as well as van der Waals and electrostatic interactions, which has 
the effect of unwinding and lengthening the DNA double helix.26 An example 
of an intercalating molecule is ethidium bromide, which is used as a nucleic 
acid stain in applications such as gel electrophoresis as it shows an increase 
of fluorescence upon intercalation (Figure 1.13). Ethidium bromide displays 
a high affinity for DNA and is a potent mutagen and carcinogen as a result.27 
 
 
Figure 1.13 a, Chemical structure of the ethidium bromide. b, Crystal 
structure of ethidium bromide intercalating between DNA base pairs (NDB ID: 
DRB006). c, Ethidium bromide as a DNA stain in gel electrophoresis.28 
 
1.2.3 Small molecule binding to quadruplex DNA 
As well as irreversibly binding to quadruplex DNA, a molecule may 
reversibly bind with the loops, grooves, end-stack or intercalate between 
successive G-tetrads. There have been numerous compounds reported to 
stabilise quadruplex DNA and such complexes tend to have a large planar 
aromatic surface area with many possessing a positive charge. Examples of 
quadruplex-stabilising small molecules include the cationic porphyrin 
TMPyP429 and the trisubstituted acridine-based compound BRACO-1930 
(Figure 1.14), both of which are potent inhibitors of telomerase. 
Furthermore, BRACO-19 has been shown to inhibit tumour growth in vivo; 
consistent with the notion that quadruplex binding molecules may be 
effective therapeutics by interfering with mechanisms of telomere length 
maintenance.30 
a b c
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Figure 1.14 Quadruplex DNA-stabilising molecules TMPyP4 and BRACO-19. 
 
1.3 Cellular uptake of small molecules 
To interact with DNA in living cells, molecules must be able to enter the 
interior of cells. Eukaryotic cells are surrounded by a cell membrane 
composed of a phospholipid bilayer. This bilayer contains phospholipids, 
composed of a hydrophilic head group attached to hydrophobic 
hydrocarbon chains, and a variety of proteins and lipids to regulate the 
cellular uptake of extracellular particles. The hydrophobic interior of the 
bilayer means that membrane diffusion is determined by the polarity and 
size of the molecule; the more polar or larger the molecule, the more 
difficult it is to permeate the membrane. Generally if a molecule is more 
polar than water or larger than 500 Da it will require a transport 
mechanism to facilitate cellular uptake.4  
 
1.3.1 Passive and active transport 
Vital molecules such as amino acids, sugars and ions pass across the cell 
membrane through the action of membrane pumps, channels or carrier 
proteins.  This may be energy-independent (passive transport), driven by an 
electrochemical gradient, or energy-dependent (active transport), usually 
driven by the conversion of ATP to ADP (Figure 1.15). These mechanisms 
TMPyP4 BRACO-19
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are highly selective and rely upon protein-specific binding to a target 
molecule or ion.4 
 
Figure 1.15 Passive and active transport across the cell membrane. 
 
1.3.2 Endocytosis 
Typically used to internalise large, polar molecules, endocytosis involves the 
invagination and pinching off of the cell membrane to form endocytic 
vesicles which carry their contents to the target organelle within the cell. 
This is frequently triggered by a specific protein-binding event at the cell 
surface to a receptor. Endocytic pathways usually involve the delivery of 
internalised molecules to early endosomes for sorting. The contents can 
then be released, delivered to a target organelle, processed in late 
endosomes, digested in lysosomes or released into the extracellular fluid via 
exocytosis, as required, with the exact fate depending upon the uptake 
pathway. All endocytic pathways are energy-dependent and are divided into 
phagocytosis (uptake of solids) and pinocytosis (uptake of liquids).31 
 
1.3.2.1 Mechanisms of endocytosis 
Phagocytosis is the cellular engulfing of large molecular aggregates, solid 
particles, such as cell debris and bacteria, and is distinct from the processes 
required to internalised liquids. Macropinocytosis involves cell surface 
ruffling and the formation of macropinosomes (diameter >1 µm). The 
ruffling is controlled by the cell and can vary with cell type and external 
passive 
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active 
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signalling. This process provides an efficient route for non-selective 
endocytosis of soluble macromolecules.32 Clathrin-mediated endocytosis is 
the main route of endocytosis used by most cells and involves the molecule 
binding to specific receptors on the surface of the cell membrane and the 
formation of clathrin-coated pits (diameter 100-150 nm), which are then 
internalised to generate clathrin-coated vesicles. Clathrin then disassociates 
and the uncoated vesicles fuse together, forming early endosomes. The 
progressive acidification of early endosomes promotes the dissociation of 
internalised molecules from their receptors which are subsequently 
recycled to the membrane surface.33 Other mechanisms of internalisation 
include the formation of caveolae, small pits in the cell membrane (diameter 
50-100 nm), which provide a non-acidic mechanism of internalisation and 
are used to transport molecules such as cholesterol. In addition to this, 
numerous clathrin- and caveolae-independent endocytosis mechanisms 
have also been described.34 The different mechanisms of endocytosis are 
shown in Figure 1.16. 
 
 
Figure 1.16 Mechanisms of endocytosis. 
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1.4 Binding of metal complexes to DNA 
Metal complexes, because of their cationic nature, three-dimensional 
structures and chemical activity, possess a natural ability to bind to DNA. 
This can occur either by irreversible binding or reversible-binding via the 
mechanisms described in Section 1.2. Coordination complexes are ideal for 
designing DNA-interactive molecules due to attributes such as: available 
coordination sites for DNA binding, the ability to perform redox reactions 
with DNA or generate reactive oxygen containing species (an attribute 
particularly relevant to photodynamic therapy (PDT)). The specific ability to 
bind to and then cleave DNA means that there is the potential to develop 
these systems as therapeutics via interfering wizth the essential cellular 
processes of transcription and translation. The photophysical properties of 
numerous complexes also mean that metal complexes are being examined 
as diagnostic probes of DNA. 
 
1.4.1 Irreversible binding 
Irreversible binding of metal complexes to DNA occurs by the formation of 
coordination bonds from the Lewis acid metal centre of the complex to the 
lone pairs of nitrogen or oxygen atoms of the DNA molecule, which function 
as the Lewis base.  
 
1.4.1.1 Platinum-based anti-cancer drugs 
One of the most famous examples of a metal complex that binds to DNA 
irreversibly is the chemotherapy agent cisplatin (cis-
diaminedichloroplatinum(II)) – Figure 1.17a. Originally developed by 
Rosenberg and co-workers,35 cisplatin and its derivatives are still some of 
the most widely used anti-cancer drugs.36 The proposed mechanism of 
cytotoxicity is derived from the displacement of the labile Cl- ligands 
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followed by the formation of covalent bonds between the Pt(II) centre and 
available nitrogen atoms on the nucleotide bases of DNA, commonly N7 
atoms on the two purine bases (Figure 1.17b). The generation of a covalent 
intrastrand cross-link in vitro has the effect of kinking the structure of the 
DNA molecule, as demonstrated by crystal structure37 and NMR solution 
structure38 (Figure 1.17c). This has been suggested to inhibit DNA 
replication and transcription in vivo, ultimately leading to apoptosis 
(programmed cell death) or cell cycle arrest.39  
 
Figure 1.17 a, Platinum anti-cancer drugs cisplatin and carboplatin.                        
b, Irreversible binding of cisplatin derivatives to DNA. c, NMR solution 
structure of cisplatin bound to B-DNA (NDB ID: 1A84). 
 
The high toxicity of cisplatin and severe side-effects led researchers to 
develop cisplatin derivatives such as carboplatin, which has a bidentate 
dicarboxylate leaving group instead two Cl- ligands (Figure 1.17a). The 
presence of a more stable leaving group was designed to lower toxicity 
without affecting the antitumour efficiency and, as a result, carboplatin 
exhibits slower DNA binding kinetics but also displays reduced side-
effects.36  
a
c
cisplatin carboplatin
b
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A major limitation of cisplatin-based chemotherapy arises from drug 
resistance, which may occur by: a reduction in cisplatin uptake, an increase 
in platinum-DNA adduct repair and/or increased drug inactivation.40 To 
combat the issue of acquired cisplatin-resistance in tumours, recent years 
have seen the development of new platinum-based agents, such as 
satraplatin and picoplatin, which exhibit a broader spectrum of antitumour 
activity.36  
 
1.4.1.2 Non-platinum-based anti-cancer drugs 
Due to the limitations of cisplatin and derivatives, metallo-pharmaceuticals 
based on non-platinum metal centres have been explored in the ongoing 
search for new therapeutics. Advantages over platinum-based drugs are: 
additional coordination sites, aptitude for redox activation, lower toxicity 
and reduced side effects.41 Specifically in this area, ruthenium (Ru(II) and 
Ru(III)) complexes have shown promise and a number of organometallic 
and coordination systems containing labile leaving groups have been 
investigated for anti-cancer activity.42-44 This “targeted chemotherapy” 
approach has seen drugs such as NAMI-A (Figure 1.18a) enter clinical trials.  
 
 
Figure 1.18 Ruthenium anti-cancer drugs. a, Ru(III) complex NAMI-A. b, Ru(II) 
arene complexes [Ru(η6-arene)(en)Cl]+ (en = ethylenediamine, R = arene). 
 
a b
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Although less toxic than cisplatin, NAMI-A has the advantage that it can be 
orally administered, is active against a range of tumours and exhibits 
antimetastatic activity.45 In other work, the Sadler group have developed 
Ru(II) arene complexes as potential anti-cancer agents (Figure 1.18b). 
Displaying a similar toxicity to cisplatin, these complexes specifically target 
guanine bases in DNA where they form strong monofunctional adducts.46, 47 
It is thought they display a different mechanism of toxicity than Pt(II)- or 
Ru(III)-based anti-cancer drugs and work is now moving towards clinical 
trials.47  
 
1.4.2 Reversible binding 
In addition to complexes able to form irreversible coordination (covalent) 
bonds with DNA, metal coordination complexes are of interest for their 
ability to reversibly bind to DNA. Such systems possess a metal centre 
coordinated to a rigid, three-dimensional arrangement of ligands. These 
ligands can be easily interchanged and modified to control the DNA-binding, 
DNA-recognition, hydrophobic, cellular uptake and photophysical 
properties of the molecule as a whole, something not offered by 
conventional organic molecular recognition agents. The specific selectivity 
in the DNA-binding of these molecules means that such complexes may find 
future potential applications as probes of DNA structure and function in 
roles ranging from molecular biology to medicine. This area of research has 
been dominated by octahedral d6 metal polypyridine complexes (most 
commonly Ru(II), Rh(III) and Re(I) metal centres) due to their kinetic 
inertness, well-developed substitution chemistry and useful photophysical 
properties.  
 
1.4.2.1 Early work 
Early work on the reversible DNA binding of metal complexes focussed on 
octahedral Ru(II) tris(phenanthroline) complexes and derivatives. Ru(II) 
Chapter 1: Introduction 
22 
 
complexes were chosen because of their chemical stability, high 
luminescence and intense metal-to-ligand charge-transfer (MLCT) band in 
the visible spectrum.48 The polypyridine ligands initially used were the 
bidentate ligands 2,2'-bipyridine (bpy), 1,10-phenanthroline (phen) and 4,7-
diphenyl-1,10-phenanthroline (DIP) (Figure 1.19).49 By examining the 
variation in photophysical properties in the presence of DNA it was shown 
that [Ru(bpy)3]2+ showed little or no binding, while results for [Ru(phen)3]2+ 
and [Ru(DIP)3]2+ suggested two binding modes to duplex DNA, comprising 
of an electrostatic and intercalative interaction. As the complexes are chiral, 
the syntheses produce a mixture of the Λ and Δ enantiomers.  This chiral 
mixture was resolved and the DNA-binding of each enantiomer studied. 
Significant enantiomeric selectivity observed for the complex containing the 
most extended ligand, [Ru(DIP)3]2+, where the Δ isomer was able to 
intercalate while the Λ isomer could only bind electrostatically to DNA. The 
binding affinity of these complexes was low (equilibrium binding constant 
Kb ~ 103 M-1) and Barton and co-workers realised that to enhance the 
binding affinity for DNA a further increase in ligand surface area was 
required.  
 
 
Figure 1.19 Octahedral Ru(II) tris(phenanthroline) complexes and derivatives. 
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1.4.2.2 The DNA light switch effect 
Research then focussed on using the dipyrido[3,2-a:2’,3’-c]phenazine (dppz) 
ligand, which possesses a large aromatic surface area for intercalation. The 
DNA binding studies on [Ru(bpy)2(dppz)]2+ and [Ru(phen)2(dppz)]2+ then 
resulted in breakthrough work in this field, with the Barton group reporting 
that the dppz-based complexes bind to DNA with a high affinity                     
(Kb ~ 106 M-1) and, importantly, display intense MLCT luminescence on the 
addition of DNA as a direct result of intercalation whereas luminescence of 
the unbound complex is quenched (Figure 1.20).50, 51 This was termed the 
DNA “light switch” effect and has been used extensively to study the 
interaction of a wide variety of metal complexes with DNA as the binding 
process can be measured using UV-visible and fluorescence spectroscopy.52 
 
 
Figure 1.20 a, Metallo-intercalator [Ru(bpy)2(dppz)]2+. b, The light switch effect 
of [Ru(bpy)2(dppz)]2+ upon the addition of DNA.50 
 
The MLCT luminescence was characterised by Sauvage et al. and they 
deduced that the light-induced charge transfer is directed from the 
Ruthenium atom to a π* orbital primarily located on the dppz ligand.53 This 
1MLCT excited state then decays rapidly via intersystem crossing to a 3MLCT 
excited state primarily localised on the phenazine nitrogen atoms. In 
aqueous conditions water quenches this excited state by hydrogen bonding 
with the phenazine nitrogen atoms54 but when the dppz is shielded from 
water (as during intercalation) the luminescence is activated and the 
complex effectively acts as though it is in organic solvent (Figure 1.21). As 
+ DNA
- DNA
a b
Chapter 1: Introduction 
24 
 
the mechanism of the light switch effect specifically involves the dppz 
ligand, it follows that in many cases the ancillary ligands may be substituted 
and the light switch effect will still be preserved.55  
 
 
Figure 1.21 Jablonski diagram showing excited states involved in the DNA light 
switch effect and the primary location of the relative electron orbital.               
GS = ground state, MLCT = metal-to-ligand charge-transfer. ISC = intersystem 
crossing. hv = excitation energy, hv’ = emission energy. 
 
Norden and Lincoln examined the photophysical properties of the resolved 
Δ  and Λ  isomers of [Ru(phen)2(dppz)]2+.56 They confirmed that 
intercalation is the binding mode for both Δ and Λ isomers and found that 
the relative quantum yield of the Δ isomer bound to DNA is 6-10 times 
higher than that of the Λ isomer, meaning the Δ isomer contributed 85% of 
the light switch emission observed for the racemic [Ru(phen)2(dppz)]2+. 
This work also confirmed the presence of two emitting species, one with a 
significantly longer lifetime than the other. Possible interpretations of such 
a finding include the existence of two different intercalative geometries, one 
of which sees the ligand buried more deeply within the double helix. Studies 
into the exact binding geometry of Δ-[Ru(phen)2(dppz)]2+ have been 
inconclusive in determining whether the complex binds via the minor or 
major groove,57, 58 suggesting that this may be dependent upon the DNA 
sequence or an artefact of the techniques employed to measure the binding. 
1MLCT
ISC
hν
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1.4.2.3 Site-specific recognition agents 
As metallo-intercalators have a rigid three dimensional structure with well-
defined symmetry and easily interchangeable ancillary ligands, this makes 
them candidates for the selective recognition of specific DNA sequences – a 
suggested part in the potential use of DNA-intercalators as antitumoral 
drugs.59 Extensive research by the Barton group on a large number of 
metallo-intercalators, commonly using Ru(II), Re(I) and Rh(III) systems, has 
revealed that both stereochemistry and van der Waals interactions between 
ancillary ligands and bases are key factors in developing site-specific 
recognition agents for a variety of different DNA sequences.60, 61 Figure 1.22 
shows the crystal structure of the sequence-specific photo-oxidant 
[Rh(Me2Trien)(Phi)]3+ (Me2Trien = 2,9-Diamino-4,7-diazadecane, Phi = 
9,10-phenanthrenequinone diimine) intercalating system bound to its 
target sequence.62 This complex is able to cause DNA strand cleavage and 
promote electron transfer through the double helix, which can damage DNA 
bases and may be able to influence cellular function.  
 
Figure 1.22 a, Site-specific [Rh(Me2Trien)(Phi)]3+ intercalating complex.          
b, Crystal structure of the Rh(III) complex bound to its target TGCA DNA 
sequence (NDB ID: UD0005). 
a b
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Work in the Thomas group has seen the development of numerous d6 
transition metal complexes able to reversibly bind to DNA with sequence- 
and structure-specificity.52 These include: achiral dppz intercalating 
systems that demonstrate sequence-specificity in their DNA binding63, 64 and 
a Ru(II)-Re(I) hetero-bimetallic dppz metallo-intercalator that displays both 
DNA light switch and DNA-cleaving properties (Figure 1.23).65  
 
 
Figure 1.23 a, Hetero-bimetallic Ru(II)-Re(I) dppz metallo-intercalator.           
b, Luminescence increase upon the addition of DNA to the complex.                 
c, Photocleavage of DNA by Ru(II)-Re(I) complex: Lane 1 is untreated plasmid, 
lanes 2 – 4 show increasing cleavage over time (30, 60, 90 mins).  DNA stained 
with ethidium bromide.65  
 
1.4.2.4 Mismatch recognition 
Mismatched DNA can occur as a result of errors during DNA replication and, 
if left uncorrected, these mismatches can lead to potentially harmful genetic 
mutations, including the formation of cancerous tumours.4 Work by the 
Barton group has included the development of several Ru(II) and Rh(III) 
imine complexes for high-affinity DNA base-pair mismatch recognition.61, 66-
68 The steric bulk of the intercalating imine ligand promotes localisation at 
CC (for the Ru(II) complexes) and CA or CT (for the Rh(III) complexes) 
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mismatch base-pairs, with the complexes then able to act as luminescent 
probes for the mismatch sites. The most notable of these complexes is 
[Rh(bpy)2(chrysi)]3+ (chrysi = chrysenequinone diimine) (Figure 1.24a), 
which selectively binds to CA base pair mismatch sites in the double helix 
and is also able to cleave the DNA backbone upon photoactivation.66 
 
1.4.2.5 Metallo-insertion 
Insertion refers to the circumstance wherein a planar aromatic ligand 
extends into the stack of base pairs in the DNA double helix upon binding, 
similar to an intercalator, but instead of unwinding the DNA, displaces and 
ejects a single base pair.25 The planar aromatic ligand acts as a direct π 
stacking replacement for the ejected base pair. X-ray crystallographic 
structural studies into the mechanism of binding to duplex DNA of the 
mismatch-detecting complex [Rh(bpy)2(chrysi)]3+ revealed that this 
mismatch targeting occurs by insertion, rather than intercalation (Figure 
1.24b).69, 70 These results are the first time metallo-insertion as a mode of 
binding has been observed. 
 
 
Figure 1.24 a, Mismatch recognition complex [Rh(bpy)2(chrsi)]3+. b, Crystal 
structure of [Rh(bpy)2(chrsi)]3+ bound to DNA (NDB ID: DD0088). The 
molecule displays two modes of binding: metallo-intercalation (†) and metallo-
insertion (‡), * designates each ejected base.  
*
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1.4.3 Metal complexes and quadruplex DNA 
Numerous groups have developed metal complexes as quadruplex DNA-
binding agents. Metal complexes are ideal in such a role as they possess well 
defined (and modifiable) geometries, ligands containing delocalised π 
systems that can stack on the face of the quadruplex, a positively charged 
metal centre that can associate in the centre of the G-tetrad and also charged 
terminal groups that can bind favourably with the grooves and loops of the 
quadruplex.71 Numerous such complexes have been developed and recent 
research in this area has included nickel and platinum complexes that 
selectively stabilise quadruplex structures over duplex DNA72, 73 and work 
by the Thomas group has produced ruthenium complexes that are capable 
of spectroscopically differentiating between duplex and quadruplex 
structures74, 75 (Figure 1.25). 
 
 
Figure 1.25 Quadruplex DNA-binding metal complexes. a, Metal salphen 
complex with cyclic amine side arms. b, Dimetallic [{Ru(bpy)2}2(4-azo)]4+ 
complex (4-azo = 4,4’’-azobis(2,2’-bipyridine)). 
 
 
a
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1.5 Metal complexes in cellular imaging applications 
As previously discussed, there has been a large amount of research into 
metal complexes that reversibly bind to DNA in vitro and attention to their 
application in biological systems is growing. DNA represents a particularly 
attractive target molecule due its biological significance and role in 
processes such as transcription and replication. In this context, the use of 
luminescent, kinetically inert metal complexes that possess 
spectroscopically active metal centres are attractive potential probes of 
DNA structure and function. Advantages of such systems are their high DNA 
binding affinities, sequence- and structure- specificity, interesting 
photophysical properties and flexible chemistry, which allows both ancillary 
and DNA-binding ligands to be interchanged or functionalised. Specifically 
for cellular imaging, metal complexes offer a very attractive set of optical 
imaging properties which include: photostability, low MLCT excitation 
energies in the visible region of the spectrum and high Stokes shifts (the 
difference between excitation and emission energies), which helps eliminate 
the problem of autofluorescence due to endogenous (organic) fluorophores. 
 
With this in mind, the study of the cellular uptake properties and in cellulo 
DNA binding of metal complexes is of key importance in their development 
towards biological applications. Specifically, the ability of many complexes 
to act as luminescent light switches when bound to DNA presents a method 
by which to assess cellular uptake and DNA binding using fluorescence-
based techniques such as confocal laser scanning microscopy (CLSM) and 
flow cytometry. There has been much research into the mechanism of 
uptake of anticancer drugs such as cisplatin, as internalisation routes can 
affect uptake kinetics and intracellular location, thereby determining the 
fate, and resultant biological activity, of the molecule. Consequently there 
have been numerous recent studies into the cellular internalisation of this 
class of metal complexes and the progress in this area will now be reviewed. 
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1.5.1 MLCT light switch complexes 
In one of the earliest reported studies, the intercalator [Ru(bpy)2(taptp)]2+ 
(taptp = 4,5,9,18-tetraazaphenanthreno[9,10-b] triphenylene) was observed 
to act as an indicator of cell viability for both flow cytometry and confocal 
microscopy.76 This non-membrane-permeable complex was found to 
exclusively stain the nuclei of dead cells in a manner analogous to the dead 
cell stain propidium iodide (PI). A key early study in this area was 
conducted by Norden, Lincoln et al. where the potential of the liposome-
permeable, high DNA-affinity bisintercalating complex Δ-Δ [µ-C4(cpdppz)2-
(phen)4Ru2]4+ (Kb ~108 M-1) (cpdppz = 12-cyano-12,13-dihydro-11H-
cyclopenta[b]dipyrido[3,2-a:2’,3’-c]phenazine-12-carbonyl)77 to interfere 
with DNA metabolism was investigated by examining the uptake in V79 
Chinese hamster cells.78 The potential use of the complex as a nuclear DNA 
stain was clearly illustrated by the complex staining the chromosomes in 
fixed cells and using electroporation to facilitate membrane-diffusion in live 
cells (Figure 1.26). A low cytotoxicity over a 24 hour incubation time was 
observed, although at a higher concentration (100 µM) cell viability dropped 
to 55%. They suggested that a pinocytic mechanism of uptake was occurring 
due to small areas of low emission in the cytoplasm.  
 
 
Figure 1.26 a, Norden and Lincoln’s Ru(II) dimer. b, Image of chromosomes in 
fixed V79 Chinese hamster cell. Scale bar = 10 µm. c, Nuclear DNA stained in 
electroporated V79 cells. Scale bar = 20 µm.78 
a b c
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Having pioneered research into reversibly-binding metal polypyridine 
complexes, the Barton group turned their attention towards examining the 
cellular uptake properties of their well-characterised dppz DNA-binding 
systems using the MLCT light switch emission of the complexes to assess 
cellular uptake and localisation.79 Using flow cytometry and confocal 
microscopy, a series of Ru(II)dppz complexes were found to be internalised 
by the HeLa human cervical cancer cell line. They found that uptake  
efficiency was dependent on the nature of the ancillary ligands, with more 
hydrophobic ancillary ligands such as DIP (Figure 1.27a) promoting 
increased cellular uptake, consistent with a mechanism of passive diffusion 
into the cytosol (Figure 1.27b,c).80 A surprising result of this work was the 
absence of MLCT emission from the nuclei of cells (Figure 1.27d). A later 
study showed a fluorescein-tagged related complex to be “redirected” to the 
nucleus in comparison to the untagged complex. The fluorescein emission 
clearly demonstrated nuclear localisation of the complex but again no 
nuclear MLCT luminescence was observed.81  
 
Figure 1.27 a, Hydrophobic DIP ligand. b, [Ru(DIP)2(dppz)]2+. c, CLSM image 
showing cellular uptake of [Ru(DIP)2(dppz)]2+ in HeLa cells and emission intensity 
profile (d).79 
a b
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These results illustrated the main factor inhibiting the use of these 
complexes in cellulo; that of limited membrane-permeability. This is not 
surprising when we consider that such molecules are usually large, 
positively charged, hydrophilic and polar. In the attempt to produce 
membrane-permeable DNA-binding metal systems, research has seen the 
employment of hydrophobic ancillary ligands such as DIP, conjugation to 
biological molecules such as peptides or steroids, or a combination of both 
approaches. For example, Amoroso et al. used a rhenium fac-tricarbonyl 
bisimine system specifically designed for high hydrophobicity and their 
preliminary studies revealed high cytotoxicity but some in cellulo non-
specific MLCT fluorescence.82 Their subsequent work then showed a 
monocationic, small Re(I) fac-tricarbonyl bipyridine complex with a long 
luminescence lifetime and large Stokes shift to accumulate in mitochondria 
of MCF-7 cells, as demonstrated by colocalisation studies. The specific 
localisation within mitochondria upon internalisation was achieved using 
the addition of a chloromethyl group for thiol-reactivity (Figure 1.28).83 This 
illustrates how metal coordination complexes may be designed for specific 
intracellular targeting via ligand reactivity. 
 
 
Figure 1.28 a, Re(I) fac-tricarbonyl bipyridine complex functionalised with 
chloromethane group. b, Mitochondrial staining observable by CLSM and MLCT 
luminescence.83 
 
The Barton group used a cell-penetrating peptide to facilitate diffusion and 
nuclear uptake of a mismatch-specific rhodium intercalator although the 
a b
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specificity of the DNA binding was lost upon conjugation to the peptide.84 K. 
Lo et al. have designed luminescent probes based on polypyridine 
ruthenium complexes chemically attached to estradiol units, with the aim of 
functioning as biological probes for estrogen-receptors. The DIP ligand was 
employed in an ancillary role to increase hydrophobicity of the molecule 
and facilitate passive diffusion, with the results showing drug accumulation 
in the cytoplasm of HeLa cells as imaged by MLCT-luminescence (Figure 
1.29).85 Neugebauer et al. presented two polyarganine labelled ruthenium 
polypyridine complexes which display long lived, intense and oxygen-
sensitive luminescence, finding one of these complexes to be transported 
across the cell membrane by passive diffusion.86 
 
 
Figure 1.29 a, Steroid-conjugated Ru(II) complex. b, Uptake of steroid-
conjugated complex shows non-nuclear localisation.85 
 
In other work, Yu et al. showed two Ir(III) organometallic complexes to be 
phosphorescent dyes for live cell imaging. These two membrane-permeable 
molecules were internalised by cells rapidly (20 µM, 10 mins) where they 
located in the cytoplasm (Figure 1.30).87 Advantages of these systems are 
their large emission lifetimes and reduced photobleaching. Both complexes 
a
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display a large Stokes shift, with the complex containing the extended 
polypyridyl ligand (Figure 1.30c) possessing the greater Stokes shift (> 200 
nm); an example of how the emission properties can be tuned by subtle 
ligand modification. 
 
Figure 1.30 a, General structure of phosphorescent Ir(III) complexes.            
b, c, CLSM images of HeLa cells incubated with each Ir(III) complex.87  
 
1.5.2 Non-MLCT luminescent metal complexes 
Musatkina et al. presented a membrane-permeable Ru(II) complex (Figure 
1.31a) that acts as an effective DNA dye for living cells, with the complex 
remaining inside the cell for multiple days.88  
 
Figure 1.31 a, Dicarboxylic polypyridyl Ru(II) complex. b, Cellular DNA 
staining by the complex (outset) as confirmed by DAPI co-staining (inset).88 
a
b
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Using the DIP ligand to achieve cellular uptake, the mode of binding of the 
complex to DNA is electrostatic and via π–π stacking, with the carboxylated 
pyridine involved in the binding site. In this study, the monomers tested 
were not light switch complexes (i.e. they are luminescent before going into 
cells) so the signal to background noise ratio was inadequate for good 
contrast, but co-staining experiments using the commonly used DNA dye 
DAPI (4',6-diamidino-2-phenylindole) did prove the nucleus was being 
targeted (Figure 1.31b). The molecule has the advantage of low cytotoxicity, 
excitation in the visible area (λex = 450 - 490 nm) of the spectrum and a 
Stokes shift of 170 nm. 
 
Pascu et al. investigated the potential of Zn(II) and Cu(II) 
bis(thiosemicarbazonato) complexes as in cellulo probes (Figure 1.32).89 
They found that the intrinsically fluorescent Zn(II) complex is soluble in 
biocompatible media and is taken up by HeLa cells, where it is then 
observable throughout the cell by epifluorescence microscopy (λex = 330- 
380 nm, λem = 523-643 nm) and CLSM (λex = 488 nm, λem >515 nm). A later 
study showed such complexes demonstrate a toxicity of the same magnitude 
as cisplatin, apparently via mitochondria disruption.90  
 
 
Figure 1.32 a, Zn(II) bis(thiosemicarbazonato) complex. b, c, Epi- and CLSM 
fluorescence microscopy images of Zn(II) complex in HeLa (b) and MCF-7 
human breast cancer cells (c).89  
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Williams and co-workers have successfully developed charge-neutral 
platinum(II) complexes of the general formula [PtLCl] (where HL = 1,3-di(2-
pyridyl)benzene and derivatives) that display low cytotoxicity, microsecond 
lifetimes and high emission quantum yields, which have been examined for 
their cellular imaging potential.91, 92 They showed that [PtLRCl] (R = H, 
Figure 1.33a) is rapidly accumulated by a range of live cell types and 
preferentially localises in intracellular nucleic acid structures, in particular 
nucleoli (Figure 1.33b,c). The long lifetime of these platinum complexes 
makes them candidates for use in time-resolved emission imaging 
microscopy, a technique designed to eliminate the short emission lifetime 
autofluorescence. 
 
 
Figure 1.33 a, Pt(II) based imaging agent that displays nuclear staining in CHO 
Chinese hamster cells (b) with a microsecond lifetime emission (c).91 
 
1.5.3 Lanthanide complexes 
Cellular imaging using metal complexes is not limited to transition metal 
chemistry and lanthanide complexes have also been proposed as potential 
cellular imaging and biomolecular probes. The Parker group has conducted 
extensive research into the development of numerous lanthanide complexes 
towards cellular imaging agents. Their work has included the incorporation 
of a lanthanide metal centre (typically Eu(III) or Tb(III)) into a seven- or 
nine-coordinate ligand which acts as the sensitising chromophore.93-102 Fast 
energy transfer between the two then results in the luminescence emission 
a cb
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of the lanthanide.94 They have used this methodology to develop a wide 
range of emissive complexes that localise within various intracellular 
regions, including mitochondria99, 100 and nucleoli (Figure 1.34a-c).95-97 
Specifically for DNA-targeting, they showed that complexes containing 2-
tetraazatriphenylene, a ligand structurally similar to dppz, are taken up by 
N1H 3T3 cells and tend to localise inside the cell nucleus when a sufficient 
external concentration gradient is present (Figure 1.34d,e).93 For these 
cationic lanthanide systems, a common result was cellular uptake takes 
place via macropinocytosis101 although certain complexes were shown to be 
membrane-permeable.95 
 
 
Figure 1.34 a, Eu(III) complex that displays nucleolar luminescence in live (b) 
and fixed (c) N1H 3T3 cells.95 d, Eu(III) complex that stains the DNA of NIH 
3T3 cells (e). 93 
 
In other work on lanthanide-based systems, the Bunzli group have been 
developing highly luminescent lanthanide bimetallic helicates that consist of 
a b c
d e
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the three ligand strands self-assembled around two metallic centres as 
potential cellular imaging probes.103-106 These systems offer tunable 
chemical and photophysical properties, intense luminescence and low 
cytotoxicity. The helicates are stable chemical species which remain intact 
within the cell medium and cytosolic uptake and staining is observed. Using 
co-staining experiments, they suggested that the helicates enter the cells by 
endocytosis and are then are transported to the endoplasmic reticulum via 
lysosomes.106 
 
1.6 Summary 
Due to the biological significance of DNA, small molecules that bind to DNA 
find a variety of applications ranging from biomolecular imaging agents to 
anti-cancer therapeutics. Metal complexes, particularly d6 octahedral 
polypyridyl complexes that reversibly bind to DNA, offer an attractive 
scaffold for the design of specific probes of DNA structure and function. 
Their high binding affinities, structure- and sequence- specificities along 
with distinctive photophysical properties - such as acting as luminescent 
light switches for DNA - make such complexes ideal candidates for the 
development of highly sensitive and structure-specific DNA probes. As a 
result, there is now growing attention being drawn to their biological 
function(s), in particular developing these complexes as biomolecular 
probes for cellular applications. The luminescent properties of the 
complexes means that their cellular internalisation and in cellulo DNA 
binding can be directly measured using techniques such as confocal laser 
scanning microscopy and flow cytometry. 
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1.7 Aim of studies 
The aim of this thesis was to investigate the cellular internalisation and DNA 
targeting of luminescent Ru(II) systems developed by the Thomas group 
that bind reversibly to DNA in vitro. The ability of such complexes to act as 
molecular light switches for DNA means that in cellulo DNA binding and 
cellular uptake may be examined in high resolution by confocal laser 
scanning microscopy. The luminescent properties of these complexes mean 
that there exists the potential they may be used DNA imaging agents in cells 
and so the application of such complexes in cellular imaging for both live 
and fixed cell microscopy was explored. As such complexes have been 
designed to bind to DNA with a high affinity, they have potential to interfere 
with cellular process such as DNA replication and transcription, and so the 
cytotoxicity towards selected cancer cell lines was assessed. 
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Chapter 2 
Ru(II) metallo-intercalators 
 
2.1 Introduction 
Ever since the discovery that [Ru(bpy)2(dppz)]2+ and [Ru(phen)2(dppz)]2+ 
(bpy = 2,2’-bipyridine, dppz = dipyrido[3,2-a:2’,3’-c]phenazine, phen = 1,10-
phenanthroline) can intercalate into DNA with the characteristic activation 
of MLCT luminescence,1, 2 there has been a large amount of research into the 
in vitro DNA-binding properties of metallo-intercalators, especially those 
which contain dppz as the intercalating ligand and ruthenium(II) as the 
metal centre (Figure 2.1). This chapter is concerned with the in cellulo DNA 
binding properties and cytotoxicity of Ru(II) metallo-intercalators, including 
dppz-based systems. It describes work exploring their potential as 
luminescent DNA imaging agents in live and fixed cells and also as 
therapeutic agents. 
 
 
Figure 2.1 a, dppz intercalating ligand. b, Ru(II)dppz metallo-intercalator 
[Ru(N^N)2(dppz)]2+ containing two bidentate ancillary N^N ligands. 
 
a
dppz
b
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2.1.1 Ru(II)dppz complexes 
Work by the Thomas group has developed a series of achiral ruthenium-
dppz “light switch” systems that bind to DNA with a high affinity and 
sequence-specificity.3 Employing the tridentate tpm (tpm = tris-(1-
pyrazolyl)methane) “scorpionate” ligand to cap one face of the octahedral 
geometry, these complexes offer synthetic advantages over 
[Ru(N^N)2(dppz)]2+ systems, in particular a vacant coordination site which 
can be easily modified by substitution to modulate the DNA binding 
properties of the molecule as a whole (Figure 2.2). Indeed, 2D NMR binding 
studies on a series of related [Ru(tpm)(L)(dppz)]2+ complexes containing 
pyridine derivatives as the axial ligand, L, have revealed how the nature of 
this ligand has a profound effect on the DNA binding mode and affinity, even 
to the extent of preventing intercalation.4  
 
 
 
 
Figure 2.2 [Ru(tpm)(L)(dppz)]n+ metallo-intercalator. 
 
To examine the cellular internalisation and potential of these complexes in 
cellular DNA imaging applications, two such complexes were synthesised: 
[Ru(tpm)(NCMe)(dppz)]2+ [2.1] and  [Ru(tpm)(py)(dppz)]2+ [2.2], 
containing acetonitrile (NCMe) and pyridine (py) in the available 
coordination site respectively (Figure 2.3a). Both complexes have 
previously been demonstrated to bind to DNA with a high affinity (Kb = 
2.9×106  and 4.7×106 M-1 for [2.1] and [2.2] respectively) and to display the 
light switch effect upon intercalation (Figure 2.3b,c).3, 4 Each complex 
therefore represents a useful model for the investigation of the cellular DNA 
binding of this class of complexes. 
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Figure 2.3 a, [Ru(tpm)(L)(dppz)]2+ complexes relevant to this study where L = 
NCMe [2.1] or py [2.2]. b, Light switch effect of [2.2] upon addition of DNA.3 
c, Structure of [2.2] intercalated with DNA via the minor groove (PDB file 
courtesy of Dr P. Waywell). 
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2.1.2 Ru(II)tpphz complexes 
Not limiting this study to Ru(II) complexes containing the dppz intercalating 
ligand, the two metallo-intercalators [Ru(phen)2(tpphz)]2+ [2.3] and 
[Ru(bpy)2(tpphz)]2+ [2.4], both of which contain the tpphz (tetrapyrido[3,2-
a:2’,3’-c:3’’,2’’-h:2’’’,3’’’-j]phenazine) intercalating ligand (Figure 2.4),  were 
also investigated. In two almost identical studies, [2.4] was reported to 
show a high affinity for DNA (Kb = 8.8 × 106 M-1),5, 6 a higher affinity than 
that reported for the analogous dppz complex. The binding parameter 
estimates for [2.3] (Kb = 3.0 × 105 M-1)7 are comparable to those previously 
reported for [2.4], with [2.4] displaying the greater affinity for DNA.  
 
 
Figure 2.4 a, tpphz intercalating ligand. b, Ru(II)tpphz metallo-intercalators with 
either 1,10-phenanthroline [2.3] or bipyridine [2.4] as the ancillary ligands. 
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2.2 Synthesis 
2.2.1 Ru(II)dppz complexes 
The ligands tpm and dppz, through the intermediate dpq (1,10-
phenanthroline-5,6-dione), were synthesised by published procedures 
(Scheme 2.1).8, 9  
 
 
Scheme 2.1 a, Synthesis of tpm (yield = 33 %). b, Synthesis of dppz (overall 
yield = 30 %). 
 
The synthesis of Ru(tpm)Cl3 and [Ru(tpm)(Cl)(dppz)]+ were accomplished 
by adapted literature procedures (Scheme 2.2a).3, 10 Using 
[Ru(tpm)(Cl)(dppz)]+ as a precursor complex, the derivatives 
[Ru(tpm)(NCMe)(dppz)]2+ [2.1] and [Ru(tpm)(py)(dppz)]2+ [2.2] were 
synthesised by substitution of the chloride ligand with acetonitrile and 
pyridine respectively (Scheme 2.2b).3  
 
dppz
tpm
dpqphen
a
b
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Scheme 2.2 a, Synthesis of [Ru(tpm)(Cl)(dppz)]2+ precursor (overall yield = 17 
%). b, Synthesis of [2.1] and [2.2] (yields ranged from 45-77 %). 
 
Each complex was synthesised as their hexafluorophosphate salt and 
characterised by NMR and mass spectroscopy. They were converted into 
their water-soluble chloride salts by counter-ion metathesis.  
 
2.2.2 Ru(II)tpphz complexes 
[Ru(phen)2(tpphz)]2+ [2.3] and [Ru(bpy)2(tpphz)]2+ [2.4] and were 
synthesised according to published procedures and characterised by H. 
Derrat.7, 11 Both complexes were used as their chloride salts. 
 
 
 
 
 
L = NCMe [2.1]
py [2.2]
a
b
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2.3 Partition coefficients 
To traverse the cell membrane, a molecule needs to be hydrophobic enough 
to pass through the lipid bilayer but not so hydrophobic that it remains 
within the membrane. Generally, if a molecule is more polar than water it 
will be membrane-impermeable. The octanol/water partition coefficient, log 
P (Equation 2.1), is a ratio of the solubility of a molecule in the two solvents 
and thus provides a measure of the hydrophobicity/hydrophilicity of the 
molecule. Molecules with a negative log P are more soluble in the water 
phase and therefore are hydrophilic whereas a positive log P value indicates 
the molecule is more soluble in the octanol phase and therefore is 
hydrophobic. This in turn gives an indication of lipophilicity; lipophilic 
molecules will posses large octanol/water partition coefficients, although it 
should be noted a hydrophobic molecule is not automatically lipophilic. Log 
P is frequently used in addition with factors such as molecular weight to 
evaluate the drug-likeness of a compound in medicinal chemistry and 
pharmacology.12 Work by Puckett and Barton showed the cellular uptake of 
a series of Ru(II)dppz systems to be “lipophilicity”-based; by varying the 
ancillary ligand, complexes with a greater hydrophobicity were shown to 
display the greater uptake in cells.13 
 
water
octanol
wateroctanol
complex
complex
][
][
logPlog /  
Equation 2.1 Calculation of octanol/water partition coefficient log P. 
 
The octanol/water partition coefficients of [2.1] - [2.4] were measured 
using the “shake flask” method and the results are displayed in Table 2.1 
along with the mass of each complex, excluding the counter-ion, to provide a 
measure of the relative size of each complex. 
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Complex Mass / Da log P 
[Ru(tpm)(NCMe)(dppz)]2+ [2.1] 639 -1.19 ± 0.10 
[Ru(tpm)(py)(dppz)]2+ [2.2] 677 -0.74 ± 0.08 
[Ru(phen)2(tpphz)]2+ [2.3] 846 -1.24 ± 0.12 
[Ru(bpy)2(tpphz)]2+ [2.4] 798 -2.08 ± 0.15 
[Ru(phen)2(dppz)]2+  744 -1.48* 
[Ru(bpy)2(dppz)]2+ 696 -2.50* 
 
Table 2.1 Measured octanol/water partition coefficients for [2.1] - [2.4] along 
with complex mass. *[Ru(bpy)2(dppz)]2+ and [Ru(phen)2(dppz)]2+ are included for 
comparison.13 
 
As can be seen from Table 2.1, both [2.1] and [2.2] possess a negative log P 
value, indicating that they are more soluble in water than octanol and 
therefore hydrophilic, with the larger complex [2.2], which contains 
pyridine as the axial ligand, being the more hydrophobic. The log P values 
measured correlated well with data obtained via the molinspiration 
chemical properties calculation software.14 This log P calculation software 
was developed by fitting calculated with experimental log P values for more 
than twelve thousand drug-like molecules, to obtain hydrophobicity values 
for multiple fragments and group contributions. Although not able to 
calculate log P for coordination complexes, ligands may be directly 
compared if they have an equal denticity. As shown in Table 2.2, pyridine is 
more hydrophobic than acetonitrile (calculated log P values of 0.70 and 0.47 
respectively) and accordingly [2.2] is more hydrophobic than [2.1] by a 
similar order of magnitude.  
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The two Ru(II)tpphz systems display a greater hydrophilicity (log P = -1.24 
and -2.08 for [2.3] and [2.4] respectively) than the Ru(II)dppz complexes 
(Table 2.1). Although still strongly hydrophilic, each complex is more 
hydrophobic than its respective dppz analogue, as shown by the literature 
values for [Ru(phen)2(dppz)]2+ and [Ru(bpy)2(dppz)]2+ (-1.48  and -2.50  
respectively).13 This is in agreement with the calculated log P values for 
each intercalating ligand from Table 2.2, with tpphz displaying a greater 
hydrophobicity than dppz (log P = 4.18 and 3.70 for tpphz and dppz 
respectively). Accordingly, the difference in log P values between the 
relevant Ru(II)dppz and Ru(II)tpphz complex is a similar order of 
magnitude as the difference between the two intercalating ligands. 
 
Ligand Mass / Da Volume / Å3 log P 
NCMe 41 46 0.47 
py 79 80 0.70 
bpy 156 147 1.44 
phen 180 163 1.90 
dppz 282 243 3.71 
tpphz 384 323 4.18 
 
Table 2.2 Calculated ligand octanol/water partition coefficients, masses and 
molecular volumes. Log P and molecular volume values calculated using 
molinspiration property calculation software.14 
 
From these values, it would not be predicted that any of these complexes 
could diffuse across the cell membrane as they are large, polar, hydrophilic 
molecules; although for accurate quantification diffusion studies across an 
artificial membrane would be required.  
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2.4 Live cell uptake and imaging 
Since all complexes bind to duplex DNA with high affinity and display light 
switching effects their cellular uptake can, potentially, be measured by 
luminescent microscopy. Using this approach, each complex would be 
predicted to behave as a luminescent probe of cellular DNA if they are 
internalised and therefore the cellular uptake properties of each complex 
can be examined. To examine the potential of [2.1] - [2.4] for such a role, 
MCF-7 human breast cancer cells were incubated with solutions of each 
complex and the cellular uptake and in cellulo DNA binding was examined 
using CLSM (confocal laser scanning microscopy). CLSM is a high-resolution 
fluorescence imaging technique and offers numerous advantages over 
conventional fluorescence microscopy, in particular the ability to eliminate 
out-of-focus emission. For biological imaging, cells are usually labelled with 
organelle- or macromolecule-specific fluorescent dyes, although unlabelled 
samples may be viewed directly using phase contrast bright field imaging.  
 
In each individual case, the Ru(II) complex was excited at 458 nm using a 
He-Ne laser and the luminescence emission at 640-700 nm  (for [2.1] and 
[2.2]) or 600-640 (for [2.3] and [2.4]) recorded. These wavelengths 
correspond to 1MLCT excitation and the resultant 3MLCT emission observed 
from the corresponding in vitro DNA binding study.3, 6 These luminescent 
properties mean that each Ru(II) complex has a Stokes shift value of >150 
nm; a considerable advantage in an imaging context, as discussed in Section 
1.5. To determine the health of the cells after incubation, a standard 
live/dead staining procedure using the two commercially available dyes 
SYTO 9 (®) and propidium iodide (PI) was performed. SYTO 9 is a green-
emitting nucleic acid dye which stains the DNA and RNA of live cells, while 
the purple-emitting PI stains the DNA of non-viable cells upon intercalation. 
The live/dead staining properties of each molecule can essentially be 
explained in terms of membrane-permeability: SYTO 9 (log P = 0.93)15 is a 
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membrane-permeable molecule whereas PI (log P = -3.73)14 is membrane-
impermeable. These properties are implied by the respective 
hydrophobicity or hydrophilicity of each molecule. As the membrane of a 
dead cell is usually perforated, PI is able to enter and bind to nuclear DNA; 
therefore PI staining provides an indication of cell viability. In addition to 
nuclear staining, SYTO 9 generally shows mitochondrial staining as the 
molecule is able to diffuse into these organelles and bind to mitochondrial 
DNA. 
 
2.4.1 Ru(II)dppz complexes 
As shown by Figure 2.5, incubation of MCF-7 cells with [2.1] or [2.2] (200 
µM, 24 hrs) displays no in cellulo luminescence in either live or dead cells. 
 
Figure 2.5 CLSM of MCF-7 cells incubated with [2.1] (a) and [2.2] (b) (100 
µM, 24 hrs). From left to right: luminescence emission of [2.1] or [2.2] (red), 
live cell stain SYTO 9 (green), dead cell stain propidium iodide (PI) (purple) and 
phase contrast image. 
 
The absence of luminescence from live cells would be explained by a poor 
rate of cellular uptake and is not a surprising result; both molecules are 
SYTO 9 PI[2.1]
SYTO 9 PI[2.2]
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20 μm
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hydrophilic, relatively large and polar and so would not be predicted to be 
membrane permeable. However, the absence of luminescence in dead cells 
was unexpected; a non-membrane-permeable nucleic acid dye should 
behave in a manner analogous to PI, but the Ru(II)dppz complex is clearly 
not demonstrating this behaviour. This effect is highlighted in Figure 2.5b, 
where cells stained by PI show no emission due to [2.3]. The live/dead 
staining also shows that neither complex demonstrates significant toxicity, 
where the majority of cells remain viable under these incubation conditions. 
 
2.4.2 Ru(II)tpphz complexes 
In contrast to the achiral Ru(II)dppz systems, incubation of MCF-7 cells with 
Ru(II)tpphz complexes [2.3] and [2.4] does result in CLSM-observable in 
cellulo luminescence (Figure 2.6). Examining the cellular location of the 
emission in more detail, Figure 2.7 shows that in cellulo luminescence 
appears to be from non-nuclear locations, although the low emission signals 
makes further deductions difficult. 
 
Considering the lack of luminescence observed for each Ru(II)dppz complex, 
these results were especially encouraging. The DNA binding properties of 
metallo-intercalators is a much-researched area and developing molecules 
that bind with a high affinity and specificity to DNA is a key goal in this 
research. Such complexes can function as DNA imaging agents due to their 
favourable photophysical properties, which include: novel 
excitation/emission wavelengths, photostability, water solubility and 
chemical stability.  Additionally, nuclear accumulation of such complexes 
would indicate that they could have potential as therapeutics by interfering 
with various cellular processes such as transcription and translation. 
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Figure 2.6 a, b, CLSM imaging of MCF-7 cells incubated with Ru(II)tpphz 
complexes [2.3] (a) or [2.4] (b) (100 µM, 24 hrs). c, Negative control. From 
left to right: luminescence emission of Ru(II)tpphz complex (red), SYTO 9 
(green), PI (purple) and phase contrast image. 
 
 
Figure 2.7 Location of MLCT luminescence. Images of MCF-7 cells incubated 
with Ru(II)tpphz complexes [2.3] (a) or [2.4] (b) (100 µM, 24 hrs). The Ru(II) 
signal and phase contrast images are overlaid. 
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2.4.3 [Ru(phen)2(tpphz)]
2+ 
With the observation of in cellulo luminescence of [2.3], and in an attempt to 
improve the uptake and nuclear staining properties of the complex, staining 
experiments were repeated in serum-free conditions and the effects of 
concentration were also investigated. Co-staining experiments with 
currently used DNA stains were also carried out to investigate whether the 
molecule is imaging cellular DNA. 
 
2.4.3.1 Effects of serum and concentration 
Many currently used protocols in biology require serum-free conditions as 
serum proteins can bind to active molecules and so impede cellular uptake. 
It was found that serum-free media clearly improved the cellular uptake of 
[2.3] resulting in evidence of nuclear staining by the complex (Figure 2.8).  
 
Figure 2.8 CLSM of MCF-7 cells incubated with 100 µM [2.3] in serum-free 
media for 1 hr (a) or 3 hrs (b). Left: Ru(II)tpphz emission (red). Right: Overlay 
image of Ru(II)tpphz emission and phase contrast. 
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In an attempt to further increase nuclear staining, the concentration of the 
complex was increased to 200 µM and, as Figure 2.9a shows, this resulted in 
clearer apparent nuclear staining. Using this higher concentration, the 
nuclei of cells appear stained in both serum and serum-free conditions – 
with a greater uptake being observed in serum-free conditions (Figure 2.9b 
and Table 2.3). As no nuclear staining was observed at 100 µM for 24 hrs 
compared to multiple cell nuclei stained using 200 µM in a short space of 
time, this apparent non-linear behaviour of concentration v. time indicates 
the complexity of the cellular internalisation process of this complex. 
 
 
Figure 2.9 CLSM of MCF-7 cells incubated with 200 µM [2.3] in either serum-
containing media (a) or serum-free media (b) for 1 hr. Left: [2.3] emission (red). 
Right: Overlay image of [2.3] emission and phase contrast. 
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Conditions Nuclei stained / % 
Rel. emission 
intensity / % 
- serum 96 ± 3 100 
+ serum 93 ± 2 65 
 
Table 2.3 Extent of nuclear staining of MCF-7 cells by [2.3] (200 µM, 1 hr) in 
serum-free and serum-containing conditions. For relative emission intensity / cell, 
incubation in serum-free conditions used as 100 %. 
 
This demonstrates that factors such as: concentration, incubation time and 
the presence of media serum can determine the rate of cellular uptake and 
extent of nuclear staining (with the associated toxicity properties) of the 
complex. Clearly this is of relevance in the development of such systems for 
in cellulo applications. Indeed, in a recent study by Puckett and Barton the 
use of serum-free conditions was also found to optimise the uptake of 
luminescence ruthenium peptide conjugates.16  
 
2.4.3.2 Co-staining with nucleic acid stains 
Co-staining with the commonly used nuclear DNA marker stain DAPI 
(Figure 2.10) shows a strong overlap of the two emission signals (indicated 
by the white signal in Figure 2.10c), confirming that [2.3] is indeed targeting 
the nuclei and strongly suggesting that it is DNA being imaged. In contrast, 
co-staining with SYTO 9, which binds to RNA and mitochondrial DNA in 
addition to nuclear DNA, shows a much lower overlap of emission signals 
with [2.3] (Figure 2.11). As [2.3] requires intercalation to activate the light 
switch, binding to single stranded RNA would not be predicted to result in 
luminescence and so should not be observed in these experiments. These 
experiments also show staining by [2.3] is nuclear specific; for example, 
there is no apparent mitochondrial DNA staining. 
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Figure 2.10 a, Co-staining of [2.3] (red) with DAPI (blue). b, Negative control 
experiment. c, Co-localisation of [2.3] and DAPI emission signals (blue = region 
2, DAPI, red = region 1, [2.3], white = region 3, overlap).  
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Figure 2.11 a, Co-staining of [2.3] (red) with SYTO 9 (green). b, Negative 
control experiment. c, Co-localisation of [2.3] and SYTO 9 emission signals 
(green = region 2, SYTO 9, red = region 1, [2.3], white = region 3, overlap).  
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2.4.3.3 Emission profile 
To characterise the emission profile in more detail, a lambda stack 
experiment, which collects the emission intensity across a range of 
wavelengths, was conducted. A representative example shows the emission 
profile of [2.3] in the nuclei of cells to be relatively broad, with the 
maximum emission located at 620-630 nm (Figure 2.12). This is in good 
agreement with in vitro DNA binding luminescence titration data, where 
intercalation is accompanied by such emission,7 and offers further evidence 
that [2.3] is targeting cellular DNA in live cells. 
 
 
Figure 2.12 Emission profile of [2.3] in cellulo luminescence (right) from stained 
cell (left, highlighted in red). 
 
These results show a Ru(II) metallo-intercalator can target nuclear DNA in 
living cells and successfully demonstrates the use of Ru(II)-based MLCT 
luminescence in biological imaging. 
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2.4.3.4 Toxicity 
At longer incubation times the toxicity of the complex presents a problem, 
with the greater rate of cellular uptake and DNA staining by [2.3] being 
accompanied by an increase in cell death, as observable by positive staining 
by PI (Figure 2.13). 
 
 
Figure 2.13 CLSM of MCF-7 cells incubated with 200 µM [2.3] in serum-free 
media for 1 hr (a) or 3 hrs (b). From left to right: luminescence emission of 
[2.3] (red), SYTO 9 (green), PI (purple) and phase contrast image. 
 
When the concentration is increased even further (500 µM), this has the 
effect of killing all the cells in a short incubation time (~1 hr). This is evident 
by co-staining with PI, shown in Figure 2.14a. The co-staining with PI is in 
agreement with the DAPI co-staining data, providing further confirmation 
that [2.3] images cellular DNA.  Using a shorter incubation time at this 
concentration (30 minutes), cells initially appear healthy but, after removal 
of the complex and subsequent CLSM imaging, cell death is then observed 
20 minutes later (Figure 2.14b,c). This observation would suggest that it is 
the cellular internalisation of [2.3] that is directly responsible for the toxic 
effects observed.  
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Figure 2.14 CLSM of MCF-7 cells incubated with [2.3]. a, 500 µM, 1 hr. b, 500 
µM, 30 mins. c, 500 µM, 30 mins, cells then imaged 20 mins after removal of 
complex. From left to right: [2.3] (red), PI (purple), overlay (including phase 
contrast) image. 
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2.4.4 [Ru(bpy)2(tpphz)]
2+  
Applying the same strategy developed for [Ru(phen)2(tpphz)]2+ to achieve 
nuclear staining, cells were incubated with the bipyridine-analogous 
complex [2.4] at concentrations 200 µM or greater in serum-free medium. 
Although a much lower intensity luminescence is observed relative to [2.3], 
MCF-7 cells incubated with [2.4] in these conditions do display nuclear 
staining (Figure 2.15a). A higher concentration (500 µM) improves the 
amount of nuclear staining observed (Figure 2.15b) but even under these 
conditions the intensity of staining is inconsistent, with some cells 
displaying much more intense staining than others. The reason for this is 
unclear, but may be due to cell-to-cell variation in uptake activity, perhaps 
dependent upon cell cycle stage. Co-staining with PI reveals [2.4] to be less 
toxic than [2.3], with cells incubated with the former remaining viable using 
conditions that led to total cell death when [2.3] was used (Figure 2.15b and 
Figure 2.14a for [2.4] and [2.3] respectively). 
 
Figure 2.15 CLSM of MCF-7 cells incubated with [2.4]. a, 200 µM, 1 hr. b, 500 
µM, 1 hour. From left to right: luminescence emission of [2.4] (red), PI (purple), 
and overlay (including phase contrast) image. 
[2.4] PI overlay
20 μm
a
b
20 μm
[2.4] PI overlay
Chapter 2: Ru(II) metallo-intercalators 
70 
 
2.5 Fixed cell imaging 
Ideally, imaging experiments should involve minimal cell preparation 
methods so that the natural internal structure that exists within living, 
functioning cells can be preserved and examined. However, fixing and 
permeablising cells prior to staining is a commonly used technique for DNA 
imaging. The great advantage of this procedure is that it allows the use of 
non membrane-permeable stains and, for example, this can be used to 
identify DNA damage or cell cycle phase or facilitate the evaluation of 
properties of a new DNA stain. With this in mind, the ability of each Ru(II) 
metallo-intercalator to bind to DNA in fixed, membrane-permeablised cells 
was investigated. The resultant DNA binding was assessed using CLSM, with 
the same excitation/emission wavelengths parameters used for live cell 
imaging being employed. 
 
2.5.1 Ru(II)dppz complexes 
Experiments on ethanol fixed and membrane-permeablised MCF-7 cells 
incubated with [2.1] or [2.2] showed zero luminescence emission (Figure 
2.16), despite co-staining with propidium iodide confirming that cells had 
been rendered membrane-permeable. This was a surprising result 
considering that each compound is known to bind to DNA with a distinct 
luminescence signature. Experiments conducted without PI staining also 
displayed the same behaviour, eliminating the possibility that PI displaces 
the Ru(II)dppz complexes through competition for binding sites. The PI 
staining also shows the effect of fixation upon DNA structure, with the 
heterochromatin staining pattern appearing in a more condensed form 
around nucleoli than that observed in live cell staining.17 
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Figure 2.16 CLSM of fixed MCF-7 cells stained with [2.1] (a) or [2.2] (b) (100 
µM, 10 mins). Propidium iodide staining is included as a positive control for 
membrane-permeablisation. From left to right: luminescence emission of 
Ru(II)dppz complex (red), PI (purple) and phase contrast image. 
 
2.5.2 Organometallic Ru(II)dppz systems 
Given the surprising lack of MLCT luminescence from [2.1] or [2.2] in fixed 
and membrane-permeablised cells, two further achiral Ru(II)dppz systems 
were investigated as DNA stains in fixed cells (Figure 2.17).  
 
Figure 2.17 Organometallic [Ru(tpm)(L)(dppz)]n+ complexes, with L = CO (n = 
2) [2.5] or CN- (n = 1) [2.6].  
PI[2.1] phase
PI[2.2] phase
20 μm
20 μm
a
b
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Synthesised by A. Mlitan, these organometallic complexes contain either 
carbon monoxide [2.5] or cyanide [2.6] ligands in the free coordination and 
were found to bind to DNA via intercalation with a characteristic light 
switch emission.18 Both complexes emit at a lower wavelength than [2.1] 
and [2.2] and so the emission energy was adjusted to 600-650 nm 
accordingly. As shown in Figure 2.18, there is no luminescence from fixed, 
permeablised cells from either complex, strongly suggesting that neither 
complex is intercalated with cellular DNA and in agreement with the results 
observed for [2.1] and [2.2]. 
 
 
Figure 2.18 CLSM of fixed MCF-7 cells stained with [2.5] (a) or [2.6] (b) (100 
µM, 10 mins). From left to right: luminescence emission of Ru(II)dppz 
organometallic complex (red), PI (purple) and phase contrast image. 
 
These results indicate that the cellular location of these four Ru(II)dppz 
complexes is unobservable by CLSM even when the barrier of the cell 
membrane, and therefore a functional mechanism of cellular uptake, is 
PI[2.5] phase
PI[2.6] phase
a
b
20 μm
20 μm
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removed. The lack of MLCT emission is evidence that Ru(II)dppz complexes 
are not intercalating with cellular DNA. These experiments are also in 
agreement with the lack of emission of [2.2] observed in dead cells in 
Section 2.4.1. These experiments illustrate a significant drawback to using 
CLSM to investigate the cellular uptake of DNA light switch complexes: if 
there is no luminescence observed in fixed, permeablised cells then the 
complex clearly does not bind to cellular DNA with an associated light 
switch emission and therefore CLSM (or other fluorescence-based 
techniques) cannot be used reliably to investigate the cellular uptake of the 
molecule. 
 
2.5.3 Ru(II)tpphz complexes 
In contrast to Ru(II)dppz complexes, both [2.3] and [2.4] are excellent DNA 
stains in fixed cell conditions (Figure 2.19). When the barrier of transport 
across the cell membrane is eliminated, the luminescence emission of each 
complex is much brighter than that observed for live cell imaging and both 
complexes display similar levels of luminescence. This is in agreement with 
the hypothesis that it is the poorer rate of cellular uptake of [2.4] that is 
responsible for the lower staining observed in live cells in comparison to 
[2.3]. 
 
Figure 2.19 CLSM of fixed MCF-7 cells stained with Ru(II)tpphz complexes 
[2.3] (a) and [2.4] (b) (100 µM, 10 mins). 
[2.3] [2.4]
20 μm
a b
20 μm
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The addition of PI indicates that the cells are indeed permeablised and that 
the Ru(II)tpphz and PI signals show significant overlap, which would 
indicate that both molecules are bound to nuclear DNA (Figure 2.20). These 
experiments also demonstrate that Ru(II)tpphz complexes and PI may be 
used together without overlap of signals or quenching effects, which is a 
useful property as it allows the two stains to be used together in co-staining 
experiments. [2.3] and [2.4] additionally function as positive controls for 
the Ru(II)dppz experiments, suggesting that it is it is the difference between 
Ru(II)dppz and Ru(II)tpphz complexes that is responsible for the lack of 
MLCT luminescence observed for Ru(II)dppz complexes and not 
experimental error. 
  
Figure 2.20 CLSM of fixed MCF-7 cells stained with Ru(II)tpphz complexes 
[2.3] (a) or [2.4] (b) (100 µM, 10 mins). From left to right: luminescence 
emission of Ru(II)tpphz complex (red), PI (purple) and overlay image. c, Negative 
control. 
[2.3] PI overlay
20 μm
20 μm
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b
a
c
[2.3] PI overlay
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Other evidence that cellular DNA is successfully targeted includes the 
observation of condensed chromosomes of cells undergoing mitosis. Figure 
2.21 shows four distinct phases of mitosis observed through staining by 
[2.4]; prophase, where the chromosomes condense from chromatin; 
prometaphase, containing highly condensed chromosomes; metaphase, 
where the chromosomes align themselves at the centre of the mitotic 
spindle and prepare for separation; anaphase, where the two sets of sister 
chromosomes break apart into two separate regions which will become two 
daughter cells after cytokinesis; and telophase, which occurs post-
cytokinesis and involves the reversal of prometaphase and metaphase to 
form nuclei in each daughter cell. This is an example of how fixed cell 
imaging using luminescent DNA stains can be used to identify cell phase 
within a sample. 
 
Figure 2.21 A collection of fixed M-phase MCF-7 cells stained by [2.4] (100 
µM, 10 mins) showing the condensed chromosomes of several stages of mitosis.  
 
These experiments show that Ru(II) metallo-intercalators based on the 
tpphz intercalating ligand can function as luminescence DNA probes using 
the MLCT light switch effect in fixed cell imaging applications. This is in 
contrast to the results in this thesis for complexes based on the dppz 
intercalating ligand. 
 
 
prophase prometaphase anaphase telophasemetaphase
5 μm
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2.6 Cellular uptake mechanism 
As [2.3] and [2.4] are polar, positively charged and hydrophilic molecules, 
they are not predicted to passively permeate cell membranes. This is also 
suggested by the relatively high micromolar concentrations required for 
nuclear staining in live cells (200 µM or greater), compared to membrane-
permeable dyes such as DAPI, which are employed on the nanomolar scale 
(typically 200 nM). As luminescence provides an indication of the successful 
internalisation of each complex, the mechanism of uptake was explored 
using inhibition treatment and CLSM. 
 
MCF-7 cells incubated with [2.3] or [2.4] at 4°C resulted in no observable in 
cellulo luminescence in live cells, indicating active transport as the 
mechanism of cellular uptake for each and confirming neither molecule is 
membrane-permeable (Figure 2.22).  
 
Figure 2.22 CLSM of MCF-7 cells incubated with 200 µM [2.3] (a) and [2.4] 
(b) at 4°C for 1 hr in serum-free media.  
20 μm
20 μm
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b
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As one of the most common methods by which cells internalise membrane-
impermeable molecules is endocytosis, this specific mechanism of uptake 
was briefly examined using an inhibitor of this process. 
 
MCF-7 cells coincubated with [2.3] and the endocytosis inhibitor 
chloroquine, which prevents endosomal release by disturbing the pH 
balance between endosome and cytosol,19 clearly demonstrate nuclear 
uptake (Figure 2.23). Considering the concentration-dependency described 
in Section 2.4.3.1, and the results observed when the complex was incubated 
at 4°C, if endocytosis were the main mechanism of uptake then complete 
inhibition and no staining would be predicted to be observed (as observed 
in Figure 2.22a). These results would therefore suggest that the main 
mechanism of uptake does not occur by a receptor-mediated endocytic 
pathway. However, the toxicity of [2.3] combined with inhibitor toxicity (as 
evident in Figure 2.23a) made further study problematic. 
 
Figure 2.23 a, CLSM of MCF-7 cells coincubated with [2.3] (200 µM, 1hr) and 
endocytosis inhibitor chloroquine (100 µM). b, Negative control. PI staining is 
included to indicate cell viability. 
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b
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Successful uptake of both these hydrophilic, polar molecules via non-passive 
diffusion means that designing molecules specifically to enhance 
lipophilicity is not always required for successful cellular internalisation 
and in cellulo DNA binding of metal complexes. 
 
2.7 TEM studies 
In addition to these luminescence microscopy studies, which rely on DNA 
binding and subsequent activation of the MLCT light switch effect to observe 
the in cellulo location of the Ru(II) complex, transmission electron 
microscopy (TEM) may be employed to examine the cellular distribution of 
each complex in both live and fixed samples.  
 
TEM involves a sample being exposed to a beam of electrons: regions of high 
electronic density are able to scatter the electron beam while unscattered 
electrons pass through the sample and are detected by a fluorescent screen. 
This effect allows a contrast image of the specimen to be constructed. For 
biological imaging, ultra-thin cross-sections of cells are prepared and then 
stained with various staining agents, which usually contain a heavy metal 
capable of deflecting the electron beam. This enhances contrast and is the 
phenomenon exploited in the use of reagents such as immunogold labels, 
ruthenium red and osmium tetroxide. Figure 2.24a shows a cell stained with 
the lipid stain osmium tetroxide, where the molecule provides internal 
contrast by staining membranes. As would be predicted, in the absence of 
any contrast agent, no intracellular detail is observable (Figure 2.24b). Due 
to the smaller de Broglie wavelength of electrons than light, TEM is a higher 
resolution technique than light microscopy. 
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Figure 2.24 a, MCF-7 cell stained with osmium tetroxide. b, Negative control 
cell with no stain present. 
 
Since Ru(II) complexes incorporate a second row transition metal with a 
high electron density, these complexes can scatter the TEM electron beam; 
hence the localisation of the Ru(II) complex within cells can be determined 
through TEM with high spatial resolution. The advantage of this technique 
over CLSM is that the cellular location of the metallo-intercalator can be 
observed without the requirement of a specific binding event such as 
intercalation to activate the light-switch effect.  
 
 
 
 
 
 
 
b
2 μm
a
2 μm
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2.7.1 Ru(II)dppz complexes 
When MCF-7 cells are incubated with [2.2] using the same procedures used 
in live cell CLSM studies before preparation for TEM imaging no contrast 
effects are observable. This strongly suggests that the complex is not 
internalised by the cells. However, if the cells are fixed and permeablised 
before exposure to [2.2], TEM imaging clearly reveals cellular staining 
(Figure 2.25). As no other contrast agent was used, the observable contrast 
effects must therefore be due to [2.2]. Figure 2.25 shows that [2.2] is 
distributed throughout the cytosol and clearly located within the nucleus. 
 
Figure 2.25 TEM micrographs of fixed MCF-7 cells stained with [2.2] (100 µM, 
10 mins). 
 
As outlined in Section 2.5.1, CLSM studies showed no luminescence using 
the same conditions and yet TEM studies confirm the complex is indeed 
within the nucleus. Taken together, these results indicate that Ru(II)dppz 
systems may bind to cellular DNA through a non-intercalative mode and/or 
target another nuclear binding site, such as histone proteins. In either case, 
this suggests that the mode of binding does not shield the phenazine 
nitrogen atoms of the dppz ligand from water so that the light switch effect 
is not activated. Although an unexpected result, these observations shed 
light on a recent study by Puckett and Barton in which related membrane 
permeable Ru(II)dppz complexes are clearly internalised by cells, yet no 
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nuclear MLCT luminescence is observed.13 In a later study by the same 
group, a Ru(II)dppz complex was tagged with fluorescein and nuclear 
localisation demonstrated by fluorescein emission but no nuclear staining 
due to the Ru(II) complex was observed,20 strongly suggesting that the 
molecule is not intercalated with cellular DNA. In this context, this work - 
showing that the two Ru(II)dppz complexes do not interact with nuclear 
DNA in cells in the manner documented using in vitro luminescence 
titrations - has significant implications as metallo-intercalators containing 
the dppz moiety have been much studied as putative DNA-binding 
substrates; if their in cellulo properties are different to their behaviour in 
vitro, the development of such systems will be considerably hampered. 
 
2.7.2 Ru(II)tpphz complexes 
As shown in Section 2.4, both [2.3] and [2.4] are taken up by live cells. To 
further probe the intracellular location of [2.3], cells were incubated as for 
CLSM studies, and then fixed and examined using TEM. Figure 2.26 shows a 
MCF-7 cell strongly stained with [2.3], revealing that the complex is evenly 
distributed throughout the cytosol of the cell. Notably, the nucleus shows 
strong heterochromatin staining (Figure 2.26a,b), indicating that [2.3] 
possesses a high affinity for densely-packed DNA. Interestingly, the TEM 
micrographs show contrast signal from mitochondrial regions in addition to 
nuclear staining (Figure 2.26c), indicating that [2.3] is located within these 
organelles. The CLSM studies showed minimal luminescence from cytosolic 
regions, including mitochondria, which implies that the complex is not 
located within a hydrophobic region, such as bound to DNA. This in turn 
suggests that [2.3] is not bound to mitochondrial DNA and that the 
luminescence is only activated upon delivery of the molecule, and 
subsequent intercalation, at the DNA-rich nucleus. This could indicate the 
complex is bound to a non-DNA target (for example, if it were protein-
bound) or located within the space that divides the inner and outer 
membrane of mitochondria. 
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Figure 2.26 TEM micrographs of MCF-7 cells incubated with complex [2.3] 
(200 µM, 1 hr). a, Image showing even distribution of the stain throughout the 
cytosol. b, Detailed image of nucleus reveals clear heterochromatin staining. c, 
d, Detailed images revealing intracellular localisation and distinctive granular 
patterning of the distribution of [2.3] within the cytosol.  
 
Furthermore, [2.3] can be observed in small, distinct regions of the cytosol 
(Figure 2.26c,d). High magnification reveals these “dots” to be ~10 nm in 
diameter (Figure 2.26d) and are localised close to membranes (Figure 
2.26c). These dots also display evidence of internal structure, where they 
are aligned in rows, rather than dispersed randomly. This would suggest a 
relationship with a component of the cytoskeleton as opposed to the 
complex bound to free RNA or proteins within the cytosol. One suggestion 
would be that the dots are macromolecular-bound complex which are being 
a b
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0.1 μm0.2 μm
nucleus
mitochondria
c d
cell membrane
cell membrane
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transported along microtubule networks, however, further work would be 
required to investigate and develop this hypothesis.  
 
Cells fixed and permeablised before incubation with [2.3] show a similar 
distribution to that observed in live cells, although with less well-defined 
heterochromatin aggregation (Figure 2.27). Again, at high magnification, 
[2.3] can be seen to occupy distinct locations (as ~10 nm “dots”) within the 
cytosol (Figure 2.27c,d). 
 
 
Figure 2.27 TEM micrographs of fixed MCF-7 cells stained with [2.3] (100 µM, 
10 mins). a, Image showing even distribution of the stain throughout the cytosol 
and nucleoli are observable. b, c, d, Images revealing distinctive granular 
patterning of the distribution of [2.3] within the cytosol. 
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These results make [2.3] and [2.4] of interest as multifunctional DNA stains 
for use with both CLSM and TEM, a unique property of DNA-binding metal 
complexes. These results additionally demonstrate how TEM improves 
understanding of the intracellular location of the complex: as specific 
binding event need not occur for visualisation, the Ru(II) complex can be 
observed directly and at a higher resolution than offered by CLSM. 
 
2.8 Cytotoxicity 
2.8.1 MCF-7 cells 
As complexes [2.1] – [2.4] bind to DNA with a high affinity and two of these, 
[2.3] and [2.4], have been shown to target the nucleus upon cellular 
internalisation, they have potential to interfere with cellular process such as 
DNA repair, replication and transcription. Indeed, recent research has 
shown the recently commercialised DNA dye DRAQ5 (®) to adversely affect 
cellular function, with this intercalating organic molecule inhibiting DNA 
repair, replication and transcription by modifying the location and mobility 
properties of several DNA-binding proteins.21 With this in mind, toxicity 
towards the MCF-7 human breast cancer cell line was assessed through MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay and 
IC50 values (the concentration that would induce 50% cell death) thus 
obtained. The anti-cancer drug cisplatin was employed as a positive control.  
 
As can be seen by Figure 2.28 and Table 2.4, neither [2.1] or [2.2] 
demonstrate significant toxicity towards MCF-7 cells over a 24 hour 
incubation time (IC50 values of 190 and >200 µM respectively), with [2.1] 
being the more toxic of the two complexes. In contrast, the anti-cancer drug 
cisplatin is much more toxic towards the cell line, as reflected by its low IC50 
value (12 µM). These results are in agreement with the low rate of cellular 
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uptake, as observed by TEM, of each Ru(II)dppz complex. In contrast to 
[2.1] and [2.2], complexes [2.3] and [2.4] show IC50 values that are more 
comparable to cisplatin (Figure 2.29 and Table 2.4), with complex [2.3] 
displaying the higher toxicity towards MCF-7 cells (IC50 values of 36 and 53 
µM for [2.3] and [2.4] respectively). As the Ru(II)dppz complexes bind to 
DNA with a higher affinity than the Ru(II)tpphz complexes (Section 2.1), and 
this work has shown the Ru(II)tpphz complexes to demonstrate the greater 
rate of cellular uptake (Section 2.4), cytotoxicity therefore correlates more 
closely with the relative uptake of the complexes and not their overall 
binding affinity to DNA.  
 
 
Figure 2.28 Cytotoxicity of Ru(II)dppz complexes [2.1] and [2.2] towards 
MCF-7 breast cancer cells (24 hour incubation time). 
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Figure 2.29 Cytotoxicity of Ru(II)tpphz complexes [2.3] and [2.4] towards 
MCF-7 breast cancer cells (24 hr incubation time). 
 
Complex IC50 / µM 
[2.1] 190 ± 10 
[2.2] >200 
[2.3] 36 ± 3 
[2.4] 53 ± 7 
cisplatin 12 ± 2 
 
Table 2.4 IC50 values of Ru(II) metallo-intercalators towards the MCF-7 cell line 
(24 hour incubation time). 
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2.8.2 Cisplatin-resistant cancer cells 
While cisplatin remains the first step in treating a variety of cancers, 
including ovarian cancers, acquired drug resistance represents a key 
challenge in cancer treatment. As the mechanism of DNA-binding by [2.3] is 
different to cisplatin, binding by a reversible mechanism rather than 
irreversible, this complex offers potential as a lead for a new class of 
therapeutics. With this in mind, the toxicity of [2.3] and [2.4] towards 
A2780 human ovarian cancer cells and the derived cisplatin-resistant 
A2780-CP70 daughter cell line22 was investigated (Figure 2.30 and Table 
2.5).  
 
It was found that both complexes demonstrate a higher toxicity towards 
A2780 cells than that observed for MCF-7s, again with [2.3] demonstrating 
a greater toxicity than [2.4] (IC50 values of 11 and 36 µM respectively) with 
the IC50 value of [2.3] equal to that of cisplatin – Figure 2.29 and Table 2.5. 
Significantly, both [2.3] and [2.4] retain their cytotoxic potency towards the 
cisplatin-resistant A2780-CP70 cell line (IC50 values of 20 and 47 µM 
respectively) while, in contrast, cisplatin experiences a decrease in toxicity 
compared to the cisplatin-sensitive parental A2780 cell line (IC50 values of 
55 and 12 µM respectively). The IC50 values obtained for cisplatin are in 
agreement with the values reported in the literature.22 
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Figure 2.30 Cytotoxicity of Ru(II)tpphz complexes towards cisplatin-resistant 
cancer. a, b, Ru(II) tpphz complexes [2.3] (a) and [2.4] (b) show no decrease 
in toxicity for cisplatin-resistant CP70 ovarian cancer cells compared to parental 
cisplatin-sensitive A2780 cells. This behaviour is in contrast to cisplatin (c). 
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Complex 
IC50 / µM 
A2780 CP70 
[2.3] 11 ± 2 20 ± 5 
[2.4] 36 ± 6 47 ± 6 
cisplatin 12 ± 2 55 ± 8 
 
Table 2.5 IC50 values of Ru tpphz complexes and cisplatin towards MCF-7 
human breast cancer, A2780 cisplatin-sensitive ovarian cancer and A2780-CP70 
cisplatin-resistant ovarian cancer cell lines. 
 
2.9 Conclusions and future work 
In this chapter, the cellular DNA binding properties of four Ru(II) metallo-
intercalators, containing either dppz or tpphz as the intercalating ligand, in 
both live and fixed cells were investigated by a combination of CLSM and 
TEM microscopy while the cytotoxicity towards cancer cell lines was 
assessed. 
 
In contrast to their in vitro DNA binding, it was found that there was no 
observable in cellulo MLCT light switch effect from achiral Ru(II)dppz based 
systems in either live, non-viable or permeablised (fixed) cells. This is 
surprising as, even if they are not internalised by healthy cells, it would be 
expected that each complex would be able to intercalate and luminescence 
within non-viable and fixed cells. To further investigate the cellular location 
of Ru(II)dppz complexes, TEM studies on cells incubated before and after 
fixation, using the Ru(II)dppz complex as a contrast agent, were conducted. 
These studies revealed that, while there is no uptake in live cells, the 
complex was clearly located in the nucleus of fixed and permeablised cells. 
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Considering the absence of a luminescence light switch in fixed and 
permeablised cells (using CLSM) and evidence of nuclear location for cells 
treated using the same conditions using TEM, it was concluded that the 
complex is not intercalated with cellular DNA. These results indicate that 
the in cellulo DNA binding properties of the Ru(II)dppz complexes examined 
are different to their in vitro binding behaviour; this implies that only using 
CLSM to study the uptake properties of such complexes is not completely 
reliable. 
 
In contrast to Ru(II)dppz systems, studies on two Ru(II)tpphz systems, 
[Ru(bpy)2(tpphz)]2+ and [Ru(phen)2(tpphz)]2+, reveals that they are 
successfully internalised by the MCF-7 cell line, where they function as 
imaging contrast agents for both CLSM and TEM, a unique property of this 
class of metal complexes. CLSM and co-localisation studies with the DNA 
stains DAPI and PI strongly suggests that both complexes bind to nuclear 
DNA in live and fixed cells. TEM studies clearly show nuclear localisation of 
both complexes in fixed cells and a strong association with nuclear 
heterochromatin. Cells incubated with [Ru(phen)2(tpphz)]2+ before fixation 
show that the complex is uptaken by live cells. TEM imaging reveals that, in 
addition to the expected nuclear staining, the complex is distributed 
throughout the cytosol. It was concluded that binding to DNA is responsible 
for the nuclear luminescence observable by CLSM and the emission energies 
are in agreement with an intercalative mode of binding.  
 
Using CLSM in conjunction with inhibition treatment, the cellular uptake 
mechanism for each Ru(II)tpphz complex was shown to be via active 
transport, in agreement with the hydrophilicity of each complex, and a non-
endocytic pathway was suggested as part of these uptake studies. It was 
found that the complex incorporating phen ancillary ligands display a 
greater rate of cellular uptake compared to the bpy-based complex, possibly 
Chapter 2: Ru(II) metallo-intercalators 
91 
 
as a result of a molecule-specific binding event occurring during the uptake 
pathway.  
 
Cell viability studies and IC50 values, summarised in Table 2.6, show that 
both Ru(II)tpphz complexes display a significantly higher toxicity than the 
Ru(II)dppz complexes towards MCF-7 cells, reflecting their more efficient 
cellular uptake and live cell DNA binding properties. As shown by the 
compiled IC50 values, the phen complex displays a greater toxicity than the 
bpy complex, again suggesting that uptake of the complex is responsible for 
the observed toxicity. The Ru(II)tpphz complexes display cytotoxicity 
comparable to cisplatin and furthermore they retain toxicity against 
cisplatin-resistant tumour cells, thus signifying the potential of these 
complexes as dual function imaging/therapeutic agents.  
 
Complex log P 
IC50  / µM 
MCF-7 A2780 CP70 
[2.1] -1.19 190 ± 10 - - 
[2.2] -0.74 >200 - - 
[2.3] -1.24 36 ± 3 11 ± 6 20 ± 5 
[2.4] -2.08 53 ± 7 36 ± 6 47 ± 6 
cisplatin   -2.53* 12 ± 2 12 ± 2 55 ± 8 
 
Table 2.6 Compiled octanol/water partition coefficient and IC50 values of Ru(II) 
metallo-intercalators towards the MCF-7, A2780 and CP70 cancer cell lines (24 
hour incubation time). *Value obtained from Screnci et al.23 
 
 
Chapter 2: Ru(II) metallo-intercalators 
92 
 
Metallo-intercalators, especially those containing the dppz moiety, have 
been subject to a large amount of research into their DNA-binding 
properties, and so these results are of significance to the development of 
metallo-intercalators in intracellular applications, specifically showing that 
Ru(II)tpphz systems hold much greater potential than Ru(II)dppz systems 
for both imaging and therapeutic applications.  
 
The cytotoxicity properties of [2.3] and [2.4] are of great interest, 
particularly those of [2.3]. This complex, and further derivatives based on 
the tpphz intercalating ligand, offer great potential as leads for the 
development of a new class of multifunctional anti-cancer chemotherapy 
drug. Future work in this area will investigate the toxicity of [2.3] and [2.4] 
on a wider range of cancer cell lines. As both Ru(II)tpphz complexes bind to 
DNA via a different mechanism than platinum-based drugs, it seems that the 
mode of action is also different. To further investigate this hypothesis, 
studies into the mechanism of toxicity will be conducted.  A starting point 
would be to establish if [2.3] induces apoptosis by using commercially 
available apoptosis staining kits, and further assessing the toxicity by cell 
counting techniques. Of additional interest is the ability of this class of Ru(II) 
complexes to generate singlet oxygen, a potent cytotoxic agent.24 With this 
in mind, the phototoxicity of [2.3] would be examined and it would be 
hoped that toxicity would increase with exposure to light, a concept which 
would be of relevance to photodynamic therapy (PDT).  
 
Since the uptake mechanism also proved to be an undetermined form of 
active transport, further work to establish the exact mechanism could prove 
useful in the development of cancer specific therapeutics and also provide a 
probe for the identified transport mechanism. In particular, the flexible 
substituent chemistry of these complexes allows the synthesis of many 
Ru(II)tpphz derivatives allowing modulation of the DNA binding, 
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photochemical, cellular uptake and toxicity properties of the complexes by 
ancillary ligand substitution. Thus, a series of dual imaging/therapeutic 
molecules active against a wide range of cancers may be developed. 
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Chapter 3 
Dinuclear Ru(II)tpphz complexes 
 
Results within this chapter have been published as: 
M. R. Gill, J. Garcia-Lara, S. J. Foster, C. Smythe, G. Battaglia and J. A. Thomas, A 
ruthenium(II) polypyridyl complex for direct imaging of DNA structure in living cells, 
Nat. Chem., 2009, 1, 662-667.  
The full paper is included in the Appendix. 
 
3.1 Introduction 
In the previous chapter, mononuclear Ru(II)tpphz intercalating systems 
were found to display cellular uptake and to stain the nuclear DNA of living 
and fixed cells. To build upon the success of these complexes, the two 
dinuclear Ru(II)tpphz systems [{Ru(phen)2}2(tpphz)]4+ [3.1] and 
[{Ru(bpy)2}2(tpphz)]4+ [3.2] (Figure 3.1), which contain the tpphz ligand as 
a ditopic linker for two Ru(II) centres, were synthesised and the in cellulo 
DNA-binding properties examined using a combination of CLSM and TEM by 
the methodology developed in Chapter 2. 
 
Previous work conducted by the Thomas group has demonstrated both 
[3.1] and [3.2] to bind to duplex DNA with a higher affinity than any mono-
intercalating complex (Kb = 1.1×107 and 3.3×108 M-1 for [3.1] and [3.2] 
respectively) and additionally displayed a high affinity for G3 quadruplex 
DNA (Kb = 4.4×106 and Kb = 9.6×106 M-1 for [3.1] and [3.2] respectively).1 
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The light-switch effect was observed with both forms of DNA upon MLCT 
excitation with a large luminescence enhancement (>60 times) and, 
intriguingly, binding to quadruplex results in blue-shifted emission and 
greater emission lifetime compared to duplex binding (Figure 3.2a). This 
indicates that the complex has the potential to discriminate between 
different DNA structures spectroscopically.  
 
 
Figure 3.1 Dinuclear Ru(II)tpphz complexes, with either phen [3.1] or bpy 
[3.2] as the ancillary ligands. 
 
While it was initially thought that these complexes bind to duplex DNA by 
intercalation,1 a later study by C. Turro et al. demonstrated that [3.2] does 
not intercalate but binds to DNA via groove binding.2 These results 
therefore confirm earlier studies that intercalation is not a requirement for 
light-switch behaviour.3 Based upon these findings, the same mode of 
binding would be predicted for [3.1] due to the structural similarity of the 
two complexes.  
[3.1]
[3.2]
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As [3.1] and [3.2] each contain two chiral Ru(II) metal centres, three 
stereoisomers of each complex exist: ΛΔ (meso), ΛΛ and ΔΔ. 2D NMR 
binding studies on the resolved stereoisomers have provided evidence that 
the primary binding mode of these complexes to quadruplex DNA is by end 
stacking, with the central tpphz ligand of the complex bound to both the 
lateral and diagonal loop ends of the quadruplex structure (Figure 3.2b).4 
The high affinity for quadruplex DNA is of particular interest as small 
molecules able to induce/stabilise this non-duplex form of DNA hold 
particular attraction as a molecular target for new anti-cancer therapeutics, 
as previously discussed in Section 1.2.3. 
 
 
Figure 3.2 a, Luminescence emission for [3.2] when bound to duplex and 
quadruplex forms of DNA.1 b, Structural model from 2D NMR binding studies 
of [3.2] bound to quadruplex DNA.4 
a
b
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3.2 Synthesis 
3.2.1 Ligand synthesis 
The tpphz ligand was synthesised by a method described by Bolger et al. 
(Scheme 3.1).5 
 
Scheme 3.1 Synthesis of tpphz ligand (yield = 34 %). 
 
3.2.2 Complex synthesis 
The two precursor complexes Ru(phen)2Cl2 and Ru(bpy)2Cl2 were prepared 
as described by Sullivan et al. (Scheme 3.2a).6 They were then reacted with 
tpphz to produce the final products [{Ru(phen)2}2(tpphz)]4+ [3.1]  and 
[{Ru(bpy)2}2(tpphz)]4+ [3.2] , shown by Scheme 3.2b.1, 5 
 
Scheme 3.2 a, Synthesis of [Ru(N^N)Cl2] precursors (yields ranged from 61 - 
82 %). b, Synthesis of [3.1] and [3.2] (yields ranged from 64 – 85 %). 
tpphzdpq
= phen [3.1]
bpy [3.2]
a
b
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Both complexes were synthesised as their hexafluorophosphate salts and 
characterised by NMR and mass spectroscopy. They were converted into 
their water-soluble chloride salts by counter-ion metathesis using acetone 
solutions of tetrabuylammonium chloride. Each complex was used as a 
mixture of stereoisomers. 
 
3.3 Partition coefficients 
The octanol/water partition coefficients of [3.1] and [3.2] were measured 
using the “shake flask” method and the results are displayed in Table 3.1. 
The mass of each complex, excluding the counter-ion, is included to provide 
a measure of the relative size of each complex. The partition coefficients for 
the analogous mononuclear complexes [Ru(phen)2(tpphz)]2+ [2.3] and 
[Ru(bpy)2(tpphz)]2+ [2.4], as recorded in Chapter 2, are included for 
comparison. 
 
Complex Mass / Da log P 
[{Ru(phen)2}2(tpphz)]4+ [3.1] 1308 -0.96 ± 0.09 
[{Ru(bpy)2}2(tpphz)]4+ [3.2] 1212 -1.61 ± 0.10 
[Ru(phen)2(tpphz)]2+ [2.3] 846 -1.24 ± 0.12 
[Ru(bpy)2(tpphz)]2+ [2.4] 798 -2.08 ± 0.15 
 
Table 3.1 Measured octanol/water partition coefficients for [3.1] and [3.2]. 
The data for the analogous monometallic complexes [2.3] and [2.4] from 
Chapter 2 are included for comparison. 
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As shown by the log P values in Table 3.1, both [3.1] and [3.2] are 
hydrophilic molecules, with [3.2] the more hydrophilic of the two 
complexes. This is due to phen being a more hydrophobic ligand than bpy 
(log P = 1.44 and 1.90 for bpy and phen respectively7) as it has a greater 
aromatic surface area. 
 
Even though [3.1] and [3.2] each possess a formal 4+ charge, both 
complexes are more hydrophobic than their respective monometallic 2+ 
complexes [2.3] and [2.4]. The presence of the second Ru(II) centre for the 
dinuclear complexes decreases overall hydrophilicity as the tpphz ligand is 
now ditopic, increasing hydrophobicity as there are no uncoordinated 
nitrogen atoms available for hydrogen-bonding, and further hydrophobicity 
is provided by the two additional ancillary ligands. These two effects 
counteract the increase in charge, resulting in each dinculear complex 
displaying a greater hydrophobicity than the respective mononuclear 
analogue.  
 
Similarly to the complexes in Chapter 2, it would not be predicted that 
either [3.1] or [3.2] would be able to diffuse across the cell membrane as 
both are large, polar and hydrophilic molecules. 
 
3.4 Live cell uptake and imaging 
To examine the cellular uptake of the complexes MCF-7 cells were incubated 
with solutions of [3.1] and [3.2] and then imaged using CLSM. The 
excitation wavelength used was 458 nm and the emission measured at 670-
700 nm (Stokes shift >212 nm), corresponding to the previously observed 
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MLCT luminescent “light switch” effect of each complex binding to DNA in 
vitro.1  
 
MCF-7 cells incubated for 24 hrs with 100 µM of [3.1] or [3.2] displayed low 
levels of MLCT luminescence (Figure 3.3). The cellular location of the 
observed luminescence is clearly not from the nuclei of cells and these 
results are similar to the equivalent experiments for [2.3] and [2.4] (Section 
2.4.2). 
 
 
Figure 3.3 CLSM images of MCF-7 cells incubated with dinuclear Ru(II)tpphz 
complexes [3.1] (a) or [3.2] (b) (100 µM, 24 hrs). Left: Ru(II) emission. Right: 
Overlay image of Ru(II) emission and phase contrast. 
 
 
[3.2]
[3.1] overlay
overlay
a
b
20 μm
20 μm
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3.4.1 [{Ru(phen)2}2(tpphz)]
4+ 
Chapter 2 showed how an increase in concentration along with incubation 
in serum-free media can result in nuclear staining in a short incubation time 
by the active molecule so, accordingly, MCF-7 cells were incubated with 
[3.1] at concentrations 200 µM or greater and without the presence of 
serum in the incubation media, with the aim of improving cellular uptake 
and nuclear staining by the complex. 
 
3.4.1.1 Effects of serum and concentration 
As shown by Figure 3.4, when the concentration is increased to 200 µM and 
serum-free conditions are employed low levels of nuclear staining by [3.1] 
are now observable. 
 
 
Figure 3.4 CLSM of MCF-7 cells incubated with 200 µM [3.1] in serum-free 
media for 1 hr (a) or 3 hrs (b). Left: [3.1] emission (red). Right: Overlay image 
of Ru(II) emission and phase contrast. 
overlay[3.1]
20 μm
overlay[3.1]
a
b
20 μm
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The luminescence intensity is much lower than that observed for the 
equivalent experiments for [2.3] (Section 2.4.3.1). As both complexes 
display a comparable increase in luminescence with the addition of DNA and 
similar binding affinities,1, 8 this is therefore most likely due to a poorer rate 
of cellular uptake (resulting in a reduced nuclear accumulation) of [3.1] in 
comparison to [2.3]. As [3.1] is more hydrophobic than [2.3], this effect 
therefore is not solely an effect of hydrophilicity – factors such as the higher 
charge and greater steric bulk of the molecule could well be responsible for 
the decreased uptake in comparison to [2.3]. 
 
To attempt to further increase the uptake and improve the nuclear 
accumulation of [3.1], the incubation concentration was increased to 500 
µM and, as Figure 3.5 shows, at this high concentration there is now strong 
nuclear staining observable in MCF-7 cells. The emission at 670-700 nm 
corresponds to activation of the well-documented “light switch” effect upon 
reversible binding to DNA. This high incubation concentration does not 
compromise cell viability, as shown by the positive SYTO 9 and negative PI 
staining. 
 
When cells were incubated with 500 µM [3.1] for 1 hr in either serum-
containing or serum-free media the effect of serum inhibiting uptake is 
apparent (Figure 3.5 and Table 3.2). This effect was also observed for [2.3] 
although serum inhibition is more pronounced for [3.1]. These effects 
would be in agreement with an overall poorer rate of cellular uptake of the 
dinuclear complex compared to its mononuclear analogue and these results 
further establish the use of serum-free media in conjunction with a high 
incubation concentration as a successful strategy to attain nuclear 
localisation of Ru(II) complexes. 
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Figure 3.5 a, b, CLSM of MCF-7 cells incubated with 500 µM [3.1] in either 
serum-containing media (a) or serum-free media (b) for 1 hr. c, Negative 
control. From left to right: luminescence emission of [3.1] (red), SYTO 9 
(green), PI (purple) and phase contrast image. 
 
Conditions Nuclei stained / % 
Rel. emission 
intensity / % * 
- serum 98 ± 3 100 
+ serum 60 ± 4 35 
 
Table 3.2 Extent of nuclear staining of MCF-7 cells by [3.1] (500 µM, 1 hr) in 
serum-free and serum-containing incubation conditions. Minimum of 200 cells 
counted for each experiment. *For relative emission intensity / cell, incubation in 
serum-free conditions used as 100 %. 
 
SYTO 9 PI[3.1] overlay
SYTO 9 PI[3.1] overlay
SYTO 9 PIcontrol overlay
20 μm
20 μm
20 μm
a
b
c
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The live/dead co-staining also demonstrates that the dinuclear complex 
[3.1] is less toxic than the mononuclear analogue [2.3]. The equivalent 
experiment for [2.3] caused total cell death (Section 2.4.3.4), in comparison 
to [3.1] which does not appear to compromise cell viability (Figure 3.5), as 
shown by the relevant PI co-staining after incubation with each complex. 
However, when cells were incubated with [3.1] for longer incubation times 
this did affect cell viability, indicating that there are more subtle toxic effects 
that need to be considered. As the ability not to induce cell death upon 
uptake and nuclear staining is an advantage in live cell microscopy, [3.1] 
therefore displays more favourable properties than [2.3] in this capacity. 
 
3.4.1.2 3D luminescence location 
To examine the location of the observed MLCT luminescence in 3 
dimensions, a z-stack image, which takes a series of 2D images at different 
depths within the sample, was taken. Figure 3.6a shows that the observed 
[3.1] luminescence is near-spherical in three dimensions, corresponding to 
the cell nucleus. Co-staining with SYTO 9 was used as a reference stain to 
confirm the intracellular location of [3.1] (Figure 3.6b). 
 
Figure 3.6 a, CLSM z-stack showing 3D location of in cellulo [3.1] 
luminescence. b, As for a with accompanying SYTO 9 staining for reference. 
   
y
z
xz
20 μm20 μm
y
z
xz
a b
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3.4.1.3 Co-staining with nucleic acid dyes 
Higher resolution imaging and co-staining with other commercially 
available fluorescent nucleic acid stains suggest that [3.1] is targeting 
nuclear DNA. Incubation of MCF-7 cells with [3.1] and co-staining with the 
commonly used DNA dye DAPI shows a strong overlap of the two emission 
signals (Figure 3.7).  This is confirmed in co-localisation studies, where the 
two emission signals show a high degree of co-localisation – as shown by the 
region labelled white in Figure 3.8. 
 
Figure 3.7 a, b, Co-staining of [3.1] (red) with DAPI (blue) and overlay image. 
c, Negative control.  
 
DAPI[3.1] overlay
DAPIcontrol overlay
DAPI[3.1] overlay
20 μm
20 μm
10 μm
a
b
c
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Figure 3.8 Co-localisation of [3.1] and DAPI emission signals (blue = region 2, 
DAPI, red = region 1, [3.1], white = region 3, overlap). 
 
Conversely, co-staining with the cyanine dye SYTO 9, a general nucleic acid 
stain, shows a clear difference in cellular localisation of the two emission 
signals (Figure 3.9). Notably SYTO 9 binds RNA in addition to DNA and, as a 
consequence, nucleoli, the site of rRNA synthesis and tRNA processing, are 
distinctly imaged through the dye’s intense green emission. It is clear that 
[3.1] is a DNA-specific stain as, in contrast to SYTO 9, no emission from the 
complex is observed from nucleoli regions. SYTO 9 also labels 
mitochrondrial DNA and it is clear that there is no non-nuclear 
luminescence due to [3.1], making [3.1] a nuclear DNA specific imaging 
agent when using these incubation conditions. The co-localisation studies 
with [3.1] and SYTO 9 clearly illustrate this behaviour; the overlap of the 
emissions from each molecule is minimal and is restricted to the 
nucleolus/nucleus boundary (Figure 3.10). 
 
 
20 μm
overlap
D
A
P
I
[3.1]
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Figure 3.9 a, b, Co-staining of [3.1] (red) with SYTO 9 (green) and overlay 
image. c, Negative control. 
 
10 μm
SYTO9[3.1] overlay
SYTO9control overlay
20 μm
20 μm
[3.1] SYTO9 overlay
a
b
c
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Figure 3.10 Co-localisation of [3.1] and SYTO 9 emission signals (green = 
region 2, SYTO 9, red = region 1, [3.1], white = region 3, overlap). 
 
3.4.1.4 Visualisation of mitotic chromosomes 
In addition to these co-localisation studies, analysis of cells stained with 
[3.1] indicate that this molecule reports the characteristic structural 
changes in nuclear DNA as cells progress through the cell cycle, furthermore 
establishing the complex as a DNA-specific stain. When asynchronous cells 
are imaged the majority of labelled cells are in interphase but cells 
undergoing mitosis (~5%) are also clearly observed. Figure 3.11 shows the 
mitotic phases shown stained by [3.1] including; prophase, where the 
duplicated chromosomes begin to condense; prometaphase, where the 
nuclear envelope breaks down and sister chromatids may be  visualised; 
and metaphase, where the chromosomes align themselves at the centre of 
the mitotic spindle and prepare for separation. 
 
Figure 3.11 A collection of mitotic cells stained by [3.1] visualising 
chromosome aggregation through progression of m-phase. 
10 μm
overlap
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To image condensed chromosomes in more detail, cells were halted in 
prometaphase using colchicine, which acts as a mitotic spindle poison and 
arrests mitosis,9 stained with [3.1] and then mounted onto slides before 
imaging. This technique allows clear visualisation of the aggregated 
chromosomes (Figure 3.12). 
 
 
Figure 3.12 High magnification images of mitotic cells showing individual 
chromosomes stained by [3.1]. 
 
3.4.1.5 A structure-sensitive DNA imaging agent 
One application in using such systems as cellular DNA probes is their ability 
to display a high degree of sensitivity in their DNA binding. For example, 
there is currently a great deal of interest in four stranded DNA structures, 
such as quadruplexes. As discussed in Section 1.1.7, the 
induction/stabilisation of quadruplex DNA in G-rich sequences of DNA 
located at the ends of chromosomes (telomeres) is seen as a potential anti-
cancer strategy but nevertheless, to date, the actual detection of quadruplex 
formation in living cells has remained elusive. Previous in vitro studies have 
demonstrated that [3.1] binds to both duplex and quadruplex DNA with a 
high affinity, displaying a distinctive blue-shifted “light-switch” emission for 
quadruplex binding in comparison to the analogous duplex effect (maxima 
of 630 nm and 660 nm respectively).1 This indicates that [3.1] has the 
2 μm
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ability to discriminate between different DNA structures and, along with the 
demonstration of successful nuclear uptake, the potential of [3.1] as a 
quadruplex DNA imaging tool was explored. 
 
It was found that “light switch” emission due to the DNA bound complex 
within cells is comprised of two separate emission peaks. Lambda stacking 
experiments revealed maxima at approximately 680 and 630 nm 
respectively (Figure 3.13). 
 
 
Figure 3.13 a, Lambda stacking experiments show the emission profile of [3.1] 
in live MCF-7 cells to be composed of multiple emission peaks. The emission 
profile of two separate cellular regions (labelled red and blue) show these peaks 
to have maxima of approximately 630 and 680 nm. b, CLSM using two separate 
detection channels 670-700 nm (red) and 630-640 nm (yellow) show the 
multiple emission profile of nuclear luminescence of [3.1] bound to DNA and 
the specific localisation of the 630-640 nm emission. 
670-700 nm 630-640 nm overlay
20 μm
a
b
Chapter 3: Dinuclear Ru(II)tpphz complexes 
113 
 
A representative Lambda stack displaying the emission profile of two 
separate regions in cells reveals the non-uniform specificity of the 630 peak 
in comparison with the prevalent 680 peak (Figure 3.13a), suggesting that 
the 630 emission is from a different source. In order to observe the cellular 
localisation of each of the signals the image acquisition process was 
calibrated by defining separate 670-700 nm (coloured red) and 630-640 nm 
(coloured yellow) channels. Figure 3.13b shows that, using this setup, it is 
clear that while the red emission shows the expected nuclear chromatin 
staining, the yellow emission is localised in specific areas within nuclei and 
is not co-localised with the red emission.  
 
To determine whether this effect was due to a non-duplex structure of DNA 
being imaged we explored the ability of [3.1] to induce/stabilise alternative 
forms of DNA by using formaldehyde fixation. This produces DNA-protein 
crosslinks and has the effect of “freezing” DNA structure.10 Using the novel 
imaging properties of the complex as a marker stain, fixed cell experiments 
were conducted; with MCF-7 cells being exposed to [3.1] before and after 
fixation. The incubation of fixed, permeablised cells with [3.1] resulted in 
only the 680 nm emission being visible, with no detectable 630 nm peak 
(Figure 3.14). This would be in agreement with [3.1] being incapable of 
inducing DNA structural changes after fixation, resulting in the single 680 
nm emission arising from [3.1] binding to native duplex DNA observed.  
 
In contrast to this behaviour, when cells were fixed in an identical manner 
after incubation with [3.1] the distinctive multiple emission profile is 
maintained (Figure 3.15). We suggest that these results show that [3.1] 
induces/stabilises multiple structures of DNA in cellulo and that the 630 nm 
emission is due to an alternative non-duplex DNA structure.  
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Figure 3.14 a, Lambda stacking experiment of [3.1] in fixed MCF-7 cells 
displays only the 680 nm emission peak. b, CLSM imaging experiment for fixed 
cells show only the 670-700 nm red emission is present. 
 
 
Figure 3.15 MCF-7 cells fixed after incubation with [3.1] show the distinctive 
multiple emission properties as for live cell imaging is retained. 
 
 
670-700 nm 630-640 nm overlay
20 μm
a
b
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In an attempt to further define the nature of the 630 nm emission, we 
selected the L5178Y-R mouse lymphoma cell line for further imaging 
experiments. This cell line has a large average length of G-rich telomeric 
DNA (80 kb compared to 2 kb in MCF-7 cells)11 and therefore exhibits a 
greater potential for quadruplex formation. As shown in Figure 3.16a, the 
staining of these cells by [3.1] results in a large increase in the yellow 630-
640 nm emission compared to the MCF-7 cell line. Interestingly, this image 
also includes a mitotic cell showing three intense yellow points, apparently 
located at specific regions on the chromosomes (Figure 3.16b). This data 
would be in agreement with [3.1] functioning as a luminescent marker for 
quadruplex DNA, representing the exciting possibility that [3.1] can be used 
as an in cellulo imaging agent for this DNA structure. 
 
 
                 
Figure 3.16 a, CLSM of L5178Y-R cells incubated with [3.1] (200 M, 30 mins) 
display a large increase in 630-640 nm emission. b, L5178Y-R metaphase 
chromosomes showing specific localisation of the 630-640 nm emission peaks. 
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3.4.1.6 Cell adherence and extended imaging time 
An unexpected property of [3.1] is that the complex causes strong cell 
adherence: cells treated with the complex are then unable to be detached 
from the surface - even the application of 1% v/v Trypsin/PBS a for a period 
of 1 hr (usually used at 0.1% for 2 minutes) failed to detach the cells. In an 
imaging context, this adhesion effect is an advantage: cells incubated with 
[3.1] were imaged at regular intervals for 4 hours after removal of the 
complex and cell media. To preserve cell hydration, the cells were covered 
with a layer of PBS and Figure 3.17 shows that the majority of cells 
remained attached with minimal loss in the imaging quality and the nuclei of 
cells appear to remain intact. Untreated control cells were observed to 
detach in approximately 1 hour under these conditions. 
 
 
Figure 3.17 CLSM of MCF-7 cells incubated with [3.1] (500 M, 1 hour) 
showing luminescence emission 2 and 4 hours after removal of the complex. 
 
This cell adherence effect was also observed by Schatzschneider et al. for 
the Ru(II) DNA binding system [Ru(bpy)2(dppn)]2+, which contains the 
extended intercalating ligand dppn (benzo[i]-dipyrido[3,2-a:2’,3’-
c]phenazine) - Figure 3.18.12 Strong cell adherence was observed in their 
studies and they suggested that the complex may modify the cell-cell or cell-
matrix adhesion properties. Considering the same effect was observed for 
[3.1], this effect may be a general property of metal polypyridyl complexes. 
+ 4 hrs+ 2 hrs
20 μm
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Figure 3.18 Metallo-intercalator [Ru(bpy)2(dppn)]2+ 
 
3.4.1.7 Bacterial imaging 
In addition to these studies on the uptake of [3.1] by eukaryotic cells, 
experiments performed by Dr J. Garcia-Lara are also able to show that [3.1] 
is internalised by the bacteria Staphylococcus aureus (S. aureus) in vivo; the 
first time prokaryotic cells have been directly imaged using a metal-based 
system (Figure 3.19). 
 
 
Figure 3.19 S. aureus bacteria cells stained by [3.1]. Experiment performed by 
Dr J. Garcia-Lara. 
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3.4.2 [{Ru(bpy)2}(tpphz)]
4+ 
In contrast to [3.1], the incubation of MCF-7 cells with [3.2] and subsequent 
imaging showed no staining of live cells under the same conditions (Figure 
3.20). Using these conditions, [3.2] is an efficient indicator of cell mortality, 
as shown by co-staining with PI in Figure 3.20b. Indeed, in live/dead 
staining applications it functions in a manner identical to PI but with novel 
excitation/emission wavelengths.  
 
Figure 3.20 CLSM of MCF-7 cells incubated with 500 µM [3.2] for 1 hr. a, No 
uptake of [3.2] is observed in live cells. b, [3.2] is an effective dead cell stain by 
co-localisation with PI emission. From left to right: luminescence emission of 
[3.2] (red), SYTO 9 (green), PI (purple) and phase contrast image. 
 
At longer incubation times (500 µM, 6 hrs) nuclear staining by [3.2] is 
observed the intensity of this staining is inconsistent, with only a small 
number of cells observed to be stained weakly (Figure 3.21). As both [3.1] 
and [3.2] display a comparable increase in luminescence when bound to 
DNA, along with similar affinities for DNA (in fact [3.2] binds DNA more 
strongly than [3.1]),1 the poorer nuclear staining properties of [3.2] are 
therefore most likely due to a lower rate of cellular uptake of [3.2] 
compared to [3.1].  
SYTO 9 PI[3.2] overlay
SYTO 9 PI[3.2] overlay
20 μm
20 μm
a
b
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Figure 3.21 CLSM images of MCF-7 cells incubated with 500 µM [3.2] for 6 
hrs. Left: Ru(II) emission. Right, Overlay image of Ru(II) emission and phase 
contrast. 
 
3.5 Fixed cell imaging 
The ability of each dinuclear Ru(II)tpphz complex to bind DNA in fixed and 
membrane-permeablised cells was investigated using CLSM to observe the 
resultant DNA binding. The same excitation/emission wavelength 
parameters as for live cell imaging were used.  
 
Figure 3.22 CLSM of fixed MCF-7 cells stained with [3.1] (a) or [3.2] (b) (100 
µM, 10 mins). From left to right: luminescence emission of Ru(II) complex (red), 
phase contrast and overlay image. 
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As shown by Figure 3.22, both [3.1] and [3.2] are excellent DNA stains for 
fixed, permeablised cells. Figure 3.23 shows fixed MCF-7 cells stained with 
either [3.1] or [3.2] at a higher magnification and sub-nuclear chromatin 
structure is clearly observed. These results make both complexes of interest 
as DNA stains in fixed cell applications. As both complexes display similar 
levels of luminescence when bound to DNA in vitro1 and Figure 3.23c shows 
this to be the case in fixed and permeablised cells, this strongly suggests that 
it is the reduced efficiency of cellular uptake of [3.2] that is responsible for 
the lower staining observed in live cell experiments in comparison to [3.1] 
and not an inability of [3.2] to bind to DNA with activation of luminescence. 
 
Figure 3.23 CLSM of fixed MCF-7 cells stained with Ru(II) complexes [3.1] (a) 
or [3.2] (b) (100 µM, 10 mins). c, Relative emission intensity of [3.1] and [3.2] 
in fixed cells. 
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3.6 Cellular uptake mechanism 
The hydrophilicity and high charge of [3.1] would imply that the molecule 
does not freely diffuse across the cell membrane, a property reflected by the 
relatively high concentration required for efficient uptake. With this in 
mind, the mechanism of cellular uptake of [3.1] was investigated using the 
luminescent properties of the complex as an indication of successful cellular 
uptake. 
 
3.6.1 Temperature-dependence 
To probe whether [3.1] was taken up by a passive- or active-transport 
mechanism, MCF-7 cells were incubated with [3.1] at a temperature of 4°C. 
Figure 3.24 shows that no luminescence is observed when the cells are 
incubated with the complex at this temperature, indicating that [3.1] enters 
cells and targets the nucleus by a temperature-dependent pathway and 
confirming [3.1] is not a membrane-permeable molecule.  
 
Figure 3.24 Temperature-dependence studies of uptake of [3.1] by MCF-7 
cells. a, Cells incubated with [3.1] (500 M, 1 hour) at 4°C display no in cellulo 
luminescence. b, 37°C control. The phase contrast image is included for 
reference. 
PI[3.1] phase
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b
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3.6.2 Endocytosis inhibitors 
To investigate if the mechanism of uptake involved an endocytic pathway, 
cells were co-incubated with [3.1] and several well-documented inhibitors 
of this process. Cellular uptake was then assessed by the extent of resultant 
nuclear staining by luminescence microscopy (Figure 3.25). 
 
Co-incubation with [3.1] and the general endocytosis inhibitors chloroquine 
or ammonium chloride (two lysosomotropic agents which prevent the 
maturation of endosomes)13, 14 had no effect on the ability of [3.1] to 
function as a nuclear stain (Figure 3.25a,c,d). Co-incubation with the specific 
endocytosis inhibitors chlorpromazine (which disrupts the assembly of 
clathin lattices)15 or filipin (which prevents the formation of caveolae)16, 
which inhibit clathrin- and caveolae-mediated endocytosis respectively, do 
not inhibit the uptake of [3.1], showing that these two well-studied 
endocytic pathways are not responsible for the uptake of [3.1] (Figure 
3.25a,e,f) Furthermore, neither colchicine or nocodazole, which disrupt the 
polymerisation of microtubules and thus prevent membrane and endosomal 
trafficking,17 showed any inhibition of uptake (Figure 3.25a,g,h), suggesting 
that membrane trafficking in any form does not contribute to the process by 
which [3.1] is taken up into MCF-7 cells.  Consistent with these 
observations, our measurements of the lipophilicity of [3.1] show that the 
molecule remains hydrophilic under the mildly acidic conditions found in 
early endosomes (log P = -0.77 at pH 5 – Table 3.3) and would be unlikely 
therefore to diffuse across an endosomal membrane to gain access to the 
cytosol and subsequently the nucleus. Taken together, these results suggest 
a non-endocytic mechanism of cellular uptake by MCF-7 cells. 
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Figure 3.25 a, Relative luminescence intensity of [3.1] in MCF-7 cells after 
inhibition treatment (500 M, 1 hour). *Error bars represent ± standard error of 
the mean (SEM) with n = 3. b - h, CLSM images of MCF-7 cells incubated with 
[3.1] (500 M, 1 hour) and inhibitor: b, Negative control. c, 100 M 
chloroquine. d, 50 mM NH4Cl. e, 10 g/ml chlorpromazine. f, 20 g/ml filipin. g, 
20 M nocodazole. h, 20 M  colchicine. Left: [3.1] emission. Right: Overlay 
image including PI staining to indicate cell viability and phase contrast image.  
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pH log P 
3 -0.47 ± 0.01 
4 -0.57 ± 0.14 
5 -0.77 ± 0.02 
6 -0.94 ± 0.01 
7 -0.96 ± 0.09 
 
Table 3.3 Measured octanol/water partition coefficients for [3.1] at various 
water-phase pH values.  
 
In addition to the uptake studies on MCF-7 cells, Section 3.4.1.7 showed that 
[3.1] is internalised by the bacteria S. Aureus. As these cells do not undergo 
endocytosis, this indicates that [3.1] is able to enter cells through a non-
endocytic mechanism of uptake. This would be in agreement with the 
uptakes studies on MCF-7 cells, although the exact uptake mechanism could 
well vary depending upon cell type. 
 
3.6.3 Effects of media 
The staining experiments initiated using MCF-7 cells were repeated for 
multiple cell lines: including FaDu (human hypopharyngeal carcinoma), 
Saos-2 (human osteosarcoma) and HeLa (human cervical cancer) cancer cell 
lines. In these cell lines, however, no nuclear staining was observed using 
the same incubation conditions (500 M, 1 hour) that resulted in the well-
characterised luminescence in MCF-7 cells described in Section 3.4.1. These 
data raised the possibility that the lack of staining was due to cell-specificity 
in the cellular uptake properties of [3.1]. However, when we consider the 
ability of serum to inhibit cellular uptake and nuclear staining has been well 
documented for both [3.1] and the related monometallic Ru(II)tpphz 
Chapter 3: Dinuclear Ru(II)tpphz complexes 
125 
 
complexes described in Chapter 2 and that the cell lines which were not 
readily stained required distinct medium (DMEM compared with RPMI for 
MCF-7 cells) for optimal growth, the possibility that the media composition 
might affect uptake efficiency also existed.  
 
To explore this idea further, HeLa human ovarian cancer cells, a cell line that 
may be cultured in both DMEM and RPMI cell media,  were incubated with 
solutions of [3.1] in either DMEM or RPMI serum-free media and the extent 
of the resultant staining assessed by CLSM (Figure 3.26). 
 
 
Figure 3.26 CLSM of HeLa cells incubated with [3.1]. Cells were cultured 
either in DMEM or RPMI media before incubation with solutions of [3.1] in each 
media formulation (500 M, 1 hour). 
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Growth media Incubation media 
Rel. emission 
intensity / % 
RPMI RPMI 100 
DMEM RPMI 61 
RPMI DMEM 14 
DMEM DMEM 12 
 
Table 3.4 Relative emission intensities of HeLa cells incubated with [3.1] (500 
M, 1 hour). Growth media = RPMI, incubation media = RPMI used as 100%. 
 
As Figure 3.26 and Table 3.4 show, HeLa cells display much greater nuclear 
staining when the incubation medium is RPMI compared to DMEM. A 
greater intensity is observed for cells cultured in RPMI, indicating that the 
growth medium is a factor in the uptake of the complex, although not to the 
same extent as the incubation medium. 
 
These results indicate that DMEM inhibits the uptake of [3.1] and show that 
the medium is not merely acting as a solvent for the active molecule – it can 
interfere with the uptake and application, positively or negatively. These 
data demonstrate how, in addition to the variables (cell 
line/concentration/time/serum) described previously, the incubation 
medium is a crucial factor which needs to be considered when measuring 
the uptake of this class of membrane-impermeable complexes into live cells. 
 
3.6.3.1 Folic acid 
The observation that DMEM inhibits the uptake of [3.1] is of particular 
interest as this media formulation contains 4x the folic acid concentration of 
RPMI.18 Folate receptors are cell membrane receptors that are highly 
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expressed by numerous cancer cells and display a high affinity for their 
target ligands of folic acid and reduced folates.19 Due to this, folic acid 
conjugation is a frequently employed targeting strategy for the delivery of 
drugs to folate receptor-positive tumour cells.20 Thus, the possibility that 
the mechanism of uptake in MCF-7 cells may involve a folate receptor was 
explored by using the principle that this would be predicted to involve folic 
acid competition. To assess the effects of folic acid upon the rate of cellular 
uptake of [3.1], MCF-7 cells were therefore incubated with [3.1] in RPMI 
containing various concentrations of folic acid and the effect upon the 
resultant staining measured by CLSM. 
 
Figure 3.27 CLSM of MCF-7 cells incubated with [3.1] (500 M, 1 hour) in 
RPMI media with increasing folic acid concentration. 
 
It can be see that as the concentration of folic acid is increased from 0 mg/l 
to concentrations as high as 40 mg/l, there is no reduction in the nuclear 
staining due to [3.1], indicating that folic acid does not inhibit the uptake of 
[3.1] in MCF-7 cells (Figure 3.27). Since DMEM media contains 4 mg/l folic 
acid,18 it seems unlikely that the increased folic acid concentration is 
responsible for DMEM media inhibiting the cellular uptake of [3.1]. These 
results show that the mechanism of uptake does not involve competition 
with folic acid which in turn implies that cellular entry is not facilitated by 
the folate receptor. 
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3.6.4 Concentration-dependence 
An intriguing aspect of the mechanism by which [3.1] is internalised by cells 
is the apparent threshold concentration of [3.1] required to obtain nuclear 
staining. When cells are incubated at lower concentrations, there is evidence 
of cytoplasmic luminescence and only weak nuclear staining is observed, 
even at extended incubation times (Figure 3.28a). At an intermediate 
concentration, there is a mix of localisation and both cytoplasmic and 
nuclear staining can now be observed (Figure 3.28b). A higher 
concentration and substantially shorter incubation time results in nuclear 
staining as previously described and, under these conditions, cytoplasmic 
staining is not readily observed, presumably because it is substantially 
weaker than the nuclear signal under these incubation conditions (Figure 
3.28c). 
 
Figure 3.28 CLSM of MCF-7 cells incubated with [3.1].  
 
That a threshold concentration of [3.1] is required to obtain nuclear 
staining also suggests that nuclear uptake is a two step process: the first 
step resulting in the observable cytosol luminescence and the second to 
achieve nuclear uptake. As the nuclear pore diffusion limit is ~40 kD 
(diameter <39 nm),21 this would imply that the molecule is not present as 
the free complex diffused within the cytosol and is bound to a 
macromolecule or within an organelle.  
 
200 µM, 24 hours 500 µM, 1 hour100 µM, 24 hours
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In an attempt to characterise the cellular location of the non-nuclear 
luminescence observed for cells incubated with lower concentrations of 
[3.1], MCF-7 cells were co-stained with the specific organelle dyes 
Mitotracker Red, a thiol-reactive chloromethyl based probe which labels 
active mitochondria, and Lysotracker Yellow, an acidotropic probe used to 
label and track the acidic lysosomes in live cells. 
 
Figure 3.29 shows the co-staining of [3.1] with Mitotracker, which shows an 
apparently small co-localisation between the emission signals (Figure 
3.29b).  
 
Figure 3.29 CLSM of MCF-7 cells incubated with [3.1] (200 M, 24 hrs).  a, 
Co-staining of [3.1] (red) with Mitotracker Red (cyan) and overlay image. b, 
Co-localisation of [3.1] and Mitotracker emission signals (cyan = region 2, 
Mitotracker, red = region 1, [3.1], white = region 3, overlap). 
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Figure 3.30 shows the equivalent co-staining and co-localisation of [3.1] and 
Lysotracker, which again shows a small amount of overlap between the two 
signals, suggesting that a small amount of the signal from [3.1] is in acidic 
lysosomes.  
 
Figure 3.30 CLSM of MCF-7 cells incubated with [3.1] (200 M, 24 hrs).  a, 
Co-staining of [3.1] (red) with Lysotracker Yellow (yellow) and overlay image. 
b,  Co-localisation of [3.1] and Lysotracker emission signals (yellow = region 2, 
Lysotracker, red = region 1, [3.1], white = region 3, overlap). 
 
Taken together, the non-uniform appearance of cytoplasmic [3.1] staining 
together with its partial co-localisation with both mitochondria and 
lysosomal compartments suggests that [3.1] may stain membrane-bound 
cellular compartments including mitochondria and lysosomes. In the case of 
mitochondria it is conceivable that luminescence arises from DNA binding.  
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If [3.1] is indeed located within lysosomes or other organelles, the question 
of what is activating the luminescence of [3.1] arises. The light switch effect 
is not uniquely dependent on [3.1] binding to DNA, but is predicted to occur 
whenever [3.1] is in an environment where the phenazine nitrogen ligands 
are shielded from water. In cells, this could occur if [3.1] was protein- or 
RNA-bound, or within a hydrophobic environment such as any cellular 
membranes, as examples. The corollary of this is that a lack of luminescence 
does not inherently imply the absence of [3.1] from other organelles, as it is 
possible the complex is within such compartments but the light switch 
emission is deactivated as it is present in an aqueous environment. 
 
From these co-staining experiments, the majority of the signal localisation 
remains undefined; showing no clear overlap with either Mitotracker or 
Lysotracker, and the relatively low emission intensity makes any 
conclusions problematic. 
 
3.6.5 Cell-specific uptake 
In contrast to MCF-7 cells, [3.1] proved to be a very poor stain of primary 
human dermal fibroblast (HDF) cells. As Figure 3.31a shows, only low levels 
of nuclear luminescence are observable in HDF cells (labelled with 
CelltrackerRed – falsely coloured cyan) whereas the MCF-7 cells display the 
expected nuclear staining due to [3.1] (Figure 3.31b). This cell type-specific 
staining is still observed when the two types of cell were co-cultured 
together (Figure 3.31c); MCF-7 cells are clearly distinguishable by the 
emission due to [3.1] whereas the Celltracker-labelled HDF show poor 
staining by the complex, eliminating the possibility that differences in media 
composition or content are responsible for the failure of [3.1] to stain HDF 
cells.  
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Figure 3.31 CLSM of HDF cells (a), MCF-7 cells (b) and HDF/MCF-7 coculture 
(c) incubated with [3.1] (500 M, 1 hour). HDF cells were incubated with 
CelltrackerRed prior to seeding. From left to right: luminescence emission of 
[3.1] (red), CelltrackerRed (cyan) and overlay image. 
 
These data confirm [3.1] as a non-membrane permeable imaging agent  and 
strongly suggest that a specific uptake mechanism, whose components are 
differentially expressed in distinct cell types, operates for nuclear DNA 
staining by [3.1]. The selective staining of immortalised cancer cell lines 
derived from distinct tissues raises the possibility that [3.1] has potential as 
either a cell-type or tumour-cell specific discrimination reagent or 
diagnostic tool.     
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3.7 TEM studies 
As shown in Chapter 2, Ru(II) complexes are able to scatter the electron 
beam used in TEM imaging and therefore act as contrast agents for this high 
resolution technique. This provides a significant advantage over CLSM as 
the cellular location of each complex can be determined without requiring 
the complex to be present in an environment that causes activation of its 
luminescent properties. 
 
For comparison to the results achieved with each dinuclear Ru(II)tpphz 
complex, the control experiments, with and without phospholipid contrast 
reagent osmium tetroxide staining, are shown in Figure 3.32. 
 
Figure 3.32 a, MCF-7 cell stained with osmium tetroxide. b, Negative control 
cell with no stain present. 
 
3.7.1 [{Ru(phen)2}(tpphz)]
4+ 
MCF-7 cells incubated with solutions of [3.1] as for luminescence 
microscopy before fixation and sectioning for TEM imaging show that, while 
[3.1] is located throughout the cell cytoplasm, it is found in much higher 
concentration within the nucleus, where it localises to heterochromatin, as 
evidenced by the strong contrast in regions close to the nuclear envelope.  
b
2 μm
a
2 μm
Chapter 3: Dinuclear Ru(II)tpphz complexes 
134 
 
(Figure 3.33a,b). Interestingly, TEM images also reveal that significant levels 
of [3.1] are present in mitochondria (Figure 3.33c). Examining the sub-
mitochondrial localisation of [3.1] in more detail, it is apparent that the 
complex is located in the intermembrane space (Figure 3.33d). As 
mitochondrial DNA is located within the central lumen of the organelle22 
and these TEM images show that the complex is not located there, then this 
suggests that the observed CLSM luminescence for the same incubation 
conditions is not a result of the complex bound to mitochondrial DNA. 
 
 
Figure 3.33 TEM micrographs of MCF-7 cells incubated with complex [3.1] 
(500 µM, 1 hr). a, Image showing [3.1] especially associates within the nucleus 
where it displays strong heterochromatin staining. b, Detailed image of nucleus 
reveals clear heterochromatin staining. c, d, Mitochondria stained by [3.1].  
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Sub-nuclear localisation is further confirmed by co-staining with osmium 
tetroxide. As shown in Figure 3.34, cells co-stained with [3.1] and osmium 
tetroxide display highly contrasted nuclear heterochromatin and again the 
endosomal compartments show no presence of compound [3.1]. As 
expected, the negative control micrograph of a cell stained only with 
osmium tetroxide shows a much less contrasted nuclear area (Figure 3.32a). 
 
 
Figure 3.34 TEM micrographs of MCF-7 cells incubated with complex [3.1] 
(500 µM, 1 hr) and stained with osmium tetroxide to show greater cellular 
detail. a, Image showing highly contrasted nuclear heterochromatin due to [3.1]. 
b, c, Detailed images of nuclei reveals clear heterochromatin staining. d, Image 
showing heterochromatin and nuclear membrane detail (membrane stained with 
osmium tetroxide). 
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3.7.2 [{Ru(bpy)2}2(tpphz)]
4+ 
MCF-7 cells incubated with [3.2] before preparation for TEM show very 
limited contrast effects from within cells, making viewing problematic 
(Figure 3.35a,b). This supports the view that [3.2] is not readily internalised 
by MCF-7 cells, in agreement with the CLSM data. As TEM is a higher 
resolution technique and one that does not require a specific mode of 
binding to DNA for observation, these results provide the strongest 
indication that poor cellular uptake is responsible for the minimal nuclear 
staining observed for [3.2] in MCF-7 cells and not intracellular factors, such 
as a non-DNA target, for example.  
 
 
Figure 3.35 a, b, TEM micrographs of MCF-7 cells incubated with complex 
[3.2] (500 µM, 1 hr) display minimal intracellular contrast signal.  
 
When MCF-7 cells are incubated with [3.2] after fixation, TEM micrographs 
clearly show contrast within the cell, including strong contrast from the 
nucleus (Figure 3.36a,b). This makes [3.2] of interest as a DNA imaging 
agent in permeablised cells for transmission election microscopy. 
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Figure 3.36 a, b, Fixed MCF-7 cells stained with [3.2] (100 µM, 10 mins.) 
show intracellular contrast signal and clear heterochromatin staining.  
 
3.8 Cytotoxicity 
3.8.1 MCF-7 cells 
As [3.1] demonstrates successful cellular internalisation and the ability to 
bind to nuclear DNA in live cells, the cytotoxic properties of both [3.1] and 
[3.2] towards the MCF-7 human breast cancer cell line was determined by 
MTT assay and the IC50 value for each complex thus determined. As for 
Chapter 2, the anti-cancer drug cisplatin was included for comparison. 
 
As can be seen by Figure 3.37 and Table 3.5, neither [3.1] or [3.2] 
demonstrate significant toxicity towards MCF-7 cells over a 24 hour 
incubation time (IC50 values of 138 and >500 M respectively) and cisplatin 
demonstrates a toxicity one order of magnitude greater than [3.1] (IC50 
value = 12 M). The dinuclear complex which displays the greater cellular 
uptake, [3.1], also displays the greater toxicity and both dinuclear 
complexes are an order of magnitude less cytotoxic than their monometallic 
analogues [2.3] and [2.4] (IC50 values of 36 and 53 M respectively – 
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Section 2.8.1). The mononuclear complexes bind to DNA with a lower 
affinity but CLSM studies reveal a greater degree of nuclear staining. Thus, 
toxicity correlates better with the relative uptake of the complexes into cells 
and not their overall binding affinity to DNA. However, it should be noted 
that determination of the exact intracellular concentration of each complex 
would be required to confirm this. 
 
Figure 3.37 Cytotoxicity of dinuclear Ru(II)tpphz complexes [3.1] and [3.2] 
towards MCF-7 breast cancer cells (24 hr incubation time). 
 
As the doubling time for MCF-7 cells is ~37 hours,23 the incubation time was 
increased to 72 hours, to allowing time for cells to divide, and the 
cytotoxicity of each complex over this extended time period determined 
(Figure 3.38 and Table 3.5). Cisplatin is again included for comparative 
purposes. 
 
With the greater exposure time of 72 hours, [3.1] now demonstrates much 
greater cytotoxicity and displays a similar potency to cisplatin (an IC50 value 
of 6 M was obtained for each molecule - Table 3.5). A difference in 
behaviour between each complex is that cisplatin exhibits a greater 
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cytotoxicity at submicromolar concentrations. [3.2] also demonstrated an 
increase in toxicity but is two orders of magnitude less toxic than [3.1] and 
cisplatin (IC50 value of 168 M – Table 3.5). 
 
Figure 3.38 Cytotoxicity of dinuclear Ru(II)tpphz complexes [3.1] and [3.2] 
towards MCF-7 breast cancer cells (72 hr incubation time). 
 
Complex 24 hr IC50 / µM 72 hr IC50 / µM 
[3.1] 138 ± 6 6 ± 2 
[3.2] >500 168 ± 9 
cisplatin 12 ± 3 6 ± 2 
 
Table 3.5 IC50 values of dinuclear Ru(II) complexes towards MCF-7 cells. 
 
As discussed in Section 1.1.7, interference with the processes that maintain 
telomere length is a current strategy for the development of novel 
chemotherapeutics in anti-cancer research. Small molecules that induce or 
stabilise quadruplexes at G-rich telomeric locations (specifically the 3’ 
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overhang) are considered to be promising anti-cancer candidates and they 
have been shown to interfere with the process of telomere maintenance.24, 25 
Quadruplex formation at the telomeres of the chromosomes would be 
predicted to interfere with the process of cellular division, affecting long 
term viability of a population, not causing instant cell mortality.26 The 
cytotoxicity results for [3.1] towards MCF-7 cells show exactly this 
behaviour; the complex shows a low short-term toxicity but, over a longer 
incubation time, it demonstrates cytotoxicity comparable to cisplatin. These 
results therefore make [3.1] of interest as a molecule that inhibits cancer 
cell growth. As [3.1] and [3.2] bind to quadruplex DNA with high affinity, 
and luminescent imaging experiments with [3.1] in cellulo reveal the 
presence of a peak that corresponds to complex binding to quadruplex DNA, 
the cytotoxicity of these complexes are of great interest. Many anti-cancer 
drugs, such as cisplatin, are limited by their toxic side effects, thus the low 
short-term toxicity of [3.1] may be an advantage in this context. 
 
3.8.2 Cellular uptake and cytotoxicity 
As CLSM and TEM studies have shown [3.1] to be successfully internalised 
by live cells and the molecule has been shown to demonstrate toxic effects 
against the MCF-7 cell line which increase with exposure time, the 
relationship between the cellular internalisation properties of the molecule 
and cytotoxicity of the molecule were explored. 
 
3.8.2.1 Effects of media 
It was shown in Section 3.6.3 that incubation of MCF-7 cells in DMEM media 
had the effect of inhibiting the uptake of [3.1] in comparison to RPMI. This 
property therefore provides an easy method by which to investigate the 
effect of cellular uptake efficiency upon the cytotoxic properties of [3.1].  
HeLa cells, which may be cultured in either DMEM or RPMI media, were 
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incubated with solutions of [3.1] in DMEM or RPMI media and the effect 
upon cell viability of the complex in each media formulation determined. 
 
Figure 3.39 and Table 3.6 show that [3.1] displays a low cytotoxicity 
towards HeLa cells when the incubation medium used is DMEM (IC50 value = 
219 M). However, when the incubation medium is RPMI, there is now a 
substantial increase in cytotoxicity (IC50 = 12 M). 
 
Figure 3.39 Cytotoxicity of [3.1] towards HeLa cervical cancer cells in either 
DMEM or RPMI growth/incubation media (24 hr incubation time). 
 
Complex DMEM IC50 / µM RPMI IC50 / µM 
[3.1] 219 ± 10 12 ± 2 
 
Table 3.6 IC50 values of [3.1] towards the HeLa cell line in either DMEM or 
RPMI growth/incubation media (24 hour incubation time). 
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As the efficiency of [3.1] uptake was previously shown to be greater when  
HeLa cells were exposed to complexes in RMPI media compared to DMEM, 
these results reveal that an increase in cellular uptake of [3.1] is 
accompanied by an increase in cytotoxicity. This indicates that an 
intracellular mechanism is most likely to be responsible for the associated 
toxicity of the molecule. 
 
It is interesting to note that [3.1] demonstrates a much greater cytotoxicity 
towards the HeLa cell line than MCF-7 cells over the same time period (IC50 
values of 12 and 138 M for HeLa and MCF-7 cells respectively). As HeLa 
cells divide more rapidly than MCF-7 cells (doubling times of  22 hrs and 37 
hours for HeLa and MCF-7 cells respectively27,23) this would be in agreement 
with the toxicity of the molecule increasing as a function of increasing 
frequency of cell division.  
 
3.8.2.2 IT50 values 
In a similar fashion to the use of IC50 values (where the viability is measured 
at different concentrations for a given incubation time), the toxicity of a 
molecule may also be described by an IT50 value. This involves the viability 
being measured at different time points for a given concentration and the 
IT50 value is therefore the time at which a specific concentration would 
induce 50 % viability within the cell population.  
 
As [3.1] displays significantly different in cellulo localisation at different 
concentrations, displaying nuclear staining after incubation with 500 M in 
contrast to no observable nuclear staining after incubation with 100 M, 
MCF-7 cells were incubated with solutions of [3.1] (10, 100 or 500 M 
[3.1]) and the viability of the cells determined at time points.  IT50 values 
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calculated for each concentration allows a direct comparison of the toxicity 
at each concentration. 
 
Figure 3.40 shows the effect of cells incubated with three different 
concentrations of [3.1] and exponential decay relationships were plotted 
(data were fit to y = ae-bx, where a and b are constants, R2 >0.95). Table 3.7 
shows the derived IT50 values.  
 
Figure 3.40 Cytotoxicity of [3.1] (incubation concentration 10, 100 or 500 
M) towards MCF-7 cells. 
 
When these experiments are repeated for HeLa cells, a similar trend is 
observed (Figure 3.41). As for Section 3.8.2.1, a greater toxicity of [3.1] 
towards HeLa cells is observed, with each IT50 value being approximately 
half of that recorded for the MCF-7 cell line (Table 3.7), indicating that half 
the time is required to achieve 50% cell viability for each concentration 
measured.  
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Figure 3.41 Cytotoxicity of [3.1] towards HeLa cells (incubation concentration 
10, 100 or 500 M). 
 
[3.1] / µM 
IT50 / hrs 
MCF-7 HeLa 
10 63 ± 3 33 ± 6 
100 35 ± 3 18 ± 2 
500 16 ± 1 6 ± 1 
 
Table 3.7 IT50 values for [3.1] towards MCF-7 and HeLa cell lines. 
 
These IT50 values clearly show the toxic effects of [3.1] – when the 
concentration is increased a decrease in the IT50 value is observed, as would 
be expected, and a non-linear relationship between IT50 value and 
concentration is apparent. 
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3.8.2.3 Nuclear uptake and toxicity 
The cytotoxic effects demonstrated by [3.1] in Section 3.8.1 are of interest 
because the complex: a) binds to DNA with a high affinity and b) has been 
shown to bind to DNA in the nucleus of cells. These properties indicate that 
[3.1] has the potential to induce cell death by interfering with cellular 
process such as DNA replication and transcription.  
 
However, in Section 3.4.1 it was noted that a high concentration (> 200 M) 
and a short incubation time (1 hr) in serum-free media were factors 
required to achieve nuclear staining by [3.1] of MCF-7 cells. When MCF-7 
cells were incubated with lower concentrations of [3.1] (100 M, 24 hours), 
cells displayed minimal cellular uptake (Figure 3.3) yet these same 
incubation conditions cause the cell viability to be reduced to 56 % (Figure 
3.37). When the incubation concentration is increased to 500 M, a 
concentration shown to demonstrate significant nuclear staining (60% of 
cell nuclei stained after 1 hr – Figure 3.5), the cell viability now is 21 % after 
24 hours exposure (Figure 3.37). These toxicity studies therefore raise the 
question of how the nuclear uptake properties of [3.1] are related to cellular 
viability and particularly the rate by which [3.1] can induce cell death after 
it has reached the nucleus. 
 
To assess the effects of nuclear uptake of [3.1] upon cell health over an 
extended time period, MCF-7 cells were incubated with solutions of [3.1] 
(100 or 500 M) in either serum-free or serum-containing media for 1 hr 
and the complex-containing solution was replaced with normal cell media. 
The viability of the cells was then determined at numerous time points after 
removal. An IT50 value for each experiment was thus obtained from these 
results and these values can be used to directly compare the toxicity effects 
for each of the incubation conditions. 
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Figure 3.42 Effect on viability of MCF-7 cells incubated with 500 M (a) or 100 
M (b) [3.1] for 1 hour in either serum-containing or serum-free media. 
Complex-containing media was removed and replaced with standard growth 
media. 
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Incubation conc. / 
µM 
Incubation 
conditions 
IT50 / hrs 
500 + serum 23 ± 2 
500 - serum 14 ± 1 
100 + serum >72 
100 - serum 25 ± 2 
 
Table 3.8 IT50 values for MCF-7 cells incubated with [3.1] for 1 hr towards 
MCF-7. Complex-containing media was removed and replaced with standard 
growth media. 
 
Figure 3.42a and Table 3.8 show that the effect of incubating MCF-7 cells 
with 500 M [3.1] for 1 hour significantly affects the viability of the cell 
population over time. An exponential decay in viability is again observed for 
incubation with 500 µM [3.1] in both serum and serum-free conditions and 
100 µM [3.1] in serum-free conditions.  
 
When the uptake of [3.1] is improved by using serum-free media during the 
incubation period (previously shown to achieve 98% nuclear staining of the 
population) this has the effect of significantly increasing the toxicity, with 
cells experiencing a more rapid decay in viability than those incubated in 
serum-containing media (IT50 = 14 hrs and 23 hrs respectively for 500 µM 
[3.1]). Cells incubated for 1 hour in serum-free media now display a greater 
toxicity (IT50 = 14 hrs) than cells incubated continuously with the complex at 
the same concentration in serum-containing media (IT50 = 16 hrs). When it 
is considered that Section 3.4.1 demonstrated that serum inhibits uptake, 
this provides further evidence that cellular uptake of [3.1] is responsible for 
the toxic effects demonstrated by the complex and that the toxicity of [3.1] 
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is achieved in a relatively short exposure time to the complex at this 
concentration. 
 
When these experiments were repeated using a lower concentration (100 
µM), and one which does not lead to successful nuclear luminescence, a 
significantly reduced toxicity is observed (Figure 2.42b, Table 3.8). The 
difference between cells incubated in serum and serum-free conditions is 
more pronounced (IT50 values >72 hours and 25 hrs respectively) and again, 
cells incubated for 1 hr in serum-free media display a greater toxicity than 
constant incubation with the same concentration in serum-containing media 
(IT50 value = 35 hours).  
 
As cell imaging experiments using incubation of MCF-7 cells under these 
conditions display no evidence of DNA staining, these results show that 
nuclear uptake (at least to a level observable by CLSM) is not a requirement 
for [3.1] to demonstrate cytotoxicity properties. 
 
With this in mind, two things that would explain the observed toxicity at 
100 µM would be: 
a) A small amount of [3.1] (unobservable by CLSM) bound to nuclear DNA 
is able to achieve significant cytotoxicity, which would be in agreement 
with the high binding affinity shown by the molecule. 
b) Cytotoxicity is achieved by a non-nuclear DNA-binding mechanism. 
Given that [3.1] has also been shown to target mitochondria by TEM 
imaging, this would then represent the most likely cause of toxicity. 
Indeed, mitochondrial accumulation with associated toxicity has been 
observed for related DNA-binding Ru(II) polypyridyl complexes.28, 29 
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The previous observation that toxicity increases as a function of an 
increased frequency of cell division would support the premise that [3.1] 
achieves toxicity by interference with DNA metabolism, but a model where 
mitochondria are compromised would not be in agreement with this. These 
results raise the question of the exact mechanism by which [3.1] causes cell 
death and the possibility that more than one mechanism of cytotoxicity is 
occurring cannot be discounted. Clearly, further work in this area is 
required.  
 
3.9 Conclusions and future work 
In this chapter, the cellular DNA binding properties of two dinuclear Ru(II) 
tpphz light switch complexes in both live and fixed cells were investigated 
by a combination of CLSM and TEM microscopy. In addition, the cytotoxicity 
towards cancer cell lines was assessed. 
 
The complex containing phen as the ancillary ligand, 
[{Ru(phen)2}2(tpphz)]4+  [3.1], was found to be internalised by the MCF-7 
cell line, where it functions as an imaging agent for both CLSM and TEM. In 
CLSM studies, colocalisation with DAPI, clear visualisation of condensed 
chromosomes of mitotic cells and excitation/emission energies were all 
shown to be in agreement with previous in vitro DNA binding studies, 
strongly suggesting that the complex binds to DNA in cellulo, while TEM 
studies showed strong heterochromatin staining by the complex. Perhaps 
the most fascinating attribute of [3.1] as a DNA imaging tool is the existence 
on DNA binding of multiple emission peaks suggesting that this complex 
may find future application as an in cellulo DNA structural probe, specifically 
for quadruplex DNA. Using CLSM in conjunction with the use of specific cell 
process inhibitors, the cellular uptake mechanism was found to be via a 
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concentration-dependent, but non-endocytic, mechanism of active 
transport. In contrast to [3.1], the bypyridine analogue, 
[{Ru(bpy)2}2(tpphz)]4+  [3.2], displayed a significantly lower cellular uptake, 
however, the complex was shown to stain DNA efficiently in fixed cells and 
thus may have application  as a dead cell stain. 
 
It is interesting to note that a similar behaviour for the mononuclear 
Ru(II)tpphz complexes in Chapter 2 was observed, where the bpy analogue, 
[Ru(bpy)2(tpphz)]2+ [2.4], displayed lower levels of nuclear staining and 
cytotoxicity in live cells, presumably due to poorer cellular uptake of the 
complex in comparison to the complex containing phen as the ancillary 
ligand, [Ru(phen)2(tpphz)]2+ [2.3]. The results within this Chapter further 
demonstrate the effect of the ancillary ligand upon cellular uptake – with 
much reduced uptake for the bipyridine mononuclear and dinuclear 
complexes in comparison to the phen analogue. As the mechanism by which 
these molecules access their cellular targets involves an active uptake 
mechanism, rather than passive diffusion, this would suggest the existence 
of at least one specific receptor, and that the structural difference between 
bpy and phen determines the efficiency of cell internalisation rather than a 
physical (i.e. hydrophobic or lipophilic) effect. 
 
Cell viability studies show that [3.1] displays a low toxicity towards the 
MCF-7 cell line after 24 hour incubation but when the incubation time is 
increased to 72 hours, the toxicity of the complex is equal to that of the 
anticancer drug cisplatin (IC50 values summarised in Table 3.9). Complex 
[3.2] demonstrated a significantly lower toxicity than [3.1], suggesting that 
the greater efficiency of uptake of [3.1] is responsible for these toxic effects. 
[3.1] was shown to demonstrate a substantially greater toxicity towards 
HeLa cells when the incubation medium was RPMI compared to DMEM (IC50 
values of 12 and 219 µM respectively). As DMEM had previously been 
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shown to inhibit cellular uptake of the complex, this further establishes that 
cellular uptake is responsible for the toxic properties of [3.1] and implies an 
intracellular mechanism of toxicity. Each dinuclear complex is significantly 
less cytotoxic than the monometallic metallo-intercalator. This would be in 
agreement with a greater rate of cellular uptake of [2.3] and [2.4] but it 
should also be noted that a different DNA binding mechanism (intercalative 
compared to groove-binding) could be responsible for the difference in 
toxicity. The toxic properties of [3.1] are particularly intriguing as [3.1] 
possesses a high affinity for quadruplex DNA in vitro. Along with the 
successful cellular uptake of the complex, this signifies the potential of the 
complex to interfere with cell proliferation by the disruption of telomere 
maintenance25 making [3.1] of interest as the basis for the development of 
an anti-cancer therapeutic agent.  
 
Complex log P 
IC50  / µM 
MCF-7  
(24 hr) 
MCF-7  
(72 hr) 
[3.1] -0.96 ± 0.09 138 ± 6 6 ± 2 
[3.2] -1.61 ± 0.10 >500 168 ± 9 
cisplatin   -2.53* 12 ± 3 6 ± 2 
[2.3] -1.24 ± 0.12 36 ± 3 - 
[2.4] -2.08 ± 0.15 53 ± 7 - 
 
Table 3.9 Compiled octanol/water partition coefficient and IC50 values of Ru(II) 
complexes towards MCF-7 cells. *Value obtained from Screnci et al.30 
 
Future work in this area will investigate the toxicity of [3.1] towards a range 
of cancer and non-cancer cell lines. As the mechanism of DNA-binding of 
[3.1] is radically different to cisplatin, a reversible interaction rather than 
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direct coordination to DNA, it would be predicted that the mechanism of 
toxicity is also very different. This in turn would indicate that [3.1] will 
remain active against cisplatin-resistance cancer. Therefore, future work 
will focus on the toxicity of [3.1] towards cisplatin-resistance cancer cell 
lines and the mechanism by which [3.1] induces cell death. As the use of 
cisplatin is restricted by its high toxicity and associated side-effects, it would 
be hoped that the low short-term toxicity of [3.1] would be advantageous in 
this capacity. 
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Chapter 4 
A series of substituted dinuclear 
Ru(II)tpphz complexes 
 
4.1 Introduction 
In the previous chapter, a dinuclear Ru(II) complex with a ditopic tpphz 
ligand and phen as the ancillary ligand, [3.1], was shown to be internalised 
by cells and bind to nuclear DNA. This was observable by CLSM and TEM as 
the molecule acts a DNA imaging agent for both of these techniques. In 
addition to the imaging properties displayed by the complex, [3.1] also 
demonstrated cytotoxicity equal to that of cisplatin over an extended 
incubation time. In contrast, the dinuclear Ru(II)tpphz containing bpy as the 
ancillary ligand in place of phen, [3.2], demonstrated significantly lower 
cellular uptake and cytotoxicity. This highlights the importance of ancillary 
ligands in the bioactivity of the complex. To further explore this effect and 
with the aim of generating further bioactive molecules, a series of 
derivatives of [3.1] were prepared using ligand substitution (Figure 4.1) 
and the DNA binding, cellular imaging and cytotoxic properties of the series 
was investigated. 
 
The ligands selected were the methyl-substituted phenanthrolines 5mp (5-
methyl-1,10-phenanthroline) and dmp (2,9-dimethyl-1,10-phenanthroline) 
and the phenyl-substituted DIP (4,7-diphenyl-1,10-phenanthroline) ligand. 
Methyl-substitution offers a method by which to subtly tailor the properties 
of a molecule including the in vitro DNA binding affinity, luminescent 
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emission wavelength and hydrophobicity whereas the use of DIP as an 
ancillary ligand has been shown to promote cellular uptake as its high 
hydrophobicity often increases the membrane-permeability of complexes.1-4 
 
 
Figure 4.1 a, Structure of dinuclear Ru(II)tpphz complexes. b, Structure of 
ancillary ligands: phen, including substitution site numbers, 5-methyl-phen (5mp), 
2,9-dimethyl-phen (dmp) and 4,7-diphenyl-phen (DIP).  
 
 
a
=
b ligand structure complex
phen [3.1]
5mp [4.1]
dmp [4.2]
DIP [4.3]
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4.2 Synthesis 
4.2.1 Ligand synthesis 
The tpphz ligand was synthesised using the same method described in 
Chapter 3 (Scheme 3.1). 5 
 
4.2.2 Complex synthesis 
The final products [{Ru(5mp)2}2(tpphz)]4+ [4.1], [{Ru(dmp)2}2(tpphz)]4+ 
[4.2]  and [{Ru(DIP)2}2(tpphz)]4+ [4.3]  were prepared using the same 
method as described in Chapter 3 for the synthesis of [3.1] with either 5mp, 
dmp or DIP replacing phen as the ancillary ligand - Scheme 4.1.5-7 One 
advantage to this approach is that all three ancillary ligands are available 
from commercial sources, eliminating the need for additional synthetic 
steps. 
 
Scheme 4.1 a, Synthesis of [Ru(N^N)Cl2] precursors (yields ranged from 47 - 
56 %). b, Synthesis of [4.1] - [4.3] (yields ranged from 74 - 86 %). 
 
= 5mp [4.1]
dmp [4.2]
DIP [4.3]
a
b
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All complexes were synthesised as their hexafluorophosphate salts and 
characterised by NMR, mass spectroscopy and elemental analysis. Unless 
stated otherwise, each complex was used as the chloride salt. They were 
converted into their water-soluble chloride salts by counter-ion metathesis 
using acetone solutions of tetrabuylammonium chloride. Each complex was 
used as a mixture of stereoisomers. 
 
4.3 Photochemistry 
4.3.1 Absorption spectra 
UV-visible absorption spectra for the PF6- salt of each complex were 
recorded in acetonitrile at room temperature. Figure 4.2 shows an example 
spectrum for [4.1] and Table 4.1 displays the full spectroscopic details for 
complexes [4.1] – [4.3]. The high energy peaks (< 370 nm) can be assigned 
to ligand-centred π  π* transitions and the broad, low energy emission 
(~350 – 550 nm) is characteristic of metal-to-ligand charge-transfer from 
the Ru(II) metal centre(s) to the polypyridyl ligand(s).8 
 
Figure 4.2 UV-vis absorbance spectra of [4.1] in acetonitrile at room 
temperature. MLCT = metal to ligand charge transfer. 
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Complex 
Absorption peak 
Assignment 
λmax / nm ε / M-1 cm-1 
[4.1] 202 156000 π  π* 
 
266 93700 π  π* 
 
311 37900 π  π* 
 
371 31400 π  π* 
 
443 32200 MLCT 
[4.2] 206 168400 π  π* 
 
268 68700 π  π* 
 
311 53500 π  π* 
 
374 33100 π  π* 
 
449 22700 MLCT 
[4.3] 202 220800 π  π* 
 
271 105500 π  π* 
 
311 77100 π  π* 
 
372 31800 π  π* 
 
454 45700 MLCT 
 
Table 4.1 UV-vis spectroscopy data for [4.1] – [4.3] in acetonitrile at room 
temperature.  
 
From Figure 4.2 and Table 4.1 it can be seen that each dinuclear Ru(II) 
complex exhibits ligand-centred π  π* transitions originating from the 
polypyridyl ligands (peaks located at ~206, ~268, ~311 and ~371 nm). In 
addition to these transitions, broad Ru  N^N and Ru  tpphz MLCT 
absorptions in the visible region of the spectrum are also observed (~450 
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nm). The equivalent peaks were described for the both the parent phen 
complex [3.1] and the bipyridine analogue [3.2].9-11 
 
Examining each peak in more detail, it can be seen that the molar extinction 
coefficient for the peak at ~371 nm is equal for each complex (ε = 31400 ± 
1600 M-1 cm-1). As each molecule posses a single tpphz ligand, this band can 
therefore be assigned to a π  π*  transition primarily located on the tpphz 
ligand. The wavelength and intensity of bands at ~206, ~268 and ~311 nm 
correlate with the nature of the ancillary ligand – for example, the complex  
containing DIP as the ancillary ligand, [4.3], displays the largest molar 
extinction coefficient for each absorption peak. As the DIP ligand possesses 
the most extended delocalised π system of the ancillary ligands investigated, 
this implies that these absorption bands are due to π  π* transitions 
predominantly located on the ancillary (N^N) ligand.  
 
The UV-visible absorption spectra for the Cl- salt of [4.1] and [4.2] were 
recorded in water and the data is summarized in Table 4.2. No results for 
[4.3] were obtained as the complex was found to be insoluble in pure water. 
Unsurprisingly, each complex displays essentially the same peaks as for the 
PF6- salt in acetonitrile, although a small red shift of the MLCT absorptions 
in the visible region (450 to 455 nm) and a significant increase in the 
absorbance at 266 nm that subsumes the peak at 371 nm are observed 
when the complex is dissolved in water. 
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Complex 
Absorption peak 
Assignment 
λmax / nm ε / M-1 cm-1 
[4.1] 202 217400 π  π* 
 
266 162800 π  π* 
 
371 31400 π  π* 
 
445 34000 MLCT 
[4.2] 206 114300 π  π* 
 
268 137500 π  π* 
 
374 34600 π  π* 
 
454 25300 MLCT 
[4.3] not water-soluble - 
 
Table 4.2 UV-vis spectroscopy data for [4.1] and [4.2] in water at room 
temperature.  
 
4.3.2 Excitation and emission spectra 
1MLCT excitation in acetonitrile (λex = 450 nm) results in observable 
luminescence for all three complexes (600 – 750 nm), characteristic of 
emission from a 3MLCT state.8 Given the structural similarity of the 
complexes and the fact that the excited state involves 1MLCT and 3MLCT 
states located on the tpphz ligand, the excitation/emission spectra for each 
complex display very similar properties. An example of the 
excitation/emission spectra observed for [4.1] is shown in Figure 4.3 and 
Table 4.3 summarises the full spectroscopic details for complexes [4.1] – 
[4.3]. 
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Figure 4.3 Absorption (     ), excitation (……..) and emission (     ) spectra of 5 
µM [4.1] in acetonitrile at room temperature. λem = 660 nm and λex = 450 nm 
for excitation and emission spectra respectively. a.u. = arbitrary units. 
 
The quantum yields were calculated using Equation 4.1 and are summarised 
in Table 4.3. The quantum yield for [3.1] is included for comparison.9 
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Equation 4.1 Quantum yield. Φ = quantum yield, A = absorbance at the 
excitation wavelength, I = integrated emission intensity, η = solvent refractive 
index for the reference (ref) and sample (x). 
 
As Table 4.3 shows, when the ancillary ligand is changed from phen to 5mp, 
each dinuclear ruthenium complex displays comparable levels of 
luminescence, with [4.1] displaying the greater emission intensity (Φ = 
5×10-3 and 6.9×10-3 for [3.1] and [4.1] respectively). However, when the 
ancillary ligand is changed to dmp, the complex now demonstrates much 
lower emission intensity and the quantum yield of [4.2] (Φ = 3×10-4) is now 
an order of magnitude weaker than that of [3.1] in the same solvent. The 
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complex that contains DIP as the ancillary ligand, [4.3], displays a significant 
increase in emission intensity (Φ = 1.7×10-2) compared to the parent 
complex [3.1] and 5-methyl derivative [4.1]. 
 
Complex 
λex / nm  
(λem / nm) 
λem max / nm 
(λex = 450 nm) 
Φ  
(λex / nm) 
[4.1] 
263, 302, 366, 440 
(670) 
670 
6.9 ± 0.7 × 10-3  
(450) 
[4.2] 372, 450 (670) 670 
3 ± 2 × 10-4  
(450) 
[4.3] 
271, 303, 370, 440 
(640) 
640 
0.017 ± 0.002 
 (450) 
[3.1] - 710 
5 × 10-3  
(439) 
 
Table 4.3 Luminescence data for [4.1] – [4.3] in acetonitrile at room 
temperature. Data for [3.1] is included for reference.9 
 
As the DIP ligand possesses the greatest delocalised π system of the 
ancillary ligands for [4.1] – [4.3], this increase in emission intensity would 
suggest that the observed MLCT emission of [4.3] is comprised of a 
significant Ru  N^N MLCT emission in addition to the Ru  tpphz MLCT 
emission, a factor that would additionally be responsible for the broad and 
blue-shifted peak. The large size of the DIP ligand may also act to sterically 
protect the tpphz ligand from the bulk solvent meaning the MLCT excited 
state would interact less with solvent molecules which would cause an 
enhancement in emission intensity. These results indicate that the addition 
of a methyl group at the 5 position of the phen ligand does not significantly 
alter the luminescent properties of the dinuclear complex in acetonitrile 
whereas, in contrast, the addition of two methyl groups at the 2 and 9 
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positions decreases the luminescent properties. The addition of two phenyl 
groups at the 4 and 7 positions acts to improve the luminescent properties.  
This shows how the choice of ancillary ligand can alter the luminescent 
properties of the molecule as a whole. 
 
In water, upon 1MLCT excitation (λex = 450 nm), [4.1] displays reduced 
emission in water (Φ = 1.62×10-3)  and the emission maximum is blue-
shifted by ~70 nm to 600 nm (Figure 4.4 and Table 4.4) – this large solvent 
shift is a well-documented effect in agreement with related work.10 [4.2] 
displayed no observable luminescence. The decrease of luminescence for 
each complex in aqueous conditions in comparison to acetonitrile solvent is 
due to the well documented effect of water quenching the 3MLCT  1GS 
transition by hydrogen bonding to the phenazine nitrogen atoms of the 
tpphz ligand.12 
 
Figure 4.4 Absorption (     ), excitation (……..) and emission (     ) spectra of 5 
µM [4.1] in water at room temperature. λem = 660 nm and λex = 450 nm for 
excitation and emission spectra respectively. a.u. = arbitrary units. 
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Complex 
λex / nm  
(λem / nm) 
λem max / nm 
(λex = 450 nm) 
Φ  
(λex / nm) 
[4.1] 
263, 450  
(600) 
600 
1.6 ± 0.5 × 10-3 
(450) 
[4.2] non-emissive - - 
 
Table 4.4 Luminescence data for [4.1] and [4.2] in water at room 
temperature.  
 
The luminescence from [4.1] in water was unexpected and not observed for 
the parent complex [3.1].7 C. Turro et al. suggest that relatively small 
amounts of the monometallic complex [Ru(N^N)2(tpphz)]2+ as an impurity 
can result in shifted luminescence peaks10 but this would not explain the 
behaviour of [4.1] observed in water as the Ru  tpphz MLCT emission of 
these impurities in water would be predicted to be quenched by hydrogen 
bonding. The possibility that the observed emission at 600 nm of [4.1] is 
due to a Ru  N^N MLCT transition cannot be discounted. Indeed, work by 
Barton and N. Turro show the aqueous emission spectra of [Ru(phen)3]2+ is 
comprised of two peaks – one of which occurs at 600 nm13 – in agreement 
with the peak observed for [4.1] in water (600 nm). Why this peak is not 
observed for the parent complex [3.1] remains unclear. 
 
To fully establish the exact nature of this emission, further work involving 
purification of [4.1] by exacting separation methods such as HPLC (high 
performance liquid chromatography) and a comparison of its photochemical 
properties with related complexes such as [Ru(5mp)3]2+ would be required. 
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4.4 DNA binding studies 
As the interaction between the parent complex [3.1] and DNA results in the 
characteristic light switch effect,7 the ability of [4.1] and [4.2] to similarly 
bind to DNA in vitro with an accompanying increase in luminescence was 
investigated. 
 
As can be seen in Figure 4.5, the addition of calf thymus DNA (CT-DNA) to 
aqueous solutions of [4.1] or [4.2] resulted in a significant enhancement of 
the 3MLCT luminescence emission for each, indicating that both complexes 
are behaving as DNA light switch systems. The emission maximum for both 
[4.1] and [4.2] (~665 nm) is the same as that reported for [3.1].7 This light 
switch effect is the result of binding to DNA shielding the tpphz phenazine 
nitrogen atoms from hydrogen bonding with water, activating 
luminescence, as opposed to the quenched emission of the free complex. 
 
In addition to this being an advantageous property in an imaging context, 
the increase in luminescence intensities of each complex upon the addition 
of CT-DNA can be used to assess the binding affinity of each complex with 
DNA. This technique involves a known concentration of DNA being titrated 
into a known concentration of the complex and the intensity of the resultant 
3MLCT emission DNA measured until the emission intensity reaches a 
maximum and does not increase when further DNA is added.  
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Figure 4.5 Increase of luminescence of [4.1] (a) and [4.2] (b) in aqueous 
buffer solution (25 mM NaCl, 5 mM Tris, pH 7.0) on addition of CT-DNA. 
 
The data obtained from these luminescent titrations can then be used to 
calculate the fraction of the complex bound by the following equation:  
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Where χ is the fraction of the complex bound and Iobs, Ib and If are the 
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The ratio of the bound complex, Cb, to the concentration of DNA (in base 
pairs), r, may be given by: 
[DNA]
bCr   
]complex[bC  
And it follows that the concentration of the free complex, Cf, is given by: 
bif CCC   
Where Ci is the initial concentration. 
 
The Scatchard equation is a commonly used equation for determining the 
affinity constant of a ligand with a receptor (Equation 4.6) and a plot of r/Cf 
v. r (the Scatchard plot) can be used to determine the equilibrium binding 
constant, Kb, and the number of binding sites per molecule, n.14 
 rnK
C
r
b
f
  
The Scatchard binding model works well with 1:1 binding systems but when 
the binding is more complicated, such as for small molecules binding to 
DNA, the relationship between r/Cf and r is non-linear and, as a result, the 
Scatchard equation is an inaccurate model. To more accurately fit the data 
the McGhee-von Hippel model – Equation 4.7 - is used to fit the data.15 From 
this equation, the y-intercept yields the equilibrium binding constant Kb and 
the reciprocal of the x-intercept is equal to n, which is the number of DNA 
binding sites (in base pairs) occupied by the small molecule. 
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where 
Equation 4.3 
Equation 4.4 
Equation 4.5 
Equation 4.6 
Equation 4.7 
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As the binding reaches saturation, the number of free binding sites smaller 
than n increases significantly and an effective concentration of the complex 
up to two orders of magnitude can be required to increase the occupancy of 
binding sites from 90-100%. This has the effect of artificially increasing the 
binding constant for the molecule and so, to minimise these effects, the 
model is fit to the experimental data for 30 – 90% of the complex bound.16 
 
To measure the binding of [4.1] and [4.2] with DNA, Iobs, Ib and If were 
obtained from the luminescence binding titration of each complex with CT-
DNA and a binding curve for each complex was constructed, which is shown 
in Figure 4.6. The equilibrium binding constant for each complex with CT-
DNA was calculated by displaying the data as Scatchard plots (χ = 30 – 90%) 
and the data fit to the McGhee-von Hippel model (Figure 4.6). The model 
fitted the data well and in each case the R2 value was >0.95. Table 4.5 
contains the values for Kb and n value obtained for each complex. 
 
Figure 4.6 Binding curves (inset) and Scatchard plots with McGhee-von Hippel 
best fit (outset) obtained by luminescent titrations of [4.1] or [4.2] with DNA 
(25 mM NaCl, 5 mM Tris, pH 7.0). 
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Complex Ib / If Kb / M-1 n 
[4.1] 27 6.7 ± 0.8 × 106 1.45 ± 0.02 
[4.2] 62 5.8 ± 0.4 × 106 1.55 ± 0.02 
[3.1] ~60* 1.1 × 107* 2.9* 
 
Table 4.5 Luminescent properties, equilibrium binding constant Kb and binding 
site size n (in base pairs) for [4.1] and [4.2] binding with CT-DNA (25 mM 
NaCl, 5 mM Tris, pH 7.0). *Data for [3.1] is included for reference.7 
 
As shown by Table 4.5, both [4.1] and [4.2] display a similar binding affinity 
for DNA as the parent complex [3.1] and the DNA binding affinities of all 
three complexes lies in the 106 M-1 range. This is the same order of 
magnitude as a classical metallo-intercalator such as [Ru(phen)2(dppz)]2+.17 
As the binding affinity of the mononuclear intercalator [Ru(phen)2(tpphz)]2+ 
was found to be an order of magnitude lower (Kb = 3.0×105 M-1) 18 than that 
observed for [4.1] and [4.2] and considering that the related dinuclear 
tpphz complex [{Ru(bpy)2}2(tpphz)]4+  [3.2] interacts with DNA by a groove 
binding mechanism,10 the binding affinities of [4.1] and [4.2] with CT-DNA 
in this work are therefore in agreement with a groove binding mode of 
action accompanied by a significant electrostatic contribution due to the  
high charge (4+) of each molecule although further binding studies would 
be required to confirm this hypothesis.  
 
Other work has shown the effect of methyl-substitution on the DNA binding 
properties of metallo-intercalators to be location dependent; the addition of 
a methyl group(s) on the ancillary ligand can either display a minimal effect 
or inhibition of binding, depending upon the substitution position.19, 20 This 
implies it is the steric properties of the methyl-substituted derivative that 
govern the DNA affinity of the molecule as a whole. The results in Table 4.5 
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show that this behaviour is observed for these dinuclear Ru(II)tpphz 
systems. 
 
4.5 Partition coefficients 
The octanol/water partition coefficients of [4.1] and [4.2] were measured 
using the “shake flask” method and the log P value for each complex 
determined (Table 4.6). The mass of each complex, excluding the counter-
ion, is included to provide a measure of the relative size of each complex. 
The partition coefficient for the parent complex [{Ru(phen)2}2(tpphz)]4+  
[3.1], as recorded in Chapter 3, is included for comparison. The 
octanol/water partition coefficient for [{Ru(DIP)2}2(tpphz)]4+  [4.3]  could 
not be assessed by this method due to the extremely poor water-solubility 
of the complex, which, by definition, indicates that the molecule is strongly 
hydrophobic. 
 
Complex 
Mass / atomic 
units 
log P 
[{Ru(5mp)2}2(tpphz)]4+ [4.1] 1364 -0.81 ± 0.08 
[{Ru(dmp)2}2(tpphz)]4+ [4.2] 1420 -0.69 ± 0.06 
[{Ru(DIP)2}2(tpphz)]4+ [4.3] 1916 hydrophobic 
[{Ru(phen)2}2(tpphz)]4+ [3.1] 1308 -0.96 ± 0.09 
 
Table 4.6 Measured octanol/water partition coefficients for [4.1] and [4.2]. 
The data for [3.1] from Chapter 3 is included for comparison. 
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The molecular volume and log P value for the relevant ancillary ligands, as 
shown in Table 4.7, is in agreement with the measured log P value for each 
Ru(II) complex with the order of hydrophobicity increasing phen  5mp  
DIP. In particular, it can be seen that the high hydrophobicity of the DIP 
ligand is clearly responsible for the strong hydrophobic nature of [4.3]. 
 
Ligand Mass / atomic units Volume / Å3 log P 
phen 180 163 1.90 
5mp 194 180 2.58 
dmp 208 197 2.00 
DIP 332 307 5.95 
 
Table 4.7 Calculated ligand octanol/water partition coefficients, masses and 
molecular volumes. Log P and molecular volume values calculated using 
molinspiration property calculation software.21 
 
One anomaly that arises from these results is that the log P value for the 
dmp ligand is lower than that for 5mp. This is not in agreement with the 
principle that the addition of a methyl group would increase the 
hydrophobicity of the molecule, therefore calculations for an equivalent 
series of ligands bound to a single ruthenium atom (Figure 4.7) were carried 
out (Table 4.8). These calculations show that the 2,9-dimethyl derivative has 
a greater log P value than the 5-methyl derivative, suggesting that the result 
obtained for the free dmp ligand is due to  software inaccuracies. 
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Figure 4.7 a, Revised model for ligand log P comparison entered into 
molinspiration software. b, Relevant N^N ligands. 
 
Ligand model log P 
Ru(phen)2+ -4.90 
Ru(5mp)2+ -4.73 
Ru(dmp)2+ -4.70 
Ru(DIP)2+ -2.00 
 
Table 4.8 Calculated octanol/water partition coefficients using molinspiration 
property calculation software21 for the revised ligand models. 
 
From these values, [4.1] and [4.2] would not be predicted to be internalised 
by cells through passive diffusion whereas the strong hydrophobicity of 
[4.3] would indicate that the complex would not accumulate in hydrophilic 
cellular regions. The lack of water-solubility of [4.3] also presents a 
significant problem as potentially toxic organic solvents, such as dimethyl 
sulphoxide (DMSO), must be employed to aid dissolution, a factor which will 
affect cell viability. 
 
 
 
= phen
5mp
dmp
DIP
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4.6 Live cell uptake and imaging 
As Section 4.4 showed that [4.1] and [4.2] bind to DNA with high binding 
affinities and increases in luminescence, their cellular uptake and in cellulo 
DNA binding properties can be studied using luminescence microscopy. 
 
To examine cellular internalisation of each complex, MCF-7 cells were 
incubated with solutions of [4.1] and [4.2] and then imaged using CLSM.  
The excitation wavelength used was 458 nm and the emission measured at 
650-700 nm, corresponding to the previously observed 3MLCT 
luminescence emission maxima for each complex when bound to DNA in 
vitro (Section 4.4).  
 
4.6.1 [{Ru(5mp)2}2(tpphz)]
4+ 
MCF-7 cells incubated for 24 hours with 100 µM of [4.1] displayed low 
levels of non-nuclear in cellulo MLCT luminescence (Figure 4.8). 
 
 
Figure 4.8 CLSM images of MCF-7 cells incubated with complexes [4.1] (100 
µM, 24 hrs). Left: Ru(II) emission. Right, Overlay image of Ru(II) emission and 
phase contrast. 
 
[4.1] overlay
20 μm
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Chapter 3 demonstrated how the use of a high incubation concentration, 
short incubation time and serum-free media achieved more efficient cellular 
uptake. Accordingly, MCF-7 cells were incubated with 500 µM solutions of 
[4.1] in serum-free cell media, with the aim of improving cellular 
internalisation and achieving nuclear uptake with the associated DNA 
staining. 
 
Under these conditions, [4.1] is shown to be internalised by live cells and 
the nuclei of cells are clearly stained by the complex (Figure 4.9). The 
accompanying live/dead staining shows the viability of the cells to be 
uncompromised whereby viable cells, as indicated by SYTO 9 staining, are 
clearly stained by [4.1]. 
 
 
Figure 4.9 a, CLSM of MCF-7 cells incubated with 500 µM [4.1] in serum-free 
media for 1 hr. b, Negative control. From left to right: luminescence emission of 
Ru(II) complex (red), SYTO 9 (green), PI (purple) and phase contrast image. 
 
 
SYTO 9 PI[4.1] phase
20 μm
a
SYTO 9 PIcontrol phase
20 μm
b
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Figure 4.9 shows [4.1] to display a similar behaviour to the parent complex 
[3.1]; both are internalised by cells and nuclear location is observable by 
CLSM in a concentration-dependent manner with no observable short-term 
toxicity.  
 
To further compare the behaviour of [4.1] and [3.1], and specifically to 
attempt to identify whether [4.1] is targeting DNA in cells, the cellular 
location of the complex and mechanism of internalisation of [4.1] was 
examined using a combination of CLSM and TEM by the methods described 
in Chapters 2 and 3. 
 
4.6.1.1 Co-staining with nucleic acid dyes 
Incubation of MCF-7 cells with [4.1] and co-staining with the commonly 
used DNA dye DAPI shows the distinct overlap of the two emission signals 
in MCF-7 cells (Figure 4.10a). This is clearly shown in the co-localisation 
image (Figure 4.10b), where the two emission signals display overlap in the 
majority of cells, which is a strong indication that both molecules are bound 
to nuclear DNA. Interestingly, co-staining with DAPI reveals that not all cells 
are stained by [4.1]; there are clearly cells stained by DAPI that show poor 
signal from [4.1]. 
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Figure 4.10 CLSM of MCF-7 cells incubated with [4.1] (500 µM, 1 hr). a, Co-
staining of [4.1] (red) with DAPI (blue) and overlay image. b, Co-localisation of 
[4.1] and DAPI emission signals (blue = region 2, DAPI, red = region 1, [4.1], 
white = region 3, overlap). 
 
Co-staining experiments with [4.1] and SYTO 9 show a much lower co-
localisation of the two emission signals than that observed with DAPI 
(Figure 4.11). As SYTO 9 fluorescently labels RNA and mitochondrial DNA, 
this indicates that [4.1] is a nuclear-specific stain in a manner analogous to 
[3.1]. 
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Figure 4.11 CLSM of MCF-7 cells incubated with [4.1] (500 µM, 1 hr). a, Co-
staining of [4.1] (red) with SYTO 9 (green) and overlay image. b, Co-localisation 
of [4.1] and SYTO 9 emission signals (green = region 2, SYTO 9, red = region 1, 
[4.1], white = region 3, overlap). 
 
These co-staining experiments and the observation of condensed 
chromosomes of mitotic cell phases stained by [4.1] (Figure 4.12) present 
clear evidence that cellular DNA is successfully targeted by the ruthenium 
complex. 
 
Figure 4.12 Prometaphase (a) and late-anaphase (b) MCF-7 cells stained by 
[4.1] showing condensed chromosome structure.  
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The co-staining experiments with SYTO 9 also displayed the non-uniform 
nature of the cellular internalisation of [4.1]: the majority of cells stained by 
SYTO 9 also show emission due to [4.1] but clearly there are also SYTO 9-
stained cells which display minimal Ru(II) signal. This effect is summarised 
in Table 4.9 and the results for [3.1] are included for comparison. 
 
Complex 
Cell nuclei 
stained / % 
[4.1] 77 ± 12 
[3.1] 98 ± 3 
 
Table 4.9 Extent of nuclear staining of MCF-7 cells by [4.1] or [3.1] (500 µM 1 
hr in serum-free conditions).  Minimum of 200 cells counted for each 
experiment. 
 
The conclusion from this work is that a methyl group at the 5 position of the 
phen ligand alters the cellular uptake properties of Ru(II)tpphz systems and 
provides a cell selectivity on the basis of an as yet unknown parameter. 
 
4.6.1.2 TEM studies 
To examine the cellular location of each complex in more detail, MCF-7 cells 
were incubated with solutions of [4.1], as for luminescence microscopy, and 
then the cells were fixed and sectioned for TEM imaging. 
 
Figure 4.13 shows that [4.1] accumulates within the nucleus of MCF-7 cells 
where it associates with heterochromatin, observable by the strong contrast 
signal from these regions of densely-packed DNA. This makes [4.1] of 
interest as a DNA-imaging agent for both CLSM and TEM. 
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Figure 4.13 TEM micrographs of MCF-7 cells incubated with [4.1] (500 µM, 1 
hr). a, b, Images showing [4.1] associates within the nucleus where it displays 
strong heterochromatin contrast. 
 
4.6.1.3 Mechanism of uptake 
The negative (hydrophilic) octanol/water partition log P value, 4+ charge 
and large size of [4.1] would suggest that [4.1] is not a membrane-
permeable molecule. With this in mind, the uptake mechanism of [4.1] for 
MCF-7 cells was examined using inhibition studies, using the luminescence 
properties of [4.1] as an indication of the degree of cellular internalisation 
of the complex. 
 
As shown by Figure 4.14, MCF-7 cells incubated with [4.1] at 4°C resulted in 
no observable in cellulo luminescence from the complex in viable cells. This 
result indicates that [4.1] is not able to freely diffuse across the cell 
membrane and therefore is internalised by cells via a temperature-
dependent pathway (active transport). This is in agreement with the live cell 
uptake studies of [4.1] which have shown that a high concentration is 
required to achieve internalisation and the observation of non-uniform 
nuclear staining: neither effect would be predicted for a membrane-
permeable DNA dye. 
a b
1 μm 1 μm
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Figure 4.14 Temperature-dependence studies of uptake of [4.1] by MCF-7 
cells. a, Cells incubated with [4.1] (500 M, 1 hour) at 4°C display no in cellulo 
luminescence. b, 37 °C control. The phase contrast image is included for 
reference. 
 
To investigate the exact mechanism of active transport in more detail, MCF-
7 cells were co-incubated with [4.1] and chloroquine or ammonium 
chloride, which are two lysosomotropic agents which prevent the 
maturation of endosomes by disturbing the pH balance between endosome 
and cytosol,22, 23 and thus inhibit endocytosis. 
 
Figure 4.15 shows that there is no reduction of nuclear staining due to [4.1] 
for either inhibition treatment, suggesting that the complex is not 
internalised by MCF-7 cells via an endocytic pathway. Chapter 3 showed 
how [3.1] was found to be internalised by cells through a non-endocytic 
mechanism of active transport and - considering the structural similarity of 
[4.1] to the parent complex [3.1] - the results for the cellular uptake 
mechanism of [4.1] are not surprising. 
20 μm
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Figure 4.15 a, b, CLSM of MCF-7 cells coincubated with [4.1] and endocytosis 
inhibitors chloroquine (a) and NH4Cl (b). c, Negative control. PI staining is 
included to indicate cell viability. 
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4.6.2 [{Ru(dmp)2}2(tpphz)]
4+ 
MCF-7 cells incubated for 24 hours with 100 µM of [4.2] displayed no 
observable luminescence but, in a similar fashion as for [4.1], MCF-7 cells 
incubated with [4.2] at a high concentration are observed to display very 
low levels of MLCT luminescence (Figure 4.16).  
 
Figure 4.16 a, CLSM of MCF-7 cells incubated with 500 µM [4.2] in serum-
free media for 1 hr. b, Negative control. From left to right: luminescence 
emission of Ru(II) complex (red), SYTO 9 (green), PI (purple) and phase contrast 
image. 
 
This luminescence is located in the nuclei of cells (Figure 4.17) and provides 
evidence of the successful cellular uptake of [4.2]. The requirement of a high 
concentration to achieve live cell staining would indicate that the complex is 
not membrane-permeable, in agreement with the hydrophilic log P value 
recorded, although the low luminescence makes further study into the exact 
mechanism of uptake and intracellular target problematic. 
 
The low emission of [4.2] from the nuclei of cells is due to the generally 
poor luminescent properties of the molecule – both free complex and when 
SYTO 9 PI[4.2] overlay
20 μm
a
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b
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bound to DNA - in comparison to other light switch complexes. Although 
these properties make [4.2] a poor imaging agent in comparison to [3.1] 
and [4.1], this is still one of the few examples of using an MLCT light switch 
complex to image live cells.  
 
 
Figure 4.17 CLSM of MCF-7 cells incubated with 500 µM [4.2] in serum-free 
media for 1 hr. Left: Ru(II)tpphz emission (red). Right: Overlay image of 
Ru(II)tpphz emission and phase contrast. 
 
4.6.3 [{Ru(DIP)2}2(tpphz)]
4+ 
The lack of water-solubility displayed by [4.3] required the complex to be 
dissolved in DMSO (dimethyl sulphoxide) to prevent precipitation. A high 
concentration of DMSO (> 20%) was required to achieve a concentration of 
5 µM in PBS, reflecting the strong hydrophobicity of the complex. This 
concentration of DMSO is toxic to cells and not advantageous in a live cell 
imaging application however CLSM experiments were conducted to provide 
an indication of the intracellular target of the complex. 
 
[4.3] displays a markedly different intracellular localisation than [4.1] and 
[4.2] where, in contrast to the nuclear staining displayed by the methyl-
substituted complexes, luminescence emission from [4.3] is clearly 
observed from the nuclear envelope as well as distinct regions within the 
cytosol (Figure 4.18). It is possible that this complex is targeting the entire 
[4.2] overlay
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endomembrane system - an extensive membrane system that comprises 
organelles such as the Golgi apparatus, nucleus and the endoplasmic 
reticulum (ER) in cells. Indeed, the staining pattern demonstrated by [4.3] is 
similar to that obtained by DiOC6 (3,3′-dihexyloxacarbocyanine iodide), a 
fluorescent organic molecule used to stain the ER, vesicle membranes and 
mitochondria of cells.24 
 
 
Figure 4.18 a, b, c, CLSM images of MCF-7 cells incubated with 10 µM [4.3] in 
serum-free media for 10 mins. d, Internal membrane structure of protozoa 
stained with DiOC6.25  
 
As [4.3] is a strongly hydrophobic molecule, it seems reasonable to suggest 
that the molecule is associating within hydrophobic regions (i.e. 
membranes) in the cell. To determine the exact intracellular target stained 
by [4.3], co-staining experiments with specific organelle stains such as the 
5 μm
20 μm 10 μm
a b
c d
Chapter 4: A series of substituted dinuclear Ru(II)tpphz complexes 
186 
 
previously mentioned membrane stain DiOC6 or ER-Tracker Dyes, which are 
designed for live-cell endoplasmic reticulum labelling, would be required. 
However, it should be noted that the insolubility of [4.3] in aqueous media 
presents a significant challenge in the development of this molecule for 
imaging applications.  
 
These results do illustrate one drawback in designing metal complexes for 
the specific property of hydrophobicity - a molecule that is too hydrophobic 
will associate within hydrophobic regions such as membranes and the 
intended target (such as DNA) will not be imaged. This effect can also be 
observed in work by the Barton group, with their membrane-permeable 
[Ru(DIP)2(dppz)]2+ system displaying no evidence of targeting cellular DNA 
after it has traversed the cell membrane.1, 2 
 
4.7 Fixed cell imaging 
After the demonstration of live cell internalisation and nuclear staining by 
each complex in MCF-7 cells, the ability of [4.1] and [4.2] to stain fixed and 
membrane-permeabilised MCF-7 cells was investigated using CLSM. The 
same excitation/emission wavelength parameters used for live cell imaging 
were applied. 
 
As shown by Figure 4.19a, [4.1] is an excellent nuclear stain for fixed and 
permeablised cells. [4.2] does show some ability in this capacity but the low 
luminescence of the complex decreases the signal/noise ratio and the 
images obtained are of poorer quality (Figure 4.19b). 
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Figure 4.19 CLSM of fixed MCF-7 cells stained with [4.1] (a) or [4.2] (b) (100 
µM, 10 mins.). From left to right: luminescence emission of Ru(II) complex (red), 
phase contrast and overlay image. 
 
4.7.1 Relevant emission intensity 
To directly compare the emission intensity of the methyl-substituted 
derivatives [4.1] and [4.2] and the parent complex [3.1] in fixed cell 
imaging conditions, micrographs of each complex staining fixed and 
membrane-permeablised MCF-7 cells were obtained where the incubation 
concentration/time and microscope settings (laser power, pinhole and 
detector gain) for each set of images were equal. 
 
Using this approach, [4.1] and [3.1] each display comparable levels of 
luminescence in fixed, membrane-permeablised cells whereas [4.2] displays 
a significantly lower emission (Figure 4.20). This observation is agreement 
with the luminescent properties of each molecule when bound to DNA: [3.1] 
[4.2] phase overlay
[4.1] phase overlay
a
b
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and [4.1] display a similar luminescence and are each an order of 
magnitude more luminescent than [4.2] (Section 4.4). 
 
 
Figure 4.20 CLSM of fixed MCF-7 cells stained with Ru(II) complexes [4.1] (a), 
[4.2] (b) or [3.1] (c) (100 µM, 10 mins.). d, Relative emission intensity of [4.1], 
[4.2] and [3.1] in fixed cells. 
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4.8 Cytotoxicity 
As both [4.1] and [4.2] have been shown to demonstrate successful cellular 
uptake and the ability to bind to nuclear DNA in live MCF-7 cells the 
cytotoxicity of both complexes towards MCF-7 cells was investigated.  
 
Chapter 3 showed how the quadruplex DNA-binding complex [3.1] 
demonstrated a low cytotoxicity for an incubation time of 24 hours but 
cytotoxicity equal to that of the anti-cancer drug cisplatin over a 72 hour 
incubation time, indicating that the complex possesses potential as the basis 
for an anti-cancer therapeutic. With this in mind, the cytotoxicity for [4.1] 
and [4.2] towards MCF-7 cells for both 24 and 72 hour incubation time 
periods was determined by MTT assay and the IC50 value for each 
experiment obtained. 
 
As can be seen in Figure 4.21a and Table 4.10, [4.1] demonstrates a low 
cytotoxicity towards MCF-7 cells over a 24 hour incubation time (IC50 = 246 
M) but a significantly higher cytotoxicity over a 72 hours (IC50 = 16 M), 
which, under these conditions, is now of a similar potency to that of cisplatin 
(IC50 = 6 M). The methyl-substituted complex [4.1] displays a lower 
cytotoxicity than [3.1] (IC50 = 138 M) and, as [3.1] has been shown to 
demonstrate superior cellular uptake properties than [4.1] (Section 4.6), 
this would suggest that it is the cellular uptake of the complex responsible 
for the cytotoxic properties.  
 
[4.2] demonstrates a three-fold increase of cytotoxic potency over [4.1] for 
a 24 hour incubation time (IC50 = 80 M) and a cytotoxicity equal to that of 
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cisplatin for a 72 hour incubation time period (IC50 = 5 M) – Figure 4.21b 
and Table 4.10. 
 
Figure 4.21 Cytotoxicity of methyl-substituted dinuclear Ru(II)tpphz complexes 
[4.1] (a) and [4.2] (b) towards MCF-7 breast cancer cells (24 and 72 hr 
incubation times). 
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Complex 24 hr IC50 / µM 72 hr IC50 / µM 
[4.1] 246 ± 12 16 ± 2 
[4.2] 80 ± 4 5 ± 2 
[3.1] 138 ± 6 6 ± 2 
cisplatin 12 ± 3 6 ± 2 
 
Table 4.10 IC50 values of methyl-substituted dinuclear Ru(II) complexes 
towards the MCF-7 cell line. The data for [3.1] and cisplatin are included for 
reference. 
 
It is interesting to note that [4.1] and [4.2] display the same anti-cancer 
toxicity behaviour previously observed for [3.1]: a modest IC50 value for 
MCF-7 cells incubated with each complex for 24 hours but cytotoxicity 
similar to that of cisplatin when the incubation time is increased to 72 hours 
(Table 4.10). These results therefore make [4.1] and [4.2] of interest as 
potential anti-cancer therapeutic agents. 
 
4.9 Conclusions and future work 
In this chapter, three derivatives of [{Ru(phen)2}2(tpphz)]4+ [3.1] were 
synthesised by ancillary ligand substitution: [{Ru(5mp)2}2(tpphz)]4+ [4.1], 
[{Ru(dmp)2}2(tpphz)]4+ [4.2] and [{Ru(DIP)2}2(tpphz)]4+ [4.3]. The 
luminescent properties of each complex were characterised and the in vitro 
DNA binding, cellular uptake and in cellulo DNA binding properties of [4.1] 
and [4.2] investigated by CLSM microscopy while the cytotoxicity towards a 
human breast cancer cell line was assessed. 
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The complex containing the ancillary ligand with the greatest delocalised π 
system, [4.3], was shown to demonstrate a significantly greater 
luminescence than [4.1] while [4.2] displayed a low emission in acetonitrile. 
This shows how the ancillary ligand can influence the luminescent 
properties of the molecule as a whole. 
 
DNA binding studies demonstrated [4.1] and [4.2] to be DNA light switch 
complexes; demonstrating a significant increase of luminescence when 
bound to DNA in comparison to free complex (a 27- and 62-fold increase in 
luminescence for [4.1] and [4.2] respectively), and luminescence binding 
titrations showed each complex to bind to DNA with a high affinity (Kb = 6.7 
× 106 M-1 and Kb = 6.7 × 106 M-1 for [4.1] and [4.2] respectively) – Table 
4.11. 
 
Complex 
MLCT absorption / 
nm (ε / M-1 cm-1) * 
Φ * 
(λex / nm) 
Kb / M-1 
[4.1] 443 (32182) 
6.9 ± 0.7 × 10-3  
(450) 
6.7 ± 0.8 × 106 
[4.2] 449 (22716) 
3 ± 2 × 10-4  
(450) 
5.8 ± 0.4 × 106 
[4.3] 454 (45712) 
0.017 ± 0.002 
 (450) 
water-insoluble 
 
Table 4.11 Summary of the photochemical and in vitro DNA binding properties 
of [4.1] – [4.3]. * In acetonitrile. 
 
Cellular studies revealed [4.1] to be internalised by the MCF-7 cell line by a 
non-endocytic mechanism of active transport where the complex functions 
as an imaging agent for both CLSM and TEM. The co-localisation of the 
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emission signal of [4.1] with DAPI, clear visualisation of condensed 
chromosomes of mitotic cells stained by the complex and the emission 
energy were all shown to be in agreement with the in vitro DNA binding 
data, strongly suggesting that the complex binds to DNA in cellulo, while 
TEM studies showed strong heterochromatin staining by the complex. [4.2] 
also stains the nuclei of live MCF-7 cells but the poor luminescence of the 
complex made further study problematic. Both [4.1] and [4.2] were shown 
to stain fixed and membrane-permeablised cells and the relative emission 
for each complex was in agreement with the in vitro DNA binding emission 
data. 
 
It is interesting to note that [4.1] displays reduced uptake properties 
compared to [3.1] – the majority of cells were stained by [4.1] but there 
were clearly cells not stained by the complex. This structure-specificity (in 
this case favouring phen as the ancillary ligand over 5mp) further suggests 
that at least one specific receptor-binding event is likely to occur at some 
point during the uptake process into the nucleus. In particular, if the cellular 
uptake of [3.1] is facilitated by binding to a specific protein, then it is 
possible that methyl-substitution at the 5 position of the phen ancillary 
could reduce the affinity of the complex for the protein and thus inhibit 
cellular uptake. 
 
Cytotoxicity studies demonstrated that [4.1] and [4.2] show the same 
behaviour as [3.1]; a low toxicity towards the MCF-7 cell line after 24 hour 
incubation but when this incubation time is increased to 72 hours a 
significantly greater toxicity is observed (IC50 values summarised in Table 
4.12). [4.1] demonstrated a reduced cytotoxicity in comparison to the 
parent complex [3.1]. This would be in agreement with the reduced cellular 
uptake demonstrated by [4.1] which in turn implies an intracellular 
mechanism of toxicity. Complex [4.2] demonstrated a greater toxicity than 
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[4.1] and [3.1], making it the most toxic of the dinuclear Ru(II)tpphz 
complexes studied within this thesis. As [3.1] binds DNA with a greater 
affinity than [4.2] this is further evidence that it is the cellular uptake 
properties, rather than DNA binding affinity, that is the most important 
factor which governs the toxicity of the complex. Combined with the results 
from Chapter 3, the cytotoxicity of dinuclear Ru(II)tpphz complexes is, in 
decreasing cytotoxicity, [4.2] > [3.1] > [4.1] > [3.2]. This shows how the 
cytotoxicity of a metal complex can be subtly modified by the choice of 
ancillary ligand, where the order of toxicity was shown to be: dmp > phen > 
5mp > bpy. It would be interesting to synthesise further derivatives and to 
expand this “toxicity series”.  
 
Complex 
Ancillary 
ligand 
log P 
IC50  / µM 
MCF-7 
(24 hr) 
MCF-7  
(72 hr) 
[4.1] 5mp -0.81 ± 0.08 246 ± 12 16 ± 2 
[4.2] dmp -0.69 ± 0.06 80 ± 4 5 ± 2 
[3.1] phen -0.96 ± 0.09 138 ± 6 6 ± 2 
[3.2] bpy -1.61 ± 0.10 >500 168 ± 9 
cisplatin -   -2.53* 12 ± 3 6 ± 2 
 
Table 4.12 Compiled octanol/water partition coefficient and IC50 values of 
dinuclear Ru(II)tpphz complexes towards MCF-7 cells. Data for [3.1] and [3.2] 
from Chapter 3 is included for reference. *Value obtained from Screnci et al.26 
 
Future work would focus on the DNA binding properties of [4.1] and [4.2], 
specifically examining the ability of each complex to bind quadruplex DNA. 
Previous work has shown the parent complex [3.1] binds to quadruplex 
DNA in vitro with a greater affinity than duplex7 and the wavelength and 
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intensity of the emission has recently been shown to be dependent on the 
exact structure of the DNA quadruplex to which it binds.27 In this context, it 
would be hoped that the equivalent studies on [4.1] and [4.2] would 
provide new quadruplex-interactive molecules, of particular relevance 
considering that each molecule has demonstrated anti-cancer cytotoxic 
potential.   
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Chapter 5 
Future perspective 
 
5.1 Introduction 
A major aim of this work was to examine the cellular DNA binding 
properties of Ru(II) DNA light switch complexes. The demonstration of 
successful internalisation, nuclear DNA staining and cytotoxicity of several 
Ru(II) complexes within this thesis represents a significant advance towards 
the use of such systems in biological applications. 
 
This work has shown the application of such complexes for both live and 
fixed cell DNA luminescent imaging and that these complexes are 
compatible with fluorescent microscopy techniques, including CLSM. In 
addition to this, these complexes are also able to act as contrast agents for 
TEM and thus are dual imaging agents; a unique property of metal-based 
DNA binding systems. In particular, luminescent mono- and dinuclear 
Ru(II)tpphz systems which bind to DNA reversibly have shown great 
potential as DNA imaging agents and also as potential anti-cancer 
therapeutics; specifically offering an alternative to platinum-based 
chemeotherapeutics (and other derivatives), which bind to DNA 
irreversibly. 
 
Future work based on the results and ideas developed in this thesis will be 
discussed within this chapter. 
Chapter 5: Future perspective 
199 
 
5.2 Quantitative uptake studies 
The work within this thesis has used qualitative techniques to assess 
cellular uptake of luminescent Ru(II) complexes. Importantly, this has 
provided information the cellular localisation of each complex but it has not 
shown the relevant total cellular ruthenium accumulation for each complex.  
 
Therefore, future work would carry out a systematic quantitative evaluation 
of the cellular uptake of each Ru(II) complex.  Using techniques such as AAS 
(atomic absorption spectroscopy) or ICP-MS (inductively coupled plasma 
mass spectroscopy), the amount of complex internalised by cells can be 
accurately quantified and the effects of ligand substitution, incubation 
concentration, serum, incubation time upon cellular uptake and cytotoxicity 
may be more accurately described. 
 
Indeed, Schatzschneider et al. used this approach for a series of Ru(II) 
complexes and showed that the complex that displays the greatest cellular 
uptake also displays the greatest cytotoxicity.1 It would be hoped that this 
approach would provide further illumination of the relationship between 
the rate of cellular uptake and cytotoxicity of the systems within this thesis 
which in turn would provide a measure of the potency of each complex.  
 
5.3 Chirally resolved complexes 
In Chapter 3, the cellular uptake, DNA imaging and cytotoxicity studies of 
[3.1] used the complex as a mixture of stereoisomers. [3.1] is a dinuclear 
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complex which contains two chiral Ru(II) metal centres and therefore three 
stereoisomers of the complex exist: ΛΔ (meso), ΛΛ and ΔΔ (Figure 5.1). 
 
When we consider that many currently used drugs are chiral molecules and 
that frequently only one enantiomer is active, with the other being 
responsible for unwanted side-effects, this makes the separation and related 
cellular studies of the stereoisomers of [3.1] of key importance. 
 
 
Figure 5.1 Stereoisomers of [3.1]. 
 
5.3.1 Synthesis of chirally resolved dinuclear Ru(II) complexes 
Preparation of [3.1] using the synthetic route described in Scheme 3.2 
results in the mixture of stereoisomers ΛΔ: ΛΛ: ΔΔ in the ratio of 2:1:1. As 
this is a mixture of both diastereomers (ΛΔ vs. ΛΛ and ΔΔ) and enantiomers 
(ΛΛ vs. ΔΔ), this makes the resolution of each stereoisomer more difficult. 
 
Using an approach developed by Norden and Lincoln2 and utilised by 
MacDonnell and co-workers,3 work by the Thomas group has instead 
Δ ΔΛ Λ
Λ Δ
= phen
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concentrated on synthesising the enantiomerically pure starting complexes 
[Ru(phen)2(dpq)]2+ (dpq = 1,10-phenanthroline-5,6-dione) and 
[Ru(phen)2(dap)]2+ (dap = 5,6-diamino-1,10-phenanthroline), which then 
may be reacted together to form the three required stereoisomers of [3.1] – 
Scheme 5.1.3, 4 This method involves the resolution of [Ru(phen)2(dpq)]2+ 
using the bulk resolution procedure of coprecipitation with sodium arsenyl 
(+)-tartrate or sodium arsenyl (−)-tartrate salts.2 The resolved complex may 
then be reacted with hydroxylamine and BaCO3 before reduction using 10% 
Pd-C to give [Ru(phen)2(dap)]2+.5 
 
  Scheme 5.1 Synthesis of resolved stereoisomers of [3.1]. 
 
In related research, MacDonnell et al. also show how resolution of the 
stereoisomers of [3.1] can be achieved with a high efficiency by using HPLC 
with a chiral stationary phase6 while Keene and co-workers have developed 
cation exchange chromatography with a utilising a chiral eluent to separate 
the diastereomers of numerous dinuclear Ru(II) metal species.7, 8 Both 
Λ or Δ Λ or Δ
Λ Λ, Δ Δ or Λ Δ
+
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techniques offer an alternative strategy if the proposed approach is 
unsuccessful. 
 
5.3.2 DNA binding properties 
All three stereoisomers are DNA light switch complexes and binding studies 
into the DNA affinities of the stereoisomers have shown that the binding of 
the ΛΛ isomer to G3 quadruplex DNA to be three orders of magnitude strong 
than that observed for ΔΔ, whereas a similar affinity for duplex DNA (CT-
DNA) is observed (Table 5.1).4 These results indicate that the chirality of the 
complex plays a large part in the binding to quadruplex DNA. 
 
Stereoisomer CT-DNA Kb / M-1 G3 DNA Kb / M-1 
Mixture  
(25% ΔΔ, 25% ΛΛ, 50% ΔΛ) 
6.68 ± 2.21 × 106 1.77 ± 2.85 × 106 
ΔΔ 1.99 ± 0.29 × 106 2.95 ± 5.52 × 104 
ΛΛ 6.73 ± 2.21 × 106 1.16 ± 0.66 × 107 
 
Table 5.1 Equilibrium binding constants of different diastereoisomers of [3.1] 
with CT-DNA and G3 quadruplex DNA.4 
 
5.3.3 Proposed cellular studies 
Future work will investigate the effect of the chirality of [3.1] upon the 
cellular internalisation and cytotoxicity. In a similar manner to the studies 
within this thesis on the unresolved complex, the MLCT luminescent 
properties of each stereoisomer can be used to directly compare the rate of 
cellular uptake and DNA binding properties for each stereoisomer. In 
particular, there is the question of how the chirality of the molecule affects 
the cellular uptake and if the stereoisomer that displays the higher affinity 
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for quadruplex DNA also displays the greatest ability to interfere with cell 
proliferation. 
  
5.4 Mechanism of toxicity 
Cisplatin, which remains the predominant treatment for hormone-
independent breast and ovarian tumours, irreversibly creates intra-strand 
DNA cross links, provoking a cell’s DNA damage response and ultimately 
inducing apoptosis.9 Cisplatin selectively kills cancer cells because tumour 
cells, unlike normal counterparts in the same tissue, have lost the ability to 
carry out homologous recombination (HR), which is used to repair the DNA 
lesion. However, tumour cells have very high rates of DNA mutation and can 
recover their HR capability to become cisplatin-resistant.10  
 
As shown in this work, the monometallic complex [2.3] demonstrates a 
cytotoxicity comparable to cisplatin, while the dinuclear complexes [3.1], 
[4.1] and [4.2] each demonstrate a similar potency to cisplatin over an 
extended incubation time; signifying that each complex displays the ability 
to interfere with cancer cell proliferation. 
 
However, the biological mechanism by which these complexes induce cell 
death is unknown. As the mechanism of DNA-binding of each complex is 
radically different to cisplatin, a reversible association rather than direct 
coordination to the DNA double helix, it would be predicted that the 
mechanism of toxicity is also very different. This in turn would indicate that 
such complexes will remain active against cisplatin-resistance cancer, as 
demonstrated for [2.3] in Chapter 2, and thus may represent an entirely 
new class of therapeutics. 
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These complexes may photosensitise reactive species such as singlet oxygen, 
thus inducing cytotoxic effects by damaging DNA or other critical cellular 
components. Alternatively, binding of these complexes to DNA may interfere 
with some key aspect of DNA metabolism leading directly or indirectly to 
cell death. With this in mind, the mechanism of toxicity is of great interest 
and future work would be concentrated in the following areas: 
 
5.4.1 Mechanism of induced cell death 
Molecules which bring about irreparable forms of DNA damage (such as 
cisplatin) induce a defined cell death programme or apoptosis. In order to 
establish whether these Ru(II) complexes could act to induce apoptotic or 
necrotic cell death, complex-treated cells will be monitored for the timely 
appearance of key markers of apoptosis, including specific proteases such as 
activated caspase 3, the appearance of DNA single-strand breaks and plasma 
membrane-associated Annexin V, all of which may be detected by direct 
fluorescence or indirect immunofluorescence microscopy.11  
 
Something of specific interest is the possibility that [3.1] binds to 
quadruplex DNA in vivo and that this is responsible for the toxic properties 
of the complex. If so, this would be predicted to inhibit telomerase function. 
The enzymatic activity of telomerase would be quantified using the 
telomerase TRAP (telomere repair amplification protocol) assay and would 
be predicted to decrease with increasing exposure to [3.1]. 
 
5.4.2 Comparative analysis of complex cytotoxicity in cisplatin-
resistant and sensitive cell-lines 
Recent evidence has indicated that one major mechanism for the emergence 
of platinum resistance in ovarian cancers involves the re-acquisition of 
function in the breast/ovarian cancer sensitivity gene BRCA2 by mutational 
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reversion.12 Therefore, a series of experiments using BRCA2-deficient 
ovarian cancer cell lines and their wild-type BRCA2 derivatives would be 
used to establish the relationship between sensitivity to the Ru(II) 
complexes and HR capability. It would be hoped that the toxicity of the 
Ru(II) complexes is independent of cell HR capability, which would signify 
their potential as an exciting new class of anti-cancer therapeutics. 
 
5.5 Cellular uptake mechanism 
An exciting finding which emerges from the studies in this thesis is the 
observation of cell-specific uptake of [3.1], where MCF-7 breast cancer cells 
display increased staining by the complex compared to HDF primary human 
skin cells when grown together in co-culture. This raises the question of 
how the molecule enters cells and, along with the structure-specificity 
observed for the Ru(II) complex, this suggests the involvement of a specific 
(most likely, protein) receptor and internalisation pathway. The uptake 
mechanism has important implications for the activity, optimisation and 
mechanism of toxicity of this class of molecule; something of relevance to 
the role of [3.1] both as an imaging agent and novel anti-cancer therapeutic. 
 
Interestingly, [3.1] is internalised by Drosophila S2 tissue culture cells 
(Figure 5.2). The availability of whole genome information, and minimal 
redundancy of function, makes Drosophila an attractive system for the 
identification of gene products involved in any biological function. The 
technique of RNA interference (RNAi) in cells involves the introduction of a 
small RNA molecule whose base sequence is complementary to the coding 
sequence of a messenger RNA encoding a particular protein, resulting in the 
specific elimination of that protein from cells. The availability of the entire 
Drosophila genome sequence allows for the design of a complete set of RNAi 
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molecules for every gene (~16,000) in the organism.13 The emergence of 
software and hardware to analyse datasets arising from the elimination of 
each gene product separately in one single experiment makes this the 
approach of choice for the identification of components of the pathway 
involved in the cellular uptake and nuclear targeting of the Ru(II) complexes 
described here.   
 
Future work would employ the RNAi screening facility at the University of 
Sheffield for a systematic genome-wide screen in Drosophila with the aim to 
identify the genes which regulate the uptake pathway of [3.1]. This would 
use the same principle as for the inhibition studies on MCF-7 cells; the in 
cellulo luminescence of [3.1] would be used as an indication of successful 
cellular uptake in a genome-wide fluorescence assay, utilising an automated 
high content microscope to process and quantify the luminescence obtained 
in each case. Identification of a putative receptor for Ru(II) complexes 
uptake in Drosophila cells  would require subsequent validation in a human 
cell line, involving the identification of human homologue(s) of the 
Drosophila gene, and comparative  analysis of Ru(II) complex uptake into 
cell populations which retain or lack the putative receptor.  
 
 
Figure 5.2 CLSM images of Drosophila cells incubated with dinuclear Ru(II)tpphz 
complex [3.1] (500 µM, 80 mins). Left: Ru(II) emission. Centre: Phase contrast. 
Right: Overlay image of Ru(II) emission and phase contrast. 
phase[3.1] overlay
10 μm
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5.6 Application of IT50 values 
The use of IC50 values (that is, the concentration required to induce 50% cell 
death for a given incubation time) is frequently used to compare the toxic 
properties of molecules. Due variance in experimental protocols (such as 
incubation time), comparisons between research groups can be problematic.  
 
As time is a fixed quantity for a given experiment, two complexes that have 
the same IC50 value may also display significantly different toxic behaviour 
over an extended time period – this was observed where [3.1] displays an 
IC50 value an order of magnitude larger than cisplatin when cells are 
exposed to it for 24 hours, but an equal IC50 with 72 hour exposure. 
 
Another drawback is that an IC50 value does not describe the behaviour 
above and below this concentration. So two complexes may have the same 
IC50 value but one may be significantly more toxic at other concentrations –
for example, cisplatin and [3.1] have the same IC50 value for 72 hour 
incubation time but cisplatin demonstrates a higher toxicity at sub-IC50 
concentrations than [3.1]; something not reflected by the IC50 value for each 
complex. 
 
The use of IT50 values (that is, the time required to induce 50% cell death for 
a given concentration) within this thesis demonstrates an alternative to the 
IC50 method and one specific advantage of this method is it takes time as a 
variable into account, allowing a more detailed assessment to be made of the 
toxicity of a molecule. 
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When the IT50 values recorded in this thesis (Section 3.8) are plotted on a 
graph of log C vs. IT50 and an exponential relationship is observed and 
therefore the data may be fit by a standard exponential decay curve (Figure 
5.3). As the incubation time for an IC50 experiment is equal to the IT50 value 
for the IC50 concentration obtained, IC50 values may be plotted onto the 
same graph. These results show that the IC50 values for 24 and 72 hour 
incubation times are in agreement with the IT50 values measured for [3.1], 
indicating that both experimental techniques can be combined together.  
 
 
Figure 5.3 Plot of IT50 vs. log [complex] for [3.1] in MCF-7 cells. Data fit by y = 
ae-bx (a = 1.139, b = 0.797). R2 = 0.998 by least squares analysis. 
 
This approach also means that, for any given time, the associated IC50 value 
may be calculated by interpolation. For example, the IC50 value for MCF-7 
cells exposed to [3.1] for 48 hours can be determined to be 20 µM from the 
fit plotted in Figure 5.3. 
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The rate of toxicity, b, is a measurement of how toxicity varies with 
concentration: a large rate of toxicity value indicates a large variation of 
toxicity with concentration. 
 
The use of IT50 values can thus be applied in conjunction with the standard 
concentration/viability IC50 assay to describe the toxic properties of a 
molecule more completely and future work would develop this idea further 
by measuring the IT50 values for more molecules. It would be interesting to 
compare the decay curves of currently used anti-cancer drugs to those of 
potential candidates and, indeed, if there is any potential of this concept to 
be used as a model that is able to predict the drug-likeness of a molecule.  
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Chapter 6 
Experimental methods 
 
6.1 General 
6.1.1 Chemicals 
All chemicals and solvents were purchased from commercial sources and 
were used as supplied unless stated otherwise. All Ru(II) complexes were 
treated as toxic. 
 
6.1.2 Nuclear magnetic resonance (NMR) spectroscopy 
1H NMR spectra were recorded on a Bruker AM250 machine working in 
Fourier transform mode. The following abbreviations are used in the 
annotation of 1H spectra: s = singlet, d = doublet, dd = doublet of doublets, t 
= triplet and m = multiplet.  
 
6.1.3 Mass spectroscopy 
Fast-atom bombardment (FAB) mass spectra (MS) were recorded on a 
Kratos MS80 mass spectrometer working in positive ion mode. 
 
6.1.4 Elemental analysis 
Microanalyses for carbon, hydrogen and nitrogen were obtained using a 
Perk-Elmer 2400 analyser working at 975 °C. 
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6.2 Synthesis 
6.2.1 Tris(1-pyrazoyl)methane (tpm)1 
Pyrazole (20 g, 294 mmol) and tetra-n-butylammonium 
bromide (4.7 g, 14.7 mmol) were both added to distilled 
water (300 ml). With vigorous stirring using 
mechanical agitation sodium carbonate (187 g, 1.8 mol) was added. After 
cooling to room temperature, chloroform (150 ml) was added and the 
mixture boiled under reflux for three days. The solution was cooled to room 
temperature and filtered to remove excess base. An extraction with ether 
and water carried out. The combined organic layers were washed with 
saturated brine (200 ml) and dried over magnesium sulphate. The solvent 
was removed by rotary evaporation and the solid dried in vacuo. Mass = 
6.24 g (294 mmol, 33.3 % yield) orange solid. 1H NMR (acetone-d6) δ 
(splitting, integration): 6.40 (dd, 3H), 7.62 (d, 3H), 7.86 (d, 3H) 8.73 (s, 1H). 
 
6.2.2 1,10-phenanthroline-5,6-dione (dpq)2 
1,10-phenanthroline (5 g, 27.8 mmol) was dissolved into 
concentrated sulphuric acid (30 mL). Sodium bromide 
(2.6 g) and nitric acid (15 mL) were then carefully added 
and the mixture boiled under reflux for 40 minutes. The 
solution was cooled and poured over ice (400 g) and neutralised to pH 7.0 
by addition of aqueous sodium hydroxide. An extraction with chloroform 
was carried out. The collected organic layers were dried with magnesium 
sulphate and the solvent removed by rotary evaporation. The yellow 
product was recrystallised using water/methanol (1:50). Mass = 2.83 g 
(13.4 mmol, 48.2 %) yellow solid. 1H NMR (CDCl3) δ (splitting, integration):  
7.56 (dd, 2H), 8.47 (dd, 2H), 9.07 (dd, 2H).  
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6.2.3 Dipyrido[3,2-a:2’,3’-c]phenazine (dppz)2 
o-Phenylenediamine (0.6 g, 5.46 mmol) and dpq (1 g, 
4.76 mmol) were boiled under reflux in ethanol (60 
mL) for twenty minutes. The brown solid formed was 
recrystallised from ethanol/water (1:1). The solid was 
collected by filtration and dried under vacuum. Mass = 0.85 g (3.01 mmol, 
63.2 %) pale yellow solid. 1H NMR (acetone-d6) δ (splitting, integration):   
7.90 (dd, 2H), 8.10 (dd, 2H), 8.40 (dd, 2H), 9.20 (dd, 2H), 9.65 (dd, 2H). 
 
6.2.4 Tetrapyrido[3,2-a:2’,3’-c:3’’,2’’-h:2’’’,3’’’-j]phenazine (tpphz)3 
Ammonium acetate (15 g, 194.6 mmol), dpq (2.90 g, 
13.8 mmol) and sodium sulfite (300 mg, 1.72 mmol) 
were boiled under reflux in ethanol (50 mls) for 2 hrs 
at 180°C under nitrogen. The solution was cooled and 
water (20 ml) was added resulting the formation of a yellow precipitate 
which was collected and washed with water, methanol and acetone. The 
crude product was added to boiling EtOH (100 ml), filtered while hot and 
dried in vacuo. Mass = 0.906 g (2.36 mmol, 34.2 %) yellow solid. 1H NMR 
(TFA-d6) δ (splitting, integration):  8.9 (t, 4H), 9.85 (dd, 4H), 10.8 (dd, 4H). 
MS; m/z (%): 385 (100) [M+]. 
 
6.2.5 [Ru(tpm)(Cl)3]
4 
RuCl3.3H2O (1.22 g, 4.67 mmol) and tpm (1 g, 4.67 mmol) 
were boiled under reflux in ethanol (50 mL) for three 
hours. After cooling the dark precipitate was filtered and 
washed with cold ethanol and ethyl ether then dried 
under vacuum. Mass = 1.32 g (3.14 mmol, 67.2 %) brown solid. MS m/z (%) 
389 (100) [M-Cl]+. 
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6.2.6 [Ru(tpm)(Cl)(dppz)]+ 5 
[Ru(tpm)Cl3] (1.11 g, 2.61 mmol), dppz 
(0.75 g, 2.66 mmol) and LiCl (0.40 g) 
were boiled under reflux in 
ethanol/water (3:1, 100 mL) for ten 
minutes. Twelve drops of triethylamine were added and the solution boiled 
under reflux for 30 minutes under a nitrogen atmosphere.  The solution was 
cooled and the solvent removed. The residue was dissolved in methanol (20 
mL) and the fine dark solid was filtered out. The product was precipitated 
by addition of aqueous NH4PF6 and collected by filtration. The crude 
product was chromatographed on grade l alumina with acetonitrile/toluene 
(1:1). The purple band was collected and concentrated by rotary 
evaporation. Addition of diethyl ether precipitated the product as a dark 
solid. Mass= 0.66 g (0.85 mmol, 25.3 %) purple solid. 1H NMR (acetone-d6) δ 
(splitting, integration): 6.30 (td, 1H), 6.87 (m, 3H), 8.06 (dd, 2H), 8.17 (dd, 
2H), 8.42 (dd, 2H), 8.52 (dd, 2H), 8.57 (m, 3H), 9.17 (dd, 2H), 9.57 (dd, 2H), 
9.63 (s, 1H). MS m/z (%): 633 (100) [M]+, 597 (30) [M-Cl]+. 
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6.2.7 [Ru(tpm)(NCMe)(dppz)]2+ [2.1]5 
[Ru(tpm)(Cl)(dppz)](PF6) (0.1 g, 0.13 
mmol) and AgCF3SO3 (0.36 g, 0.14 
mmol, 1.1 eq.) were heated at reflux in 
freshly distilled acetonitrile (50 mL) for 
fourteen hours. After cooling, the 
solvent was removed and the residue was taken up into methanol (20 mL). 
The solution was filtered through Celite and treated with aqueous NH4PF6 to 
precipitate the product, which was collected by filtration and dried under 
vacuum. Mass = 0.054 g (0.06 mmol, 44.7 %) red solid. 1H NMR (acetone-d6) 
δ (splitting, integration): 2.29 (s, 3H), 6.37 (dd, 1H), 6.95 (dd, 2H), 7.07 (dd, 
1H), 8.22 (dd, 2H), 8.27 (dd, 2H), 8.56 (t, 2H), 8.62 (dd, 1H), 8.80 (dd, 2H), 
9.42 (dd, 2H), 9.86 (dd, 2H), 9.87 (dd, 2H), 10.01 (s, 1H). MS m/z (%): 784 
(100) [M-PF6]+, 638 (70) [M]+, 597 (80) [M-(MeCN)-2(PF6)]+. 
 
6.2.8 [Ru(tpm)(py)(dppz)]2+ [2.2]
5 
[Ru(tpm)(Cl)(dppz)](PF6) (0.10g, 0.13 
mmol) and AgNO3 (0.035 g, 0.22 mmol) 
were boiled at reflux in ethanol: water 
(3:1) (40 mL) for five hours. After 
cooling to room temperature the 
solution was filtered through Celite to remove solid AgCl. Pyridine (1 mL) 
was added and the solution boiled at reflux overnight. After cooling to room 
temperature the solution was filtered again through Celite and aqueous 
NH4PF6 was added. The precipitate was collected by filtration and washed 
with water and diethyl ether then dried under vacuum. Mass = 0.10 g (0.10 
mmol, 76.9 %) orange solid. 1H NMR (acetone-d6) δ (splitting, integration):  
6.30 (dd, 1H), 6.93 (dd, 1H), 6.98 (m, 2H), 7.15 (dd, 2H), 7.76 (dd, 2H), 7.80 
(t, 1H), 8.21 (dd, 2H), 8.24 (dd, 2H), 8.52 (dd, 2H), 8.56 (m, 2H), 8.58 (dd, 
1H), 8.85 (dd, 2H), 9.42 (dd, 2H), 9.87 (dd, 2H), 9.93 (s, 1H). MS m/z (%): 
965 (45) [M]+, 597 (55) [M-py-2(PF6)]2+. 
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6.2.9 [Ru(phen)2(Cl)2]
6 
RuCl3.3H2O (3 g, 11.53 mmol), 1,10-phenanthrolene (4.1 g, 
22.7 mmol) and LiCl (3.1 g, 73.8 mmol) were heated at 
reflux in dimethylformamide (40 ml) for 8 hours. After 
cooling to room temperature, 200 ml of acetone was 
added and then the solution was stored at 4°C for 16 
hours. The precipitate was collected by filtration, washed with water and 
ether before drying in vacuo. Mass = 3.75 g (7.05 mmol, 62.1 %) brown-
green solid. MS m/z (%): 532 (65) [M]+. 
 
6.2.10 [{Ru(phen)2}2(tpphz)]
4+ [3.1]3, 7 
[Ru(phen)2Cl2] (0.922g, 
1.73 mmol) and tpphz 
(0.267g, 0.70 mmol) were 
added to a 1:1 solution of 
EtOH/water (80 mls) and 
heated at reflux for 12 hours under nitrogen. The solution was cooled to 
room temperature then a further 16 hours at 4°C. The brown solution was 
filtered and the ethanol removed by rotary evaporation. The addition of 
NH4PF6 caused the formation of a dark brown precipitate which was 
collected by filtration, washed with water, recrystallised in acetonitrile by 
addition of diethyl ether and dried in vacuo.  Mass = 1.13g (0.60 mmol, 85.7 
%) orange/brown solid. 1H NMR (acetone-d6) δ (splitting, integration): 7.8 
(t, 8H), 8.0 (t, 4H), 8.4 (d, 4H), 8.4 (s, 8H), 8.6 (dd, 8H), 8.8 (dd, 8H), 10.1 (dd, 
4H). MS; m/z (%): 1742 (65) [M-PF6]+, 1598 (100) [M-2(PF6)]+, 1453 (45) 
[M-3(PF6)]+. 
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6.2.11 [Ru(bpy)2(Cl)2]
6 
RuCl3.3H2O (3 g, 11.53 mmol), bipyridine (3.6 g, 22.8 
mmol) and LiCl (3.12 g, 73.8 mmol) were heated at reflux 
in dimethylformamide (30 ml) for 8 hours. After cooling 
to room temperature, 200 ml of acetone was added and 
then the solution was stored at 4°C for 16 hours. The 
precipitate was collected by filtration and washed with water and ether 
before drying in vacuo. Mass = 4.513 g (9.32 mmol, 81.8 %) brown-green 
solid.  MS m/z (%): 484 (100) [M]+. 
 
6.2.12 [{Ru(bpy)2}2(tpphz)]
4+ [3.2]3, 7 
[Ru(bpy)2Cl2] (1.012 g, 
2.09 mmol) and tpphz 
(0.267g, 0.70 mmol) were 
added to a 1:1 solution of 
EtOH/water (80 mls) and 
heated at reflux for 12 hours under nitrogen. The solution was cooled to 
room temperature then a further 16 hours at 4°C. The brown solution was 
filtered and the ethanol removed by rotary evaporation. The addition of 
NH4PF6 caused the formation of a red/brown precipitate which was 
collected by filtration and washed with water. The crude product was 
recrystallised from acetonitrile/ether and dried in vacuo. Mass = 0.8 g (0.45 
mmol, 64.3 %) red solid. 1H NMR (MeCN-d6) δ (splitting, integration): 7.5 
(m, 8H), 7.7 (m, 8H), 7.9 (d, 4H), 8.0 (m, 8H), 8.3 (dd, 4H), 8.5 (m, 8H), 10.0 
(dd, 4H). MS; m/z (%): 1647 [M-PF6]+, 1502 [M-2(PF6)]+, 1357 [M-3(PF6)]+, 
1212 [M-4(PF6)]+. Elemental analysis for [3.2](PF6)4, C64H44F24N14P4Ru2: 
Calcd: C; 42.92, H; 2.48, N; 10.95. Found: C; 42.18, H; 2.57, N; 10.58. 
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6.2.13 [Ru(5mp)2(Cl)2] 
RuCl3.3H2O (1.3 g, 5 mmol), 5-methyl-1,10-
phenanthroline (5mp) (2 g, 10 mmol) and LiCl (1.4 g, 
33.3 mmol) were heated at reflux in dimethylformamide 
(40 ml) for 8 hours under a nitrogen atmosphere. After 
cooling to room temperature, 100 ml of acetone was 
added and then the solution was stored at 4°C for 24 hours. The precipitate 
was collected by filtration, washed with water and ether before drying in 
vacuo. Mass = 1.526g (2.73 mmol, 54.5 %) brown solid. MS; m/z (%): 525 
(100) [M-Cl]+.  
 
6.2.14 [{Ru(5mp)2}2(tpphz)]
4+ [4.1] 
[Ru(5mp)2(Cl)2] (0.9g, 1.61 
mmol) and tpphz (0.263g, 
0.68 mmol) were added to a 
1:1 solution of EtOH/water 
(80 mls) and heated at reflux 
for 12 hours under nitrogen. The solution was cooled to room temperature 
then a further 24 hours at 4°C. The ethanol removed by rotary evaporation. 
The addition of NH4PF6 caused the formation of a red/brown precipitate 
which was collected by filtration and washed with water. The crude product 
was recrystallised from acetonitrile/ether and dried in vacuo. Mass = 1.134g 
(0.65 mmol, 85.6 %) orange/brown solid. 1H NMR (MeCN-d6) δ (splitting, 
integration): 2.9 (s, 12H), 7.7 (m, 8H), 7.9 (m, 4H), 8.1 (m, 4H), 8.2 (s, 4H), 
8.3 (m, 8H), 8.5 (m, 8H), 10.0 (dd, 4H). MS; m/z (%): 827 (100%) [M-
2(PF6)]2+, 503 (35%) [M-3(PF6)]3+. Elemental analysis for 
[4.1](PF6)4.4.5H2O, C76H61F24N14O4.5P4Ru2: Calcd: C; 45.09, H; 3.04, N; 9.69. 
Found: C; 45.04, H; 3.03, N; 9.66. 
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6.2.15 [Ru(dmp)2Cl2] 
RuCl3.3H2O (3.12 g, 12 mmol), neocuproine (dmp) (5 g, 24 
mmol) and LiCl (3.1 g, 73.8 mmol) were heated at reflux 
in dimethylformamide (40 ml) for 8 hours under a 
nitrogen atmosphere. After cooling to room temperature, 
100 ml of acetone was added and then the solution was 
stored at 4°C for 24 hours. The precipitate was collected by filtration, 
washed with water and ether before drying in vacuo. Mass = 3.98 g (6.8 
mmol, 56.4 %) dark brown solid. MS m/z (%): 590 (80) [M]+. 
 
6.2.16 [{Ru(dmp)2}2(tpphz)]
4+ [4.2] 
[Ru(dmp)2(Cl)2] (1.02g, 
1.73 mmol) and tpphz 
(0.267g, 0.7 mmol) were 
added to a 1:1 solution of 
EtOH/water (50 mls) and 
heated at reflux for 12 
hours under nitrogen. The solution was cooled to room temperature then a 
further 24 hours at 4°C. The ethanol was removed by rotary evaporation. 
The addition of NH4PF6 caused the formation of a red/brown precipitate 
which was collected by filtration and washed with water. The crude product 
was recrystallised from acetonitrile/ether and dried in vacuo. Mass = 1.216 
g (0.11 mmol, 86.9 %) brown solid. 1H NMR (MeCN-d6) δ (splitting, 
integration): 2.9 (s, 24H), 7.7 (t, 8H), 7.9 (t, 4H), 8.1(m, 8H), 8.2 (s, 8H), 8.5 
(dd, 4H), 10.0 (dd, 4H). MS; m/z (%): 855 (20%) [M-2(PF6)]+, 537 (100%) 
[M-3(PF6)]3+. Elemental analysis for [4.2](PF6)4.2H2O, C80H64F24N14O2P4Ru2: 
Calcd: C; 47.21, H; 3.17, N; 9.63. Found: C; 46.27, H; 3.17, N; 9.69. 
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6.2.17 [Ru(DIP)2Cl2] 
RuCl3.3H2O (2.1 g, 8.03 mmol), 4-7-diphenyl-1,10-
phenanthrolene (DIP) (5 g, 15 mmol) and LiCl (2.08 g, 
49 mmol) were heated at reflux in 
dimethylformamide (20 ml) for 8 hours under a 
nitrogen atmosphere. After cooling to room 
temperature, 100 ml of acetone was added and then 
the solution was stored at 4°C for 24 hours. The 
precipitate was collected by filtration, washed with 
water and ether before drying in vacuo. Mass = 2.95g (3.5 mmol, 46.7 %) 
brown solid. MS; m/z (%): 836 (100%) [M]+. 
 
6.2.18 [{Ru(DIP)2}2(tpphz)]
4+ [4.3] 
[Ru(DIP)2(Cl)2] (1.47g, 1.76 
mmol) and tpphz (0.34g, 
0.88 mmol) were added to a 
1:1 solution of EtOH/water 
(50 mls) and heated at reflux 
for 12 hours under nitrogen. 
The solution was cooled to 
room temperature then a 
further 24 hours at 4°C. The ethanol removed by rotary evaporation. The 
addition of NH4PF6 caused the formation of a red/brown precipitate which 
was collected by filtration and washed with water. The crude product was 
recrystallised from acetonitrile/ether and dried in vacuo. Mass = 1.62 g 
(0.65 mmol, 73.8 %) red solid. 1H NMR (MeCN-d6) δ (splitting, integration): 
7.5 (d, 16H), 7.6 (d, 16H), 7.8 (m, 16H), 8.0 (m, 4H), 8.2 (s, 8H), 8.3 (dd, 4H), 
8.4 (d, 8H), 8.5 (d, 8H), 10.1 (dd, 4H). MS; m/z (%): 1103 (55%) [M-
2(PF6)]2+, 686 (100%) [M-3(PF6)]3+. Elemental analysis for 
[4.3](NO3)4.10H2O, C120H96N18O22Ru2: Calcd: C; 61.48, H; 4.12, N; 10.75. 
Found: C; 61.83, H; 4.36, N; 10.50. 
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6.2.19 Anion metatheses 
The hexafluorophosphate salt of each complex was dissolved in the 
minimum volume of acetone and a saturated solution of ammonium 
chloride in acetone added. The resultant precipitated chloride salt was 
collected by filtration, washed with cold acetone and dried in vacuo. 
 
6.2.20 Complex preparation for cellular studies 
Stock solutions of the chloride salts of each complex were made in PBS 
(typically 5 mM). Sonication and gentle heating were used to aid dissolution, 
as required. Stock solutions were filter sterilised with a 0.20 μm filter.  
 
6.3 Photochemistry 
6.3.1 Absorption spectra 
A quartz cuvette was loaded with solutions of the complex dissolved in 
acetonitrile (as the PF6- salt) or water (at the Cl- salt) and absorption spectra 
were collected using a Cary 500 Scan UV-vis-NIR Spectrophotomer working 
in double beam mode (spectral band width = 2 nm) at a scan speed of 600 
nm/min and baseline corrected. 
 
6.3.2 Molar extinction coefficients 
The absorbance, A, for each peak was recorded (path length, l = 1 cm) and 
an average value for the molar extinction coefficient, , over a range of 
concentrations, c, was calculated using the Beer-Lambert law (Equation 6.1). 
lcA   
Equation 6.1The Beer-Lambert law. 
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6.3.3 Excitation and emission spectra 
Deoxygenation for the luminescence experiments was performed by 
bubbing the solvent used for each sample with nitrogen for 30 mins. 
Solutions of each complex (5, 10, 20 µM) were dissolved in acetonitrile, 
loaded into a cuvette and the excitation and emission spectrum was 
recorded using a Fluoromax-3 Spectrophotometer (excitation and emission 
slit = 5 nm, scan speed = 100 nm/min). 
 
6.3.4 Quantum yields 
For each complex and reference sample, the emission spectra (λex = 463 nm) 
was recorded and the integrated emission intensity calculated using the 
Fluoromax-3 Spectrophotometer software. The absorbance at 463 nm was 
measured by UV-vis spectrophotometry. The quantum yield value for each 
complex calculated using Equation 4.1, where Φx and Φref are the quantum 
yields of the sample and reference respectively, Ax and Aref the measured 
absorbance of the sample and reference at the excitation wavelength, Ix and 
Iref the integrated emission intensities of the sample and ηx and ηref are the 
refractive index of the solvent of the sample and reference respectively. 
[Ru(bpy)3](PF6)2 in CH3CN (Φ = 0.062) was used as the reference.8 A graph 
of A vs. I was plotted for each complex and [Ru(bpy)3](PF6)2 . The quantum 
yield was calculated using each gradient and Equation 4.1. At least 5 data 
points were used in the construction of each graph. 
2
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Equation 4.1 Quantum yield. Φ = quantum yield, A = absorbance at the 
excitation wavelength, I = integrated emission intensity, η = solvent refractive 
index for the reference (ref) and sample (x). 
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6.4 DNA binding studies 
6.4.1 DNA preparation 
Calf thymus DNA (CT-DNA) was dissolved in aqueous buffer (25 mM NaCl, 5 
mM Tris, pH = 7) and broken into an average of 150-200 base pair 
fragments by sonication (2 × 15 mins). The purity of the sample was 
determined by UV-vis spectroscopy, with A260/A290 > 1.9 indicating a 
protein-free sample. The concentration of CT-DNA was determined by UV-
vis spectroscopy (ε280nm = 13200 M-1 cm-1). 
 
6.4.2 Luminescence titration 
A 5 µM solution of the complex was dissolved in aqueous buffer (25 mM 
NaCl, 5 mM Tris, pH = 7) and loaded into a quartz cuvette. This was allowed 
to equilibrate at 25°C for 30 mins and the emission spectra recorded. 0.5 -2 
µL of a concentrated stock CT-DNA solution in aqueous buffer (typically 200 
µM) was added and the solution mixed by pipette. The emission spectrum 
was recorded, showing an enhancement in emission, and this procedure 
was continued until the emission became constant. The emission intensity I 
for each addition of DNA was calculated using the Fluoromax-3 
Spectrophotometer software and the binding constant calculated using the 
binding model described in detail in Section 4.4. 
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6.5 Octanol/water partition coefficients 
Calculated octanol/water partition coefficients for organic molecules and 
ligands were obtained using the “Molinspiration” software.9 Experimentally 
determined octanol/water partition coefficients for each Ru(II) complex 
were obtained using the “shake-flask” method described as follows: A 
sample of the chloride salt of each complex was dissolved in deionised 
water (100 µM) and the absorbance recorded. A known volume of water 
was then mixed with an equal volume of n-octanol by inversion (x 50) and 
the two layers were allowed to separate overnight. The concentration of 
complex in each phase was quantified by absorbance at 450 nm and 
interpolated with the calibration graph of absorbance v. concentration of 
the complex in each solvent. The partition coefficient, log P, was calculated 
using Equation 2.1 (n = 3). 







water
octanol
wateroctanol
complex
complex
][
][
logPlog /  
Equation 2.1 Calculation of octanol/water partition coefficient log P. 
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6.6 Cell Culture 
MCF-7 (human breast carcinoma), A2780 and CP70 (human ovarian 
carcinoma) cell lines were cultured in RMPI-1640 medium. FaDu (human 
hypopharyngeal carcinoma), Saos-2 (human osteosarcoma) cell lines and 
primary HDF (human dermal fibroblast) cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM). HeLa (cervical carcinoma) cells were 
cultured in either RMPI-1640 or DMEM media, as specified by the 
experiment. All growth media was supplemented with 2 mM L-glutamine, 
100 IU ml-1 penicillin, 100 µg ml-1 streptomycin and 10% fetal calf serum 
(FCS). Cultures were grown as monolayers and maintained at 37°C in an 
atmosphere of 5 % CO2 / 95 % air. Cultures were subcultured routinely 
using Trypsin (0.1 % v/v in PBS) once 80-95 % confluence was achieved. 
L5178Y-R (mouse lymphoma) cells were cultured in suspension in RPMI-
1640 medium, supplemented with 2 mM L-glutamine, 100 IU ml-1 penicillin, 
100 µg ml-1 streptomycin and 10% FCS and subcultured via centrifugation. 
Cell lines were used between passage numbers 5-40 and primary cell 
cultures were used between passage numbers 3-6.  
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6.7 Confocal laser scanning microscopy (CLSM) 
6.7.1 Sample preparation for live cell microscopy 
For live cell microscopy, cell cultures were grown on 6 well plates for 
upright microscopy or microdishes (Thistle Scientific) for inverted 
microscopy and allowed to grow for a minimum of 24 hours. Cell cultures 
were then incubated with solutions of Ru(II) complex at the stated 
conditions, concentration and time for the relevant experiment. After 
incubation, the complex-containing medium was removed and the cells 
washed with PBS. 
 
6.7.2 Sample preparation for fixed cell microscopy 
For fixed cell experiments, monolayers were treated with 10% 
formaldehyde (10 minutes) or 70% cooled ethanol before incubation with 
Ru(II) complex (typically 100 M in PBS for 10 minutes). For staining after 
fixation, cells fixed using formaldehyde were additionally permeablised with 
Triton (10 minutes) before exposure to the complex. After incubation, the 
solution was removed and the cells were washed with PBS. 
 
6.7.3 Co-staining 
Where stated, co-staining was performed using the following commercially 
available stains (Invitrogen), which were dissolved in PBS unless otherwise 
indicated: SYTO9 (2 M, 2 minutes), PI (10 M, 10 minutes), DAPI (500 nM, 
2 minutes), Mitotracker Red (1 M, 20-45 minutes, serum-free culture 
medium) and Lysotracker Yellow (100 nM, 45–60 minutes, normal culture 
medium). After co-staining, cells were washed with PBS before imaging. 
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6.7.3 Image acquisition 
Cell cultures were luminescently imaged on Zeiss LSM 510 META upright 
and Zeiss LSM 510 META inverted confocal laser scanning microscopes 
equipped with Argon (λex = 458 nm, 488 nm, 514 nm), He-Ne (λex = 543 nm, 
643 nm) lasers and a blue diode laser (λex = 405 nm, inverted microscope 
only). Objectives used were: 40x, 63x and 100x long-range water-dipping 
lenses (upright microscope) or 40x and 63x oil-immersion lenses (inverted 
microscope). Ru(II) complexes were excited with an Ar-ion laser at 458 nm 
and emission collected using META detection within a 600-700 nm (red) 
range; the exact wavelengths used for each complex as stated by the specific 
experiment. SYTO9 was excited at 488 nm (Ar-ion) and emission collected 
using a 500-530 nm BP (bandpass) filter. PI was excited at 543 nm (He-Ne) 
and emission collected using META detection at 565-615 nm. DAPI was 
excited using a 405 nm diode laser and emission detected using a 420 nm LP 
(long-pass) filter. Mitotracker Red was excited at 543 nm (He-Ne) and 
emission detected using META detection at 580-620 nm. Lysotracker Yellow 
was excited at 458 nm (Ar-ion) and emission detected using a 500-560 nm 
BP filter. Image data acquisition and processing was performed using Zeiss 
LSM Image Browser. Co-localisation was performed using histogram 
analysis, with the two emissions as the parameters selected (Figure 6.1). 
Emission signals were unmixed, where appropriate. 
 
 
Figure 6.1 Colocalisation set-up. 
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6.8 Transmission Electron Microscopy (TEM) 
Sample preparation involved MCF-7 cells being grown in 6 well plates then 
incubated with Ru(II) complex at the stated concentration and time, the 
solution removed and the cells fixed using 3% glutaraldehyde. For fixed 
cellular location TEM studies, cells were fixed with cooled 70% ethanol 
prior to exposure with the complex. For both methods, cell cultures were 
dehydrated using a series of ethanol washes (70 – 100 % ethanol) and TEM 
samples sectioned in Araldite resin by microtome. Samples were examined 
on a FEI Tecnai instrument operating at 80 kV equipped with a Gatan 1 k 
CCD Camera. 
 
6.9 Inhibition treatment (uptake mechanism) 
Temperature-dependence used cells that had been cooled at 4°C for 30 
minutes then incubated with Ru(II) complex at 4°C for 1 hour. For treatment 
with endocytosis inhibitors, cells were treated with: chloroquine (5 – 100 
M),10 NH4Cl (5 – 50 mM),11 chlorpromazine (0.1 – 10 g ml-1),12 filipin (1 – 
20 g ml-1),13 nocodazole (0.1 – 10 M)14 or colchicine (0.1 – 10 M)14 for 30 
minutes then with Ru(II) complex plus each inhibitor for 1 hour before 
analysis. Each inhibitor treatment required serum-free conditions 
throughout. For qualitative uptake analysis, cells were examined using 
CLSM. For quantitative uptake analysis, the luminescence intensity (% 37 °C 
control, n = 3) was measured by ImageXpress 5000A (Axon instruments, 
Inc.) cellular screening platform data acquisition hardware and software. 
Excitation wavelength = 465 nm, emission band pass filter 600 - 680 nm.  
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6.10 Cytotoxicity (MTT assay) 
The basis of the MTT assay is that yellow MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) is reduced to a purple formazan product 
in the mitochondria of living cells by reductase enzymes. As the reduction of 
MTT can only occur within active mitochondria, this amount of formazan 
produced is directly related to the number of viable cells within a sample. 
The amount of formazan may be quantified by absorbance between 500-600 
nm and the toxicity of a sample may be deduced by comparison of the 
formazan content for cells exposed to the sample to that of an untreated 
control. As different cell samples can show different relationships between 
enzyme activity and cell number, the assay is only valid for comparative 
purposes within the same sample of cells. 
 
6.10.1 IC50 values 
Cell cultures were grown on 24 or 48 well plates and allowed to grow for 24 
hours. Cell cultures were then treated with solutions of Ru(II) complex at 
various concentrations (10% PBS: 90% medium) for the given incubation 
time in triplicate. Solutions were removed and the cells incubated with 0.5 
mg ml-1 MTT dissolved in PBS for 30-40 minutes. The formazan product was 
eluted using 200 µl/well of acidified propan-2-ol, 150 µl of this was 
transferred to a 96 well plate and the absorbance quantified by 
spectrophotometer (540 nm, referenced at 640 nm). An average absorbance 
for each concentration was obtained and cell viability was determined as a 
percentage of untreated negative control wells (10% PBS: 90% medium). 
Using Sigmaplot 11.0 software, a 3 parameter sigmoidal curve was used to 
fit each data set (R2 > 0.97 for each fit) and the IC50 value (the concentration 
corresponding to 50% viability) calculated by interpolation.  
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6.10.2 IT50 values 
Cell cultures were grown on 24 or 48 well plates and allowed to grow for 24 
hours. Cell cultures were then treated with solutions of Ru(II) complex 
(10% PBS: 90% medium) at the given concentration in triplicate. Cell 
viability was assessed by MTT assay at various time points. IT50 data was fit 
by a 2 parameter exponential decay curve (R2 > 0.98 for each fit) and the 
IT50 value (the time corresponding to 50% viability) calculated by 
interpolation. 
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A ruthenium(II) polypyridyl complex for direct
imaging of DNA structure in living cells
Martin R. Gill1,3, Jorge Garcia-Lara2, Simon J. Foster2, Carl Smythe3, Giuseppe Battaglia3*
and Jim A. Thomas1*
In the search for new biological imaging agents, metal coordination compounds able to emit from triplet metal-to-ligand
charge transfer (MLCT) states offer many advantages as luminescent probes of DNA structure. However, poor cellular
uptake restricts their use in live cells. Here, we present a dinuclear ruthenium(II) polypyridyl system that works as a
multifunctional biological imaging agent staining the DNA of eukaryotic and prokaryotic cells for both luminescence and
transition electron microscopy. This MLCT ‘light switch’ complex directly images nuclear DNA of living cells without
requiring prior membrane permeabilization. Furthermore, inhibition and transmission electron microscopy studies show
this to be via a non-endocytotic, but temperature-dependent, mechanism of cellular uptake in MCF-7 cells, and confocal
microscopy reveals multiple emission peaks that function as markers for cellular DNA structure.
S
ince the identiﬁcation of DNA as the carrier of genetic material,
work towards the understanding of DNA organization and
structure within the cell nucleus has become of great importance.
Fluorescent microscopy using luminescent, cell membrane-
permeable organic DNA-binding molecules as marker stains is a
well established technique towards achieving this goal1. However,
many of the currently available set of ﬂuorescent dyes suffer from
low water solubility, high toxicity and photobleaching2. Many of
the DNA dyes traditionally used by the cell biologist, such as 40,6-dia-
midino-2-phenylindole (DAPI) or the Hoechst stains, also require
ultraviolet (UV) light as illumination, which can induce extensive
DNA photodamage3. In addition to these points, the difference
between emission and excitation energies (the Stokes shift) is small
(typically less than 50 nm) and this can lead to unwanted background
signal due to autoﬂuorescence of endogenous ﬂuorophores1.
In this context, metal ion complexes offer a very attractive set of
optical imaging properties and recent studies have seen the develop-
ment of long-lifetime cell-permeable lanthanide and platinum
based systems as effective nuclear imaging agents4,5. Ever since the
discovery that [Ru(bpy)2(dppz)]
2þ (bpy¼ 2,20-bipyridine, dppz¼
dipyrido[3,2-a:20,30-c]phenazine) functions as a molecular ‘light
switch’ for DNA upon metal-to-ligand charge transfer (MLCT)
excitation6, there has been great attention drawn to the DNA-
binding properties of polypyridyl coordination complexes of d6
octahedral metal ions, speciﬁcally towards the development of
highly sensitive and structure-speciﬁc DNA probes7,8. As DNA
imaging tools, such complexes offer several advantages over existing
systems: MLCT excitations occur in the visible region of the spec-
trum, they possess high Stokes shifts (typically greater than
150 nm) along with chemical and photostability. Until recently
research has largely focused on the development of in vitro
probes; the few studies involving direct imaging of DNA in living
cells with such systems has had limited success, with poor mem-
brane permeability being ascribed as the limiting factor9–15.
In this study, we explore the potential of two dinuclear
ruthenium(II) systems as cellular DNA stains, showing one of
these to be successfully taken up by living cells and to act as a struc-
ture-sensitive probe of DNA.
Using previously reported methods16,17, the dinuclear Ru(II)
complexes [(phen)2Ru(tpphz)Ru(phen)2]
4þ 1 and [(bpy)2
Ru(tpphz)Ru(bpy)2]
4þ 2 (phen¼ 1,l0-phenanthroline, tpphz¼
tetrapyrido[3,2-a:20,30-c:300,200-h:2000,3000-j]phenazine; Fig. 1a) were
synthesized as their water-soluble chloride salts, and their potential
as cellular DNA stains was investigated. As both 1 and 2 are non-
emissive in water but display intense luminescence when bound
to DNA they are ideal candidates for such a role. Like in the
related dppz systems, this light switch effect arises due to the shield-
ing of the phenazine nitrogen atoms of the ditopic tpphz ligand
from water and resultant emission from the 3MLCT state16–19.
The cytotoxicity of each complex towards the MCF-7 human
breast cancer cell line was determined by MTT (MTT¼
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
assay and the derived IC50 values showed that neither 1 or 2 demon-
strates high toxicity over a 24 hour incubation period (IC50 values of
138 mM and.500 mM respectively), with 1 being the more toxic of
the two complexes.
To examine the cellular uptake of the complexes, we incubated
MCF-7 cells with solutions of 1 and 2, and then imaged them
using confocal microscopy. The excitation wavelength used was
458 nm and the emission measured at 670–700 nm, corresponding
to the previously observed MLCT luminescent ‘light switch’ effect of
each complex upon binding to DNA in vitro. To determine the
health of the cells after incubation, a standard live/dead staining
procedure using two commercially available dyes—SYTO 9 and pro-
pidium iodide (PI)—was performed. SYTO 9 (octanol/water par-
tition coefﬁcient, logP¼ 0.93)20 is a membrane-permeable nucleic
acid dye, which stains the RNA of living cells; and the intercalator
PI (logP¼ –3.73) is a non-membrane-permeable DNA stain. As the
membrane of a dead cell is highly damaged, positive staining by PI
indicates cell mortality. Figure 1b shows that 1 (logP¼ –0.96) displays
intense in cellulo luminescence in live cells—apparently located in the
cell nucleus—and does not affect cell viability, which is a critical factor
in live cell imaging applications. The emission at 670–700 nm
corresponds to activation of the well-documented ‘light switch’
effect upon reversible binding to DNA, and z-stack experiments
involving co-localization with SYTO 9 clearly show that the
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observed luminescence is spherical in three dimensions, corre-
sponding to the cell nucleus (Supplementary Fig. 1).
In contrast to 1, the incubation of MCF-7 cells with 2 (logP¼
–1.61) and subsequent imaging showed no staining of live cells
under the same conditions (Fig. 1c), which would correspond
with the lower cytotoxicity displayed by 2. Further studies have
revealed that complex 2 is an efﬁcient DNA stain in ﬁxed cell appli-
cations and is an indicator of cell mortality (Supplementary Fig. 2).
Indeed, in live/dead staining it functions in a manner identical to PI
but with novel excitation/emission wavelengths. Complex 1 displays
similar advantages over conventional probes for living cells; it is
highly water soluble, photostable (Supplementary Fig. 3) and
displays a large Stokes shift value with a long lifetime far-red emis-
sion—a factor that makes it extremely compatible with other
imaging agents, such as the heavily-used green ﬂuorescent protein
(GFP). We are also able to show that 1 clearly images bacteria
such as Staphylococcus aureus in vivo; the ﬁrst time prokaryotic
cells have been directly imaged using a metal-based system
(Fig. 1d). For visualization of the nucleoid structure, ﬁxed-cell
experiments were performed and the condensed chromosome was
clearly observable in cells (Fig. 1e).
The hydrophilicity and high charge of 1 would imply that the
molecule does not freely diffuse across the cell membrane, as
reﬂected by the relatively high concentration (.200 mM) required
for efﬁcient uptake. With this in mind, the mechanism of cellular
uptake of the complex was investigated.
To probe whether 1 was taken up by a passive or active transport
mechanism, MCF-7 cells were incubated with 1 at a temperature of
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Figure 1 | The cellular uptake properties of dinuclear Ru(II) tpphz
complexes. a, The two dinuclear ruthenium(II) tpphz systems relevant to this
study, with either phen (1) or bpy (2) as ancillary ligands. b, Uptake and
nuclear staining of MCF-7 breast cancer cell line by 1 (500mM, 1 h). From
left to right: luminescence emission of 1 (red), live cell stain SYTO 9 (green),
dead cell stain propidium iodide (PI) (purple) and overlay image. c,
Incubation with 2 (500mM, 1 h) shows no staining of live cells and the co-
localization with PI emission shows 2 to act as a dead cell stain. d, Staining
of S. Aureus by 1 (200mM, 45 min) showing the cellular uptake and in cellulo
luminescence of 1 (left) with phase-contrast image (right). e, Fixed S. Aureus
cells stained by 1 showing the condensed nucleoid structure (left) again with
phase-contrast image (right).
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Figure 2 | Mechanism of cellular uptake of Ru(II) tpphz complex. a, Relative
luminescence intensity of 1 in MCF-7 cells after inhibition treatment
(500mM, 1 h). Error bars represent standard error of the mean (s.e.m.) with
n¼ 3. b, Temperature-dependence studies of uptake of 1 by MCF-7 cells at
4 8C (500mM, 1 h) displays no in cellulo luminescence. The phase-contrast
image is included for reference. c–h, Treatment with the endocytosis
inhibitors chloroquine (100mM) (c), NH4Cl (50 mM) (d), chlorpromazine
(10mg ml21) (e), ﬁlipin (20mg ml21) (f), nocodazole (20mM) (g), and
colchicine (20mM) (h) show no inhibition of uptake of 1 by MCF-7 cells.
PI staining is included for each to indicate cell viability. All scale bars
represent 20mM.
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4 8C. Figure 2b shows that no luminescence is observed when the
cells are incubated with the complex at this temperature, indicating
that 1 enters cells and targets the nucleus by a temperature-depen-
dent pathway and conﬁrming that 1 is not a membrane-permeable
molecule. As the most common energy-dependent method by
which eukaryotic cells take up material is endocytosis, cells were
co-incubated with 1 and several well-documented inhibitors of
this process. Cellular uptake was then assessed by the extent of resul-
tant nuclear staining by luminescence microscopy (Fig. 2).
As can be seen by the relative intensities of in cellulo lumines-
cence after treatment with these inhibitors (Fig. 2a), co-incubation
with 1 and the general endocytosis inhibitors chloroquine and
ammonium chloride (two lysosomotropic agents)21 or the speciﬁc
endocytosis inhibitors chlorpromazine (clathrin-mediated)22 and
ﬁlipin (cavaeloe-mediated)23 had no effect on the ability of 1 to
function as a nuclear stain (Fig. 2a,c–f), showing that these two
well-studied endocytotic pathways are not responsible for the
uptake of 1. Furthermore, neither colchicine or nocodazole, which
disrupt the polymerization of microtubules and prevent membrane
and endosomal trafﬁcking24, showed any inhibition of uptake
(Fig. 2a,g,h). This data is therefore consistent with a non-endocytotic
mechanism of uptake. This is not a surprising result when we
consider the fact that the complex would still have to escape the
endosome to target the nucleus. Our measurements of the lipophi-
licity of 1 show that the molecule remains hydrophilic in the acidic
conditions similar to that found in endosomes (logP¼ –0.77 at pH
5) and so the effects of acidiﬁcation are unlikely to be responsible for
release of 1 into the cytosol.
In addition to these luminescence microscopy studies, which rely
on the DNA binding and subsequent activation of the ‘light switch’
effect to observe the in cellulo location of 1, we are also able to show
the cellular distribution of 1 in live cells using transition electron
microscopy (TEM). As they incorporate a second row transition
metal with high electron density, ruthenium complexes are able to
scatter the electron beam used for imaging in TEM. This enhances
contrast and is the phenomenon exploited in the use of reagents
such as immunogold labels, ruthenium red and osmium tetroxide;
hence the localization of 1 within live cells with high spatial resol-
ution can be determined through TEM.
We therefore incubated MCF-7 cells with solutions of 1, as for
luminescence microscopy, before ﬁxation and sectioning for TEM
imaging. Figure 3a shows that although 1 is located throughout
the cell cytosol, it is found in much higher concentration within
the nucleus of the MCF-7 cells, and it localizes within heterochro-
matin. Notably, as highlighted in Fig. 3b, TEM micrographs show
the absence of 1 from endosomal and lysosomal compartments,
conﬁrming that 1 is not transported into cells via an endocytotic
pathway (Fig. 3a,b). Both nuclear localization and non-endocytotic
uptake are further conﬁrmed by co-staining with the phospholipid
contrast reagent osmium tetroxide. As shown in Fig. 3c, cells incu-
bated with 1 then co-stained with osmium tetroxide display highly
contrasted nuclear heterochromatin, and again the endosomal com-
partments show no presence of compound 1. As expected, the nega-
tive control micrograph of a cell stained only with osmium tetroxide
shows a much less contrasted nuclear area (Fig. 3d).
As previously outlined, cellular uptake of hydrophilic, charged
and polar molecules is generally very poor and recently
strategies using either lipophilic ancillary ligands based on DIP
(DIP¼ 4,7-diphenyl-1,l0-phenanthroline)11–13,25 or conjugation to
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Figure 3 | Cellular localization of Ru(II) tpphz complex characterized by
transition electron microscopy. a, TEM micrograph showing the cellular
uptake of 1 by MCF-7 cells (500mM, 1 h), directly using Ru(II) tpphz
complex as a contrast agent to show cellular localization where 1 especially
associates within the nucleus and shows strong heterochromatin staining.
Note complete lack of contrast within cellular vesicles. b, The absence of 1
within an intracellular vesicle (large scale). c, MCF-7 cells incubated with 1
(500mM, 1 h) and additionally stained with osmium tetroxide to show
greater cellular detail. d, Negative control MCF-7 cell stained solely with
osmium tetroxide.
Interphase Prophase Prometaphase Metaphase
a
b
c
d
10 µm 
Figure 4 | A DNA-speciﬁc luminescent cellular imaging agent. a, Co-
staining of 1 (red, left) with DNA-speciﬁc dye DAPI (DAPI¼ 40,6-diamidino-
2-phenylindole; blue, centre) and the overlay image (right). b, Co-staining of
1 (red, left) with general nucleic acid dye SYTO 9 (green, centre) and overlay
image (right). Note the low co-localization of 1 with the green SYTO 9
emission from the nucleoli of cells. c, Asynchronous cell imaging shows
mitotic cells stained by 1 visualizing chromosome aggregation through
progression of mitosis. d, High magniﬁcation images of mitotic cells showing
individual chromosomes. All scale bars represent 10mM.
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protein/steroids14,15,26 have been employed to increase membrane-
permeability of DNA-binding metal coordination complexes.
Although this has led to successful cellular uptake of both Ru(II)
and Re(I)-based MLCT luminescent systems11–15 the in cellulo DNA
binding of such systems has not been successfully demonstrated.
The work outlined herein shows that such an approach is not
always required and represents a signiﬁcant step in the development
of these DNA binding systems towards in vivo applications.
Further work into the exact mechanism of uptake is ongoing.
[(phen)2Ru(tpphz)Ru(phen)2]
41: a probe of DNA structure
Higher-resolution imaging and co-staining with other commercially
available ﬂuorescent nuclear stains reveals that 1 is clearly targeting
nuclear DNA. Incubation of MCF-7 cells with 1 and co-staining
with the membrane-permeable DAPI (logP¼ 0.581), a DNA
minor-groove binder, shows strong co-localization of the two emis-
sion signals (Fig. 4a). Conversely, co-staining with the cyanine dye
SYTO 9, a general nucleic acid stain, shows a clear difference in local-
ization (Fig. 4b). Notably SYTO 9 preferentially binds RNA over
DNA and as a consequence nucleoli, the site of rRNA synthesis
and tRNA processing, are distinctly imaged through the dye’s
intense green emission. It is clear that 1 is a DNA-speciﬁc stain as,
in contrast to SYTO 9, no emission from the complex is observed
from nucleolar regions. Furthermore, 1 visualizes characteristic struc-
tural changes in nuclear DNA as cells progress through the cell cycle
(Fig. 4c). When asynchronous cells are imaged, the majority of
labelled cells are interphase but cells undergoing mitotic phases are
also clearly observed. To image chromosomes in more detail, cells
were halted in metaphase using colchicine as a mitotic spindle
poison, stained and then mounted onto slides before imaging, allow-
ing clear visualization of the aggregated chromosomes (Fig. 4d).
A structure-sensitive DNA imaging agent
One advantage in using such systems as cellular DNA probes is their
ability to display a high degree of sensitivity in their DNA binding.
For example, there is currently a great deal of interest in four-
stranded DNA structures. The induction/stabilization of quadru-
plex DNA in G-rich sequences of DNA located at the ends of
chromosomes (telomeres) is seen as an anti-cancer strategy27 but
nevertheless, to date, the actual detection of quadruplex formation
in living cells has remained elusive. Previous in vitro studies have
demonstrated that 1 binds to both duplex and quadruplex DNA
with a high afﬁnity; a distinctive blue-shifted ‘light-switch’ emission
is displayed on binding to quadruplex DNA compared with the ana-
logous duplex effect (maxima of 630 nm and .650 nm respect-
ively)17. This indicates that 1 has the ability to discriminate
between different DNA structures and, therefore, the potential of
1 as a quadruplex DNA imaging tool has been explored.
It was found that ‘light switch’ emission due to the DNA bound
complex within cells comprises two separate emission peaks.
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Figure 5 | Multiple-emission proﬁle as a luminescent probe of DNA structure. a, Lambda stacking experiments show the emission proﬁle of 1 in live MCF-7
cells to be composed of multiple emission peaks. The emission proﬁle of two separate cellular regions (red and blue) show these peaks to have maxima of
approximately 630 and 680 nm. The 680 nm peak is uniformly emitted from the nucleus (observed in both the red and blue region) but the 630 nm
emission is found to be located in speciﬁc regions (red region only). b, Equivalent lambda stacking experiment of 1 in ﬁxed MCF-7 cells displays only the
680 nm emission peak. c, Confocal microscopy images using two separate detection channels 670–700 nm (red) and 630–640 nm (yellow) show the
multiple-emission proﬁle of the nuclear luminescence of 1 bound to DNA and the speciﬁc localization of the 630–640 nm emission. d, Equivalent imaging
experiment for ﬁxed cells show that only the 670–700 nm red emission is present. e, MCF-7 cells ﬁxed after incubation with 1 show that the distinctive
multiple-emission properties seen in live cell imaging is retained, potentially due to 1 imaging a non-duplex DNA structure. f, L5178Y-R cells (which have
extended G-rich telomeric DNA) stained with 1 (200mM, 30 min) display a large increase in 630–640 nm emission. g, L5178Y-R metaphase chromosomes
showing speciﬁc localization of the 630–640 nm emission peaks. All scale bars represent 20mm.
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Lambda stacking experiments, which measure the emission intensity
across a range of wavelengths for a single excitation energy,
revealed maxima at approximately 680 and 630 nm respectively. A
representative Lambda stack displaying the emission proﬁle of two
separate regions in cells reveals the non-uniform speciﬁcity of the
630 peak in comparison with the prevalent 680 peak (Fig. 5a),
suggesting that the 630 emission is from a different source.
In order to observe the cellular localization of each of the signals,
the image acquisition process was calibrated by deﬁning a separate
red (670–700 nm) and yellow (630–640 nm) channel. In Figure 5c,
it is clear that the red emission shows the expected nuclear chroma-
tin staining, but the yellow emission is localized in speciﬁc areas
within nuclei and is not co-localized with the red emission. To
determine if this effect is due to a non-duplex structure of DNA
being imaged we explored the ability of 1 to induce/stabilize
alternative forms of DNA by using formaldehyde ﬁxation. This pro-
duces DNA–protein crosslinks and has the effect of ‘freezing’ DNA
structure28. Using the novel imaging properties of the complex as a
marker stain, ﬁxed cell experiments were conducted, with MCF-7
cells being exposed to 1 before and after ﬁxation. The incubation
of ﬁxed, permeabilized cells with 1 resulted in only the 680 nm
emission being visible, with no detectable 630 nm peak
(Fig. 5b,d). The observation of this single emission, which arises
from 1 binding to native duplex DNA, indicates that 1 is incapable
of inducing DNA structural changes after ﬁxation. In contrast, when
cells were ﬁxed in an identical manner after incubation with 1, the
distinctive multiple emission proﬁle is maintained (Fig. 5e). These
results suggest that 1 induces/stabilizes multiple structures of
DNA and that the 630 emission is due to an alternative non-
duplex DNA structure.
In an attempt to further deﬁne the nature of the 630 nm emission,
we selected the L5178Y-R mouse lymphoma cell line for further
imaging experiments. This cell line has a large average length of
G-rich telomeric DNA (80 kb compared to 2 kb in MCF-7 cells)29
and therefore exhibits a greater potential for quadruplex formation.
As shown in Fig. 5f, the staining of these cells by 1 results in a
large increase in the yellow 630–640 nm emission compared with
the MCF-7 cell line. Interestingly, this image also includes a mitotic
cell showing three intense yellow points, apparently located at speciﬁc
regions on the chromosomes (Fig. 5 g). These data would be in agree-
ment with 1 functioning as a luminescent marker for quadruplex
DNA; further work into ascribing the source of this in cellulo
630 nm peak is currently being undertaken.
In conclusion, we report the successful application of a dinuclear
Ru(II) polypyridyl ‘light switch’ complex as an in cellulo nuclear
DNA stain, well tolerated by eukaryotic and prokaryotic cells, and
for use with both luminescence and transition electron microscopy.
Highly unusually, despite the hydrophilicity of the molecule, it is
taken up by live cells via a structure-speciﬁc and temperature-
dependent non-endocytotic mechanism. Perhaps the most fascinat-
ing attribute of 1 as a new imaging tool is the existence on DNA
binding of multiple emission peaks suggesting that this complex
may ﬁnd future application as an in cellulo DNA structural probe,
speciﬁcally for quadruplex DNA.
Methods
Chemicals. All chemicals used were purchased from Sigma unless stated. The Ru(II)
complexes were synthesized as previously described16,17 and converted to their
chloride salts.
Partition coefﬁcients. Calculated octanol/water partition coefﬁcients were obtained
by using the Molinspiration software (www.molinspiration.com). Octanol/water
partition coefﬁcients for 1 and 2 were obtained using the ‘shake-ﬂask’ method, with
the concentration in each phase determined by UV–vis absorbance (Jasco V-630
Spectrophotometer). The partition coefﬁcient, P, was calculated using P¼ coct/ cH2O
(where c¼ concentration). The experiment was repeated three times.
Cell culture. Staphylococcus aureus strain SH1000 spa- were grown in brain-heart
infusion medium (Oxoid) at 37 8C. Colonies were incubated with 1 (200 mM) in a
rotary shaker for 15 min at 4 8C or 37 8C, washed, and resuspended in GTE solution
(50 mM Glucose, 10 mM EDTA, and 20 mM Tris. Cl at pH 7.5). A 5 ml aliquot was
spread over a polylysine-coated glass slide and allowed to dry at room temperature.
The preparation was mounted in H2O and sealed with DPXmountant (BDH) before
imaging. MCF-7 and L5178Y-R cells were cultured in RMPI 1640 medium
(Invitrogen) supplemented with 2 mM L-glutamine, 100 IU ml21 penicillin,
100 mg ml21 streptomycin and 10% fetal calf serum, at 37 8C under a 5% CO2
atmosphere. Cell cultures were treated with solutions of 1 and 2 (0.1 mM to 200 mM,
10% phosphate buffered saline solution (PBS): 90% cell media) for 24 hours before
incubation with 0.5 mg ml21 MTT (MTT¼ 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) for 40 minutes. The formazan product was eluted
using acidiﬁed isopropanol, and absorbance at 540 nm was quantiﬁed by
spectrophotometer and cell viability determined (% untreated negative control). For
imaging, MCF-7 cells were incubated with 500 mM 1 or 2 (10% PBS: 90% serum-free
media) for 1 hour, and L5178Y-R cells were cultured in suspension and incubated
with 200 mM of 1 for 30 minutes. All cells were washed with PBS before imaging.
Co-staining was performed using 2 mM SYTO 9, 10 mM PI for 10 min or 500 nM
DAPI for 2 min (in PBS). M-phase synchronization required incubation with
colchicine (500 nM) for 48 hours before cells were detached and slide-mounted for
imaging. For ﬁxed-cell experiments, monolayers were treated with 10%
formaldehyde (10 min). For staining after ﬁxation, cells were additionally
permeabilized with Triton (10 min) before exposure to 100 mM 1 or 2 (in PBS) for
15 minutes. Temperature dependence studies used cells that had been cooled at 4 8C
for 30 minutes then incubated with 500 mM 1 (10% PBS: 90% serum-free media) at
4 8C for 1 hour. Inhibitor treatment required serum-free conditions throughout.
Cells were treated with chloroquine, NH4Cl, chlorpromazine, ﬁlipin, nocodazole
and colchicine at the stated concentrations for 30 minutes, then with 1 (500 mM)
plus the inhibitor for 1 hour before imaging.
Microscopy.MCF-7 and L5178Y-R cells were luminescently imaged on a Zeiss LSM
510 META upright confocal laser scanning microscope using 40 and 100
magniﬁcation long-range water-dipping lenses for monolayer cultures or a 63 oil-
immersion lens for slide imaging. 1 and 2 were excited with an Ar-ion laser at
458 nm and emission monitored using META detection at 630–640 nm (yellow)
and 670–700 nm (red) wavelengths as stated. SYTO 9 and PI were excited using
488 nm (Ar-ion) and 543 nm (He–Ne), respectively, and emission was collected
using 500–530 nm (SYTO 9) and 565–615 nm (PI) bandﬁlters. For DAPI excitation,
a Coherent Chameleon pulsed infrared multiphoton laser was used (800 nm) and
the emission detected using a 420 nm long pass bandﬁlter. Image data acquisition
and processing were performed using a Zeiss LSM image browser. S. Aureus stained
cells were imaged using an Olympus IX70 inverted microscope with a 100 1.3 NA
oil immersion lens and digital camera. Excitation was provided by a mercury arc
lamp with an excitation band pass ﬁlter of 420–490 nm, and a longpass 560 nm ﬁlter
was used to visualize the luminescence. For quantitative uptake analysis in inhibition
studies, luminescence intensity (% of 37 8C control, n¼ 3) was determined using
data acquisition hardware and software ImageXpress 5000A (Axon Instruments),
with an excitation wavelength of 465 nm and an emission band pass ﬁlter of
600–680 nm. For TEM, MCF-7 cells were incubated with 1 (500 mM, 1 h) then ﬁxed
using 3% glutaraldehyde and dehydrated using ethanol. TEM samples were
sectioned in Araldite resin by microtome and examined on a FEI Tecnai instrument
operating at 80 kV equipped with a Gatan 1 k CCD Camera.
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